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This thesis describes several interrelated 
studies concerning the effects of diphosphonates in the 
treatment of disorders of bone turnover. 
Diphosphonates have previously been shown to 
suppress bone turnover in Paget's disease when given 
orally for at least three months. However, five daily 
intravenous infusions of the diphosphonates, clodronate, 
etidronate and a newer agent, aminohexane diphosphonate 
(AHDP), induced marked and sustained biochemical and 
clinical changes similar to those achieved with long-term 
oral treatment. These new regimens may be useful in the 
management of Paget's disease. 
The assessment of biochemical response in 
Paget's disease, particularly in re-treated patients, is 
more complex than hitherto described. The pre-treatment 
serum alkaline phosphatase and, in re-treated patients, 
the extent of biochemical relapse are important 
determinants of response. 
Little was previously known of the effects of 
high doses of diphosphonates on mineral metabolism. 
Inhibition of mineralisation occurred following all 3 
intravenous diphosphonates. However, this effect was 
partial and short-lived following clodronate or AHDP, but 
was complete and much more sustained following 
etidronate. All three diphosphonates induced 
hyperphosphataemia by increasing renal tubular 
reabsorption of phosphate. This latter effect was 
related, both temporally and quantitatively, to the 
effects of these agents on skeletal mineralisation 
suggesting a possible causal relationship. 
Hypocalcaemic responses were consistently 
observed in pagetic patients following intravenous 
clodronate or AHDP, but not following etidronate. 
Similarly, infusions of either clodronate or AHDP, but 
not etidronate, induced normalisation of mean serum 
calcium in patients with hypercalcaemia of malignancy. 
Furthermore, oral clodronate, but neither high-dose nor 
low-dose oral etidronate, induced significant 
hypocalcaemic responses in patients with primary 
hyperparathyroidism. The degree of inhibition of bone 
resorption was similar for each of the diphosphonates in 
all of the disorders studied, suggesting that the 
attenuated hypocalcaemic effects of etidronate resulted 
from the greater impairment of mineralisation that 
occurred following treatment with this agent. 
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Chapter 1I INTRODUCTION Page 8 
THE PHYSIOLOGY OF BONE AND CALCIUM 
The skeleton provides a strong rigid framework 
for the body. It is capable of growth and self repair 
and acts as a reservoir of mineral for the regulation of 
calcium concentration in the extracellular fluid. It 
achieves these various tasks by virtue of complex and 
interrelated control mechanisms which act to modulate the 
activities of both bone forming cells, the osteoblasts, 
and bone resorbing cells, the osteoclasts. The processes 
of bone formation and bone resorption are continuous and 
require to be well regulated in order both to preserve 
calcium homeostasis and to maintain the structural 
integrity of the skeleton. 
Known physiological influences on these 
processes include hormones, especially parathyroid 
hormone (PTH), 1,25 dihydroxy vitamin D (1,25(OH)2D3) and 
calcitonin. Many more factors, such as prostaglandins 
and various cytokines can be demonstrated to have potent 
effects on bone in vitro and have been implicated in the 
pathogenesis of skeletal disease although their 
physiological importance is not known. Mechanical stress 
is a further physiological bone regulatory signal and is 
likely to be of primary importance in maintaining an 
efficient bone structure (Jaworski, 1984). When stresses 
are reduced, as during bed rest or weightlessness in 
space, bone resorption greatly exceeds formation and 
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rapid bone loss ensues (Lutwak et al, 1969). Conversely, 
skeletal mass is increased in marathon runners compared 
with normal controls and even in osteoporotic subjects 
modest exercise can be shown to delay or reverse bone 
loss (Aloia et al, 1978a+b). 
In addition to these influences it is clear from 
the organised activity of osteoblasts and osteoclasts 
that these cells are capable of interacting with each 
other in order to coordinate their activities in the 
remodelling process. To date the precise nature of these 
coordinating intercellular signals has not been 
determined but there has been considerable progress in 
the understanding of the processes involved in bone 
remodelling. This knowledge has contributed greatly to 
our understanding of disease processes in skeletal 
disorders. 
Remodelling of bone 
In adults, in whom longitudinal growth has 
ceased, much of the skeletal turnover (\>95%) is accounted 
for by remodelling of bone. The remodelling process is 
comprised of a series of discrete events which are well 
characterised morphologically, but physiologically ill 
understood (for review see Parfitt, 1983). The process 
is important for the self-repair of microdamage in 
skeletal tissue (Frost, 1981). The remodelling sequence, 
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which was first described by Frost (1970) in cortical 
bone, was based on observations that a resorption phase 
preceded a formation phase and both were definable as 
discrete cellular and metabolic events in both space and 
time. It has been estimated that at any one time there 
are about 1.5 million active remodelling sites in an 
average adult skeleton with normal turnover (Parfitt, 
1983). A phase of osteoclast activation and osteoclastic 
bone resorption results in the formation of a resorption 
cavity which in trabecular bone has a final depth of 
about 60um (Parfitt, 1984). Mononuclear cells are found 
deep within resorption bays, and this is presumed to 
represent a later event in the resorption sequence (Baron 
et al, 1983). These cells move off the resorption cavity 
and may be responsible for the signals that ultimately 
attract osteoblasts to the site of previous resorption 
(Baron et al, 1983). The surface is smoothed and a 
cement substance is deposited, but the responsible cells 
are not known. The secondary attraction of osteoblasts, 
the mechanism of which is poorly understood, is known as 
coupling and is important both for the maintenance of 
skeletal mass and of structural integrity (Parfitt, 
1982). 
Once on the resorption surface, osteoblasts 
synthesise osteoid matrix, largely composed of type I 
collagen. In addition to collagen, osteoblasts 
synthesise other bone matrix components. These include 
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the gamma-carboxyglutamic acid containing protein, 
osteocalcin, which is dependent on vitamin K for 
carboxylation of three glutamate residues which enables 
it to bind calcium (Price et al, 1980). Production of 
osteocalcin is dependent on 1,25(OH)2D3 (price et al, 
1981). Osteonectin is a bone derived phosphoprotein 
which binds both calcium and collagen (Termine, 1981). 
These proteins appear to inhibit hydroxyapatite formation 
but their physiological role, and in particular whether 
they might be involved in the coupling process, is 
unknown (Menanteau et al, 1982). Many other bone 
proteins have been identified which might regulate 
skeletal metabolism. Of these, human skeletal growth 
factor, isolated from human bone (Farley & Baylink, 1981) 
appears to stimulate bone cell proliferation. Although 
such chemical signals may be important for osteoblast 
recruitment the site specificity for cell attachment is 
likely to be due to other factors such as a chemotactic 
constituent within the cement substance (Parfitt, 1982, 
1984). The rate of matrix apposition is most rapid at 
the beginning of bone formation (2-3um/day) when the 
osteoblasts are columnar or "plump". Later this process 
slows and the cells become flattened (Parfitt, 1984). 
Newly formed matrix does not mineralise immediately 
suggesting that it may have to undergo changes before 
mineralisation can occur. There is evidence that in 
growing bone osteoblasts produce matrix vesicles which 
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may be responsible for initiating mineralisation 
(Anderson, 1978). On completion of mineralisation the 
bone site enters a quiescent phase. Quiescent surfaces 
account for 80% or more of total trabecular surface in 
normal adults (Parfitt, 1984). 
In the healthy young adult, in whom bone mass is 
constant, the rate of bone resorption must be equal to 
the rate of new matrix formation and mineralisation. 
There is no direct method for measurement of the rates of 
bone formation and resorption. Radio-calcium kinetic 
studies, which measure total calcium movement into bone, 
produce estimates for calcium accretion of around 
12mmol/day (Aubert & Milhaud, 1960). However, 
considerable exchange of bone mineral, possibly mediated 
by the presence of brushite in areas undergoing 
mineralisation, occurs independently of cellular bone 
turnover (Lauffenburger et al, 1977; Neuman et al, 1982). 
Therefore, such techniques probably overestimate the rate 
of bone formation (Krane & Schiller, 1979) and the true 
rate for a normal adult is probably less (around 5mmol 
calcium per day). A closely similar amount of bone must 
be resorbed in order to maintain a relatively constant 
bone mass. 
Remodelling activity occurs on all bone surfaces 
and it is therefore not surprising that bone turnover is 
much higher in trabecular bone, which has a very high 
surface to volume ratio, than in cortical bone where this 
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ratio is much lower. At any one time approximately 
15-20% of the bone surface is undergoing bone 
remodelling, the remainder being relatively inert. 
A consideration of the remodelling process is 
important for understanding how skeletal turnover may 
become disturbed in disease. In a number of metabolic 
bone disorders despite increases in bone turnover the 
normal close quantitative relationship between the rates 
of bone formation and bone resorption is maintained. A 
good example is provided by Paget's disease of bone where 
although bone turnover may be 10-20 times greater than 
normal, overall skeletal balance is usually close to 
zero, as the anatomical coupling process ensures close 
matching of formation and resorption. This close 
matching of the rates of formation and resorption is 
demonstrated by the preserved relationship between serum 
alkaline phosphatase and urinary hydroxproline excretion 
(markers of bone formation and resorption repectively) in 
patients with Paget's disease (Figure 1.1). A similar 
"coupled" increase in bone turnover occurs in the 
majority of patients with hyperparathyroidism (Parsons, 
1979). 
In other skeletal disorders, such as 
osteoporosis or skeletal involvement in malignancy, bone 
formation and resorption rates are imperfectly matched 
and there is a resultant skeletal imbalance for calcium. 
Bone loss may occur either because osteoblasts fail to 
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Figure 1.1 Relationship between serum alkaline 
phosphatase and urinary hydroxyproline in patients with 
Paget's disease of bone. (From Douglas, 1983). 
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become attracted into the resorption cavities (true 
anatomical uncoupling) or because the amount of bone 
formed in each remodelling unit is quantitatively less 
than the amount of bone resorbed to leave a net bone 
deficit. It is likely that both of these mechanisms 
contribute to the development of postmenopausal 
osteoporosis (Baron, 1981). A relative failure of the 
coupling process may lead to a reduced osteoblast 
population on the resorption surface. In such 
circumstances the amount of new bone would be reduced 
even if each osteoblast produced the same quantity of 
bone matrix as normal (Parfitt, 1982). in multiple 
myeloma osteoclastic bone resorption is stimulated by the 
local production of osteoclast activating factors (OAFS) 
whereas the expected secondary increase in bone formation 
is suppressed (Mundy et al, 1974a, 1974b; Stepan et al, 
1984). This disease represents a true disorder of 
coupling in the sense that resorption cavities are 
produced that will never subsequently attract osteoblasts 
(Stewart et al, 1982). 
Calcium homeostasis 
Calcium is widely distributed throughout the 
tissues of the body, although by far the greatest 
proportion is found in bone (approximately 99% of total). 
Almost 1% is found in the ECF and a variable amount is 
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present inside cells. Actual free cytosolic 
concentrations of calcium are extremely low (between 10-8 
and 10-7M) but have been found, particularly in 
conjunction with the phosphoinositol pathway, protein 
kinase C and calmodulin, to be of fundamental importance 
in the regulation of a multitude of cell functions, 
including cell division, protein synthesis and 
exocytosis, in various tissues. Some aspects of this 
rapidly expanding area have been the subject of recent 
reviews (Brown et al, 1985; Rubin et al, 1982). 
Regulation of the ECF concentration of calcium 
is critical to maintain normal neuro-muscular activity. 
A fall in plasma calcium concentration results in tetany 
and convulsions whereas hypercalcaemia results in many 
adverse effects which are reviewed subsequently. 
Plasma calcium 
For over fifty years it has been appreciated 
that serum (and plasma) calcium is composed of three 
major fractions (McLean and Hastings, 1935). These are, 
free or ionised calcium (around 50 per cent), calcium 
bound to protein (mainly albumin) which is non-diffusible 
(approximately 40 per cent) and a remaining 10 per cent 
or so which is complexed to anions such as bicarbonate 
and citrate. It is the ionised fraction which has 
greatest physiological and therefore clinical relevance. 
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Unfortunately, until recently, direct measurement of this 
fraction was rarely performed because of technical 
difficulties requiring the anaerobic collection of plasma 
samples and the use of ion selective electrodes which was 
tedious and time consuming. Although in recent years 
many of these problems have been partially overcome, most 
clinicians still have to rely on the measurement of total 
rather than ionised calcium. 
Many algorithms have been proposed to give a 
value which is more closely proportional to the 
concentration of ionised calcium than is the total 
calcium concentration. Such adjustments, which "correct" 
the total plasma calcium to a chosen "normal" value of 
serum protein or albumin, may be useful, for example, in 
gross hypoalbuminaemia such as occurs in hepatic failure, 
where the consequent reduction in protein bound calcium 
results in a low total serum calcium value despite a 
normal ionised calcium. Conversely, haemoconcentration 
due to dehydration or prolonged venous stasis during 
venepuncture is associated with apparent hypercalcaemia 
due to an increase in the protein bound fraction. There 
is a close correlation between serum calcium and serum 
albumin and in different studies correlation coefficients 
of between 0.71 and 0.87 have been reported when patients 
with a large range of serum albumin concentrations are 
studied (Payne et al, 1973; Orrell, 1971). The slope of 
such regressions approximate 0.02mmol calcium per lg/l 
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change in albumin. This forms the basis for the commonly 
used adjustments such as adding or subtracting 0.02mmol/l 
from the measured total calcium for every lg/1 of albumin 
below or above 40 respectively (Anonymous, 1977; Payne 
1973). However, in order for a regression to have useful 
predictive value a correlation coefficient of greater 
than 0.9 is required (Morgan, 1983; Armitage, 1971) 
All such algorithms have several additional 
limitations in that they do not account for changes in pH 
(acidosis reduces protein binding of calcium) or the wide 
interindividual differences in the degree of binding to 
albumin and other proteins (pain et al, 1975). This is 
of particular relevance to the measurement of calcium in 
multiple myeloma where a total of six case reports have 
documented grossly raised concentrations of serum calcium 
due to calcium binding to paraproteins (Annesley et al, 
1982; Spira et al, 1980; Soria et al, 1976; Jaffe & 
Mosher, 1979; Mazzaferri et al, 1978; Lingarde & 
Zetterval, 1973). "Correction" of the serum calcium in 
these cases, because of the associated hypoalbuminaemia, 
may be misleading rather than useful. The importance of 
such calcium-immunoglobulin binding in measurement of 
serum calcium in patients with myeloma or other 
dysproteinaemias is unknown. 
In a large study comparing total serum calcium 
with values adjusted according to several algorithms none 
of the adjustments significantly enhanced the correlation 
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with ionised calcium (Ladenson et al, 1978). Thus, 
caution should be exercised in the interpretation of 
adjusted serum calcium results, particularly when these 
appear to be out of keeping with the clinical condition 
of the patient. 
Recently there has been renewed interest in the 
measurement of dialysable (ionised and complexed) 
fraction of serum calcium as this measurement may be 
achieved by simple adaptation of the currently used 
continuous automated colorimetric techniques for 
measuring total calcium (Prince & Langton, 1985). The 
technique simply involves substituting a buffer for the 
acid used to dissociate calcium from protein in the 
standard automated assay. By excluding the protein bound 
fraction the major source of variability is eliminated. 
It is likely that this technique will become widely 
adopted in future. 
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Regulation of plasma calcium 
The concentration of ionised calcium in the ECF 
is regulated by homeostatic control mechanisms. These 
include changes in the three major calcium regulatory 
hormones, PTH, calcitonin and 1,25(OH)2D3, the major 
active metabolite of vitamin D. All three hormones alter 
fluxes of calcium between the ECF and other organs. The 
major movements of calcium to and from the extracellular 
fluid are accounted for by calcium fluxes to and from the 
gut, bone and kidney (Figure 1.2). 
Intestinal absorption 
Calcium entry into the body by intestinal 
absorption is dependent on both the dietary intake of 
calcium and the efficiency of gut absorption which occurs 
by both active and passive transport mechanisms. Active 
transport is a vitamin D dependent, high affinity, low 
capacity mechanism for transport of calcium against an 
electro-chemical gradient. This system is most vigorous 
in the duodenum and proximal jejunum. However, there is 
some evidence that active transport of calcium also 
occurs in the ileum, albeit at only about one third of 
the upper jejunal rate (Krejs et al, 1983). Passive 
diffusion of calcium is a relatively slow but 
non-saturable process. Thus the active transport 
., 
Major sites of action 
of PTH, calcitonin & vitamin D 
25mmol 
5mmol 
L 
Figure 1.2 Flux diagram to show the exchange of calcium 
between the ECF and the major organs involved in calcium 
homeostasis and the sites of action of the major calcium 
regulatory hormones. (From Kanis, 1982). 
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mechanism is resposible for most of the calciurg 
absorption at low intraluminal concentrations of calcium 
whereas the diffusional mechanism becomes relatively more 
important with high dietary intakes of calcium (Nordin, 
1976). Although transport of calcium is most efficient 
in duodenum and jejunum the intraluminal calcium 
concentrations and transit times at these sites are 
considerably less than those found in the ileum (Cramer, 
1965). For these reasons, on a normal diet the greatest 
proportion of intestinal calcium absorption is probably 
accomplished in the ileum, whereas on a low calcium diet 
fractionally more may be absorbed in duodenum and jejunum 
(Cramer, 1965). With a dietary intake of around 25mmol 
(lg) of calcium per day approximately 40% (10mmol) is 
absorbed. However, intestinal loss of calcium in 
intestinal secretions reduces the net absorption to 
approximately 5mmol per day (Kenny, 1981). 
1,25(0H)2D3 has an important role in the 
regulation of calcium absorption. During calcium 
deprivation more 25 hydroxy vitamin D (25(OH)D3) is 
converted to the active metabolite 1,25(OH)2D3 because of 
an increase in activity of 25(OH) D3 1-alpha hydroxylase. 
The activity of this enzyme, which is localised within 
the kidney, is stimulated both by hypocalcaemia and by 
the secondary hyperparathyroidism that ensues (Norman et 
al, 1982). 1,25(OH)2D3 directly stimulates active 
transport of calcium in the intestine thus limiting the 
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effects of dietary deprivation (Krejs et al, 1983). 
In chronic renal failure, damage to the renal 
parenchyma and hyperphosphataemia reduce the 1-alpha 
hydroxlase activity despite increased PTH and 
hypocalcaemia (Cheung et al, 1983). Thus, concentrations 
of 1,25(OH)2D3 and, consequently, intestinal absorption 
of calcium are low in patients with renal insufficiency 
(Chesney et al, 1983). Conversely, patients with 
sarcoidosis or other granulomatous disorders may have 
raised concentrations of 1,25(OH)2D3 due to the presence 
of 1-alpha hydroxlase activity within alveolar 
macrophages (Barbour et al, 1981; Kozeny et al, 1984). 
The resultant hyperabsorption of calcium leads to 
hypercalcaemia, which has been estimated to occur in 
between 2 and 10 per cent of patients with sarcoidosis, 
and hypercalciuria, and thus an increased risk of renal 
stone formation, in up to 40 per cent of these patients 
(Goldstein et al, 1971; Sandler et al, 1984). 
Calcium fluxes across bone 
As discussed above, bidirectional fluxes in the 
order of 5mmol per day occur in the normal adult skeleton 
due to bone formation and resorption (Figure 1.2). 
During hypocalcaemia parathyroid secretion of PTH is 
stimulated. One of the actions of this hormone is to 
stimulate osteoclastic bone resorption. In vitro the 
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presence of osteoblasts is required before PTH effects to 
stimulate osteoclast activity are observed (Chambers et 
al, 1985). Indeed, receptors for PTH and increased 
adenylate cyclase activity in response to this hormone 
are demonstrable in osteoblasts but not in osteoclasts 
(Wong et al, 1977). These findings suggest that the in 
vivo action of PTH to stimulate bone resorption may be 
indirect, probably mediated by osteoblasts (Rodan & 
Martin, 1981). in vitro PTH inhibits collagen synthesis 
but, in contrast, bone formation is stimulated by PTH in 
vivo (Kream, 1980; Parsons, 1979). Thus, despite an 
increase in bone turnover, in patients with primary 
hyperparathyroidism net bone calcium balance commonly 
remains close to zero (parsons, 1979). it is also 
interesting to note that intermittent treatment with PTH 
has been found, paradoxically, to have predominantly 
anabolic effects on trabecular bone (Reeve et al, 1980). 
As indicated above, radiocalcium kinetic studies 
suggest that calcium fluxes occur due to calcium exchange 
between ECF and accessible calcium deposits within bone 
without involving matrix turnover. These may be of only 
minor importance in terms of overall body calcium economy 
as there is probably no long-term net exchange of calcium 
by this route (Lauffenburger et al, 1977). However, 
there is some evidence, reviewed by Parfitt (1976), that 
rapid changes in the calcium flux between this pool and 
the ECF may occur in response to acute changes in PTH 
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concentrations. Thus the hypercalcaemic effect of PTH is 
more rapid (10-20mins) than can be accounted for by PTH 
effects on osteclastic bone resorption. It is thought 
that this effect may be mediated by osteocytes as these 
cell show very rapid structural and metabolic responses 
to PTH and, because of their canalicular processes, these 
cell have a very large surface area of bone contact. 
In response to a calcium load, either dietary or 
by intravenous infusion, there is an increase in 
calcitonin secretion by the C-cells which are mainly 
localised within the thyroid. Calcitonin is a 32 amino 
acid peptide hormone which has a direct action to rapidly 
suppress osteoclast activity and, particularly if bone 
turnover is increased, this results in net entry of 
calcium into bone and thus an effect to lower ECF calcium 
(MacIntyre, 1983). However the inhibitory effect of 
calcitonin is not sustained despite continued high 
concentrations of calcitonin probably due to the 
down-regulation of calcitonin receptors (Tashjian et al, 
1978). Thus the most likely physiological role for 
calcitonin is to attenuate the acute hypercalcaemic 
effects of dietary calcium loads rather than as a 
long-term regulator of the overall rate of bone 
resorption (Raisz, 1983). This hypothesis is supported 
by findings in rats that thyroidectomy results in an 
impairment of postprandial calcium uptake into bone and 
that this defect can be reversed by calcitonin 
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administration (VanderWiel & Talmage, 1981). 
Renal regulation of calcium homeostasis 
From an examination of the magnitude of the 
calcium fluxes shown in Figure 1.2 it can be seen that 
the kidney is likely to have important role in calcium 
homeostasis. Thus the kidney filters approximately 
250mmol of calcium daily of which about 98% is 
reabsorbed. Small changes in the efficiency of the 
reabsorptive process may, therefore, have a very much 
amplified effect on urinary calcium excretion. The two 
determinents of calcium excretion are first, the filtered 
load of calcium and second, the tubular reabsorption of 
calcium (% of filtered load). 
Unlike the reabsorption of solutes such as 
glucose or other ions such as phosphate it is not 
possible to define a renal tubular transport maximum for 
calcium as calcium excretion increases in a curvilinear 
fashion with increasing filtered load (Peacock & Nordin, 
1968; Peacock et al, 1969; Figure 1.3). It should be 
noted from this relationship that, even in the absence of 
any other regulatory influences, quite modest degrees of 
hypercalcaemia can be expected to increase urinary 
calcium excretion several fold whereas hypocalcaemia 
might cause the opposite effect. 
In vivo the sensitivity of this mechanism is 
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further enhanced by the effects of the calcium regulatory 
hormones, particularly PTH. In hyperparathyroidism 
(primary, secondary or tertiary) the efficiency of 
tubular calcium reabsorption is increased and thus for 
any given filtered load of calcium less calcium is 
excreted. The converse is true when PTH concentrations 
are reduced. 
From a consideration of calcium fluxes (Figure 
1.2) it is important to realise that, under steady-state 
conditions, urinary calcium excretion is equal to the net 
entry of calcium from gut and bone into the ECF and is 
therefore not determined by changes in renal tubular 
reabsorption of calcium. Thus, the effect of changes in 
PTH status is to change the set point of plasma calcium 
for any given net flux of calcium entering the ECF. 
Figure 1.3 shows the relationship between plasma calcium 
and fasting urinary calcium excretion for 
hypoparathyroid, euparathyroid and hyperparathyroid 
subjects. Throughput of calcium (calcium excretion) is 
similar for all three groups but the plasma calcium 
concentrations at which this level of excretion is 
achieved differ. Incidentally, it should be noted that 
the normal or near normal fasting calcium excretion in 
hyperparathyroid subjects indicates that net bone 
resorption is not greatly increased and, as a corollary, 
the renal effects of PTH are likely to be more important 
than the skeletal effects for sustaining hypercalcaemia 
CALCIUM EXCRETION 
LL' 
a E 
E 
W 
V 
0.2 
0.1 
0 
HYPO- Eli- HYPER- 
PARATHYROID 
i 
i 
i 
i 
i 
0 00 
c)cp 
0 
.e0 00 cg) dm    a 
'' 
"""0 0 0, """" 
  o0 0"" 
15 2.5 3.5 
Cap mmolli 
N 
Figure 1.3 Relationship between plasma calcium (which 
is proportional to the filtered load of calcium) and 
fasting urinary calcium excretion (CaE) in 
hypoparathyroid, euparathyroid and hyperparathyroid 
subjects. (From Kanis et al, 1982). 
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in hyperparathyroidism (discussed later). 
In normal subjects the secretion of PTH 
increases with a fall in the concentration of ionised 
calcium in the ECF and decreases during hypercalcaemia, 
thus conserving or enhancing excretion of calcium 
respectively. This remains true in primary 
hyperparathyroidism although the response curve is 
shifted so that higher calcium concentrations are 
required to reduce PTH secretion to a given rate (Rudberg 
et al, 1982; LeBoff et al, 1985). The rate of secretion 
of PTH is related to the cytosolic concentration of 
calcium in parathyroid cells which in turn is dependent 
on the ECF calcium concentration (LeBoff et al, 1985). 
In summary, three organs, gut, bone and kidney, 
are involved in the homeostatic regulation of plasma 
calcium. The calcium fluxes between these organs and the 
ECF are modulated by PTH, 1,25(OH)2D3 and calcitonin. 
Because of the very large fluxes of calcium handled by 
the kidney this organ appears to have a central role in 
calcium homeostasis. 
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DISORDERS OF BONE TURNOVER 
As discussed above, skeletal turnover in the 
adult results from the resorption'of bone by osteoclasts 
and its subsequent replacement with new bone formed by 
osteoblasts. Rarely, there may be abnormally low rates 
of turnover. Much more commonly, however, the rate of 
bone turnover is increased in skeletal disorders. This 
high turnover group of bone diseases includes Paget"s 
disease, bone disease in neoplasia and hyperparathyroid 
bone disease. In each of these disorders increased bone 
resorption is the most important underlying mechanism for 
the development of skeletal disease. Consequently, 
therapy aimed at inhibiting this excessive bone 
resorption, such as treatment with the diphosphonates, 
might be expected to have beneficial effects in these 
conditions. The following section will provide some 
background information on the three disorders (Paget"s 
disease, hypercalcaemia of malignancy and primary 
hyperparathyroidism) which form the main areas of study 
of this thesis. 
Paget's disease of bone 
Epidemiology 
Paget"s disease affects in the region of 5 per 
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cent of the population aged 55 or over in England and 
Wales with an area of peak prevalence in Lancashire of 
around 7 per cent (Barker, 1981). The prevalence is 
higher in men (6.2%) than in women (3.9%). The disease 
is also common in Western Europe, Australia, New Zealand 
and the USA but rare in Africa, the Middle East and Far 
East and, somewhat surprisingly, in Scandanavian 
countries. Migrants between areas of low and high 
prevalence have an intermediate prevalence of the disease 
suggesting the importance of both hereditary and 
environmental factors. The aetiology of the disease 
remains uncertain, but the findings of Rebel (1981) of 
viral inclusion bodies present within pagetic osteoclasts 
suggest that a slow viral cause is likely. 
Morphologically the viral inclusion bodies appear to be 
of the paramyxoviridae family which includes measles 
virus, respiratory syncytial virus and canine distemper 
virus (Singer & Mills, 1983, Harvey et al, 1982). 
Further distinction of the exact virus involved has not 
been possible using purely morphological criteria. 
Immunocytological studies have not produced consistent 
results although positive immunocytochemical staining for 
both measles and respiratory syncytial viruses have been 
reported (Mills et al, 1984). 
Epidemiologically, however, there seems little 
to suggest measles as the causative agent. Thus the 
incidence of measles in Scandinavia and in the U. K. is 
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similar whereas Paget"s disease is much more common in 
the U. K. (Harvey et al, 1982). Of interest is a recent 
study of the association of pet ownership and Paget's 
disease which found that previous ownership of dogs, but 
not of other pets or current dog ownership, was 
significantly higher in pagetic patients than in a 
control population of maturity onset diabetics 
(O'Driscoll & Anderson, 1985). If confirmed by further 
studies this would suggest that canine distemper virus 
could be the aetiological agent and this explanation 
might fit better with the known epidemiology of the 
disease. 
The viral inclusions are thought to be specific 
for Paget's disease and are not found, for example, in 
the osteoclasts of patients with hyperparathyroidism. 
Recently, however, similar inclusions have been seen in 
osteoclasts from patients with pycnodysostosis, a rare 
inherited generalised osteosclerotic condition, in whom 
there was no evidence of coexisting Paget's disease 
(Beneton et al, in press). If, as this finding suggests, 
such inclusion bodies are not specific for Paget's 
disease then it may be that their presence is the result 
of abnormal osteoclast function rather than the cause. 
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Clinical features 
Paget's disease is a patchy disorder which can 
affect virtually any bone but occurs most frequently in 
the pelvis (56% of affected individuals), spine (50%), 
femora (46%), tibiae (38%) and skull (28%; Schmorl, 
1932). The small bones of the hands and feet are rarely 
involved. The disease may be monostotic or, at the other 
extreme, may involve almost the entire skeleton. Changes 
are frequently asymmetrical with, for example, 
localisation within one hemipelvis. 
The majority of patients with the disorder are 
asymptomatic and the diagnosis is frequently made during 
the radiological or biochemical investigation of 
unrelated symptoms. The radiographic features of Paget"s 
disease are well known and, except for very early 
changes, are diagnostic. The earliest phase is the 
appearance of a slowly progressive wave of bone 
osteolysis which may be well seen in skull radiographs as 
an area of osteoporosis circumscripta. In long bones the 
disease tends to spread from one end to the other with a 
flame shaped lytic front which advances at a fairly 
constant rate of around lcm per annum (Doyle et al, 
1974). This lytic front is followed by a phase of 
predominant bone formation with the production of 
expanded, osteosclerotic coarsely trabeculated bone often 
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associated with bony deformity. In weight bearing long 
bones bowing occurs and transverse fissure fractures may 
be seen particularly on the convex aspect of the bowed 
bones. The deformity is not due to bone softening 
(pagetic bone is in fact extremely hard) but may be 
related to the loss of normal bony architecture and the 
very rapid rate of bone turnover. Osteoarthritic changes 
are commonly seen in adjacent joints and may result in 
part from deformity of joint contours and redistribution 
of mechanical loads. In later stages of skull 
involvement the vault becomes grossly thickened and the 
base may invaginate leading to platybasia which may 
result in brain stem compression or hydrocephalus. 
The major clinical complications of Paget"s 
disease are pain, fracture, neurological complications, 
joint disease and sarcoma. Pagetic pain occurs in only a 
minority of patients with the disorder and even then may 
be present in only a proportion of involved sites in an 
individual patient. The pain may arise from pagetic bone 
itself, from microfractures, from associated joint 
disease or from neurological complications. The bone 
pain of Paget"s disease is often described as burning or 
deep seated, is characteristically not relieved by rest 
and may be troublesome at night. In contrast, 
osteoarthritic pain tends to be exacerbated by movement 
and weight-bearing and to be relieved by rest. However, 
the distinction may be very difficult in some patients. 
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The mechanism of bone pain is unknown but possible causes 
include increased intramedullary pressure, stretching of 
the periosteum or the production of local factors such as 
prostaglandins (Russell et al, 1982). 
Pathological fracture through pagetic bone is 
reasonably common particularly with more advanced Paget"s 
disease as bony deformity gives rise to abnormal 
stresses. Usually fracture healing is normal but there 
is an increased incidence of delayed or non-union of up 
to 40% (Dove, 1980). 
Neurological complications arise mainly from 
skull or spinal involvement. Deafness, which usually has 
both conductive and neuronal components, is the commonest 
complication and is found in up to 50 per cent of 
patients with skull involvement (Hamdy, 1981). However, 
pagetic patients are usually elderly and deafness due to 
causes other than Paget's disease is also common in this 
age group. Vertebral Paget's may cause nerve root or 
spinal cord syndromes, either by direct compression of 
expanded bone or by a vascular steal effect of the highly 
vascular pagetic bone which shares the same blood supply 
as the spinal cord. That this latter mechanism may be 
important is suggested by the excellent and rapid results 
of the medical treatment of spinal cord syndrome (Douglas 
et al, 1981) which has been shown to rapidly reduce bone 
blood flow (Wootton et al, 1981; Walton et al, 1983). As 
a result of the greatly increased bone vascularity 
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cardiac output is increased and, rarely with very active 
disease, this can precipitate a high output cardiac 
failure. 
The incidence of osteogenic sarcoma is much 
higher in pagetic patients than in the elderly population 
as a whole but this usually rapidly fatal complication 
occurs in fewer than 1 per cent of patients (Poretta et 
al, 1957). 
Monitoring of pagetic activity 
The extent and activity of pagetic involvement 
may vary considerably between patients and in individual 
patients changes may occur either with progression of the 
disease (Woodard, 1959) or in response to specific 
treatment. Although changes in clinical and radiographic 
features are of importance they are not sufficiently 
sensitive to be of use in monitoring changes in the 
degree of pagetic activity. Fortunately, the indirect 
biochemical markers of turnover, serum alkaline 
phosphatase and urinary hydroxyproline excretion, provide 
objective and reliable reflections of skeletal turnover 
and thus of pagetic activity. 
Alkaline phosphatase is an enyme system of 
multiple molecular forms in which heterogeneity is partly 
due to posttranslational modifications (Fishman, 1974). 
It is produced by osteoblasts where it is predominantly 
ý.. 
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associated with cell membranes (posen et all 1977). It 
is released into the circulation in direct proportion to 
osteoblast numbers and therefore acts as a marker of bone 
formation (Russell et all 1981). The half-life of 
bone-derived alkaline phosphatase within the circulation 
is of the order of 1 to 2 days (Walton et all 1975b). 
Hydroxyproline, an amino acid found almost exclusively 
within collagen, is derived mainly from the breakdown of 
collagen and excreted in small peptides in the urine 
(Krane, 1980). In disorders of increased turnover such 
as Paget"s disease, by far the greatest proportion of 
collagen degradation occurs within the skeleton and, 
despite hepatic metabolism of over 50 per cent of 
hydroxyproline by the liver, urinary excretion of 
hydroxyproline provides a reasonable marker of the 
activity of bone resorption (Krane, 1980). 
Although at focal sites in pagetic bone either 
resorption or formation may predominate, overall these 
processes remain well matched and skeletal balance as a 
whole remains close to zero. This balance is well 
demonstrated by the close correlation between serum 
alkaline phosphatase (formation) and urinary 
hydroxyproline (resorption) shown in Figure 1.1. This 
close correlation of these two independent biochemical 
measurements suggests that both alkaline phosphatase and 
urinary hydroxyproline excretion are valid markers of 
bone turnover. 
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Neither of these markers is entirely specific. 
Alkaline phosphatase is also derived from other sources, 
principally the liver, and serum values may be grossly 
increased in cases of biliary obstruction whereas 
hydroxyproline is released from non-skeletal as well as 
skeletal collagen degradation. Non-skeletal sources of 
these markers are important when the rate of bone 
turnover is low or normal but, as discussed in Chapter 3, 
these become proportionately less important with 
increasing rates of turnover. In addition, a small 
proportion of skeletal hydroxyproline (in the order of 10 
per cent) is derived from the breakdown of newly 
synthesised collagen or procollagen to be excreted in the 
urine as non-dialysable peptides and thus this fraction 
may have a role as a marker of formation rather than of 
resorption (Bienkowski et al, 1978; Krane, 1980). 
Despite these reservations, these markers are extremely 
useful for monitoring pagetic activity. Excretion of 
hydroxyproline may be expressed as a ratio to urinary 
creatinine (OHP/Cr). Measurement of OHP/Cr in fasting 
urine samples has been found to correlate well with 
OHP/Cr in 24 hour urinary specimens (Figure 1.4) and 
provides a more convenient index of bone resorption 
(Russell et al, 1981). The treatment of Paget"s disease 
will be reviewed subsequently. 
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Figure 1.4 Relationship between 
hydroxyproline/creatinine ratio (OHP/Cr) in a fasting 
urine specimen and OHP/Cr in a 24 hour collection in 
normals and patients with various disorders of bone 
turnover. (From Douglas, 1983). 
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Skeletal complications of malignancy 
Malignant disorders are extremely heterogeneous 
in virtually all aspects of their behaviour including 
their effects on the skeleton. For example, gastric 
cancer rarely metastasises to bone or causes 
hypercalcaemia. At the other extreme, carcinomas arising 
from breast or prostate almost invariably spread to bone 
at some stage of the disease. Carcinoma of breast most 
commonly induces predominantly lytic bone lesions and is 
frequently the cause of hypercalcaemia whereas prostatic 
carcinoma is associated with osteosclerosis and 
hypercalcaemia is rare. yet other solid tumours, notably 
squamous carcinoma of the lung, hypernephromas and 
squamous carcinoma of the head and neck, may induce 
generalised bone loss and hypercalcaemia by humoral 
mechanisms not involving skeletal metastasis (Myers, 
1960). Haematological malignancies, in particular 
multiple myeloma, are frequent causes of skeletal 
complications and hypercalcaemia (Kyle, 1975; MRC, 1973). 
This is perhaps not surprising in view of the 
juxtaposition of trabecular bone and the bone marrow and 
the functional interrelationships that exist between the 
two tissues. Thus there is considerable heterogeneity 
and there can be no unifying hypothesis for the skeletal 
effects of malignant disorders. It is likely that not 
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only do the mechanisms responsible for skeletal effects 
differ for the various forms of malignancy but that even 
within one diagnostic group more than one factor will be 
operating. The clinical effects of skeletal involvement 
of malignancy will be discussed following a review of the 
known mechanisms of bone loss in these disorders. 
Mechanisms of bone loss and hypercalcaemia in malignancy 
When considering mechanisms of hypercalcaemia 
and bone loss in malignancy it is useful to divide 
patients into three major subgroups. These are solid 
tumours without bony metastases (around 10%), solid 
tumours with metastases (70%) and haematological 
malignancies (20%; Myers, 1960). Most information is 
available with regard to the mechanisms in haematological 
malignancies, and these will be reviewed first. 
Myeloma is by far the most frequent 
haematological cause of hypercalcaemia. Hypercalcaemia 
is present in between 15 and 30 per cent of myeloma 
patients at the time of presentation and probably occurs 
in over 50 per cent of patients at some point during the 
course of the disease (Kyle, 1975). Radiographic 
evidence of increased bone lysis is present in over 80 
per cent of cases (MRC, 1973; Kyle, 1975). Over the last 
13 years there has been much work to implicate the 
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release of an osteoclast activating factor (OAF) from 
myeloma plasma cells in the production of bone lysis. 
OAF was discovered as a bone resorbing 
lymphokine in 1972 by Horton and colleagues (1972) who 
were investigating the cause of periodontal bone lysis. 
Originally the term was used to describe bone resorbing 
activity derived from cultures of peripheral blood 
leukocytes activated by the mitogen, phytohaemagglutanin 
A, or by other lectins (Horton et al, 1972). 
Subsequently Mundy and co-workers (1974a, b) were able to 
demonstrate the release of a similar factor from marrow 
aspirate cells taken from patients with myeloma and also 
from a human myeloma cell line in culture. Other 
lymphoid cell lines are known to be capable of OAF 
production and OAF activity has been demonstrated in 
various lymphomas, including Burkitt"s lymphoma, as well 
as in association with lymphosarcoma (Mundy et al, 1974b, 
1978). In myeloma there is a close relationship between 
estimates of the total production of OAF and the extent 
of skeletal involvement, and specific treatment of the 
myeloma is associated with a significant decrease in OAF 
production (Durie et al, 1981). 
The production of OAF by lymphocytes is 
dependent on the synthesis of prostaglandins by monocytes 
which may therefore have a regulatory role in OAF 
synthesis (yoneda & Mundy, 1979a, b). Although in vitro 
OAF synthesis can be inhibited by cyclo-oxygenase 
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inhibitors such as indomethacin in vivo these drugs are 
ineffective in reducing hypercalcaemia in most patients. 
In contrast, corticosteroids at physiological 
concentrations have no effect on OAF production in vitro 
although both in vitro and in vivo they inhibit the 
effects of OAF on bone resorption (Strumpf et al, 1978) 
and are of use in treating hypercalcaemia in myeloma. 
It is now apparent that there are different OAFS 
produced by T cells and B cells and it is probably more 
appropriate either to consider an OAF "family" of 
lymphokines or to use the term OAF as a descriptive label 
for several otherwise unrelated factors that stimulate 
osteoclasts (Mundy, 1984a). Recent studies suggest that 
T cell OAF may be related to lymphotoxin, the structure 
of which has been elucidated. Colony stimulating factor 
is a further lymphocyte product which appears to enhance 
bone resorption by causing increased recruitment or 
proliferation of osteoclast progenitors rather than by 
direct activation of pre-existing osteoclasts (Mundy et 
al, 1985). In addition, cells of the monocyte/macrophage 
lineage may also produce OAF-like substances which are 
probably related to interleukin-1 (IL-1). IL-1 can 
stimulate bone resorption by at least two mechanisms. It 
increases synthesis of prostaglandins which induce 
osteoclastic bone resorption, but also stimulates 
osteoclasts independently of prostaglandin synthesis 
(Gowen et al, 1983). 
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It is of interest that in human T-cell leukaemia 
associated with the virus HTLV-1, hypercalcaemia and 
destructive bone lesions can develop suggesting that 
production of bone resorbing factors may be enhanced by 
the presence of tumour virus (Grossman et al, 1981). 
Interferon gamma has the capacity to inhibit cytokine 
stimulated bone resorption (but not resorption stimulated 
by either PTH or 1,25(OH)2D3) and thus may be a further 
regulator of resorption (Gowen et al, 1986). In some 
patients with non-Hodgkin's lymphoma hypercalcaemia 
appears to be mediated by increased concentrations of 
1,25(OH)2D3 which is presumably a result of synthesis by 
the lymphoma cells (Breslau et al, 1984). 
There is even less certainty with regard to the 
mechanisms that produce excess bone resorption in 
patients with solid tumours. Although the osteoclast is 
probably the cell primarily responsible for bone 
resorption other cells may be involved, and both tumour 
cells and monocytes may be capable of bone resorption 
(Eilon & Mundy, 1978; Mundy et al, 1977). Tumours can 
produce local factors such as prostaglandins and 
transforming growth factors (TGFs) which stimulate 
osteoclasts. Monocytes and activated lymphocytes 
associated with the tumour may produce IL-1 and there is 
scope for many complex cellular interactions (Mundy, 
1984b). 
Much interest has centred around the 
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non-metastatic effects of tumours to produce 
hypercalcaemia and increased bone resorption. This 
syndrome of humoral hypercalcaemia was initially thought 
to be due to ectopic production of PTH by tumour tissue. 
However, tumour PTH production has not been convincingly 
demonstrated (Skrabenek et al, 1980) and techniques for 
demonstrating PTH messenger RNA have failed to detect 
substantial tumour synthesis of PTH (Simpson et al, 
1983). Prostaglandins have also been proposed as 
possible mediators of the humoral effect as certain 
prostaglandins, particularly PGE2 and prostacyclin 
(PGI2), have been found to be potent stimulators of bone 
resorption (Martin & partridge, 1980). However, 
breakdown of prostaglandins to inactive metabolites, 
particularly within the pulmonary circulation, occurs 
very rapidly with almost complete inactivation in a 
single transit (Piper et al, 1970). In a small minority 
of patients treatment with potent inhibitors of 
prostaglandin synthesis, such as indomethacin, may have a 
significant hypocalcaemic effect (Seyberth et al, 1975). 
However, these agents do not reduce serum calcium in the 
majority of patients with malignant hypercalcaemia. 
Furthermore it has proved difficult to increase serum 
calcium by infusing prostaglandins into experimental 
animals (Robinson & Parsons, 1974). Thus it is likely 
that prostaglandins do not have a major role in the 
mechanism of humoral hypercalcaemia of malignancy 
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although they may act as important local mediators of 
bone resorption. 
More recently, two other groups of factors have 
been suggested to account for the humoral effects on 
bone. These are the "PTH-like" factors and the TGFs. A 
PTH-like factor has been isolated from a human renal 
adenocarcinoma which appeared to bind to PTH receptors 
although not cross-reacting with antibodies to PTH 
(Strewler et al, 1983). Like PTH this factor increased 
renal tubular cyclic AMP production. Such a mechanism 
may account for the observation that the majority of 
patients with hypercalcaemia of malignancy have increased 
excretion of nephrogenous CAMP despite low plasma 
concentrations of iPTH (Stewart et al, 1980; Rude et al, 
1981). It might also help to explain the occurrence of 
phosphaturia and possibly the increased renal tubular 
reabsorption of calcium that occurs in some patients 
(Ralston et al, 1984). That this latter effect may be an 
important mechanism of hypercalcaemia in a proportion of 
patients with solid tumours is suggested by our studies 
of patients with breast cancer in whom a tendency to 
increased renal tubular reabsorption of calcium was 
observed despite continued saline treatment (Percival et 
al, 1985). However, the adequacy of rehydration, which 
has important effects on renal tubular reabsorption of 
calcium, is very difficult to assess in these patients, 
particularly while calcium remains increased. Such 
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uncertainties may be lessened by reducing serum calcium 
using specific inhibitors of bone resorption. For this 
reason I have studied renal tubular reabsorption of 
calcium in patients with solid tumours or haematological 
malignancies both before and after treatment of 
hypercalcaemia with diphosphonates (Chapter 5). 
TGFs of the alpha and beta type are produced by 
a variety of experimental tumours in vitro (Ibbotson et 
al, 1985). Alpha TGF is closely related to epidermal 
growth factor and competes for the same receptor. Beta 
TGF is produced by both normal and tumour tissues and 
reacts with its own distinct receptor. These factors may 
act synergistically to stimulate bone resorption by 
either endocrine or paracrine effects (Ralston et al, 
1984). 
Thus although the precise nature of 
bone-resorbing factors in malignant disorders has not 
been fully elucidated there is rapid progress in this 
field. Improved understanding of the intercellular 
mechanisms might lead to more specific therapy for the 
treatment or prevention of skeletal complications of 
malignancy including malignant hypercalcaemia. 
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Clinical features of skeletal involvement in malignancy 
The important clinical consequences of skeletal 
involvement in malignancy are bone pain, fracture and 
hypercalcaemia. Bone pain is often severe and 
intractable and adequate analgesia is often only achieved 
with the use of opiates. Several mechanisms have been 
proposed to account for the pain including increased 
intraosseous pressure, periosteal involvement, production 
of local factors such as prostaglandins, nerve entrapment 
and overt or occult fracture. 
In patients with multiple myeloma, in whom bone 
pain is common (Bergsagel, 1977), the skull is rarely a 
site for bone pain despite the frequent occurrence of 
osteolytic foci at that site (Whitelaw, 1963; Snapper et 
al, 1953) suggesting that tumour pressure is an unlikely 
mechanism. Radiographic abnormalities are present in 
only about 50 per cent of sites of bone pain in myeloma 
patients (Whitelaw, 1963), but it is of interest that, in 
a small study, increased uptake of bone seeking isotopes 
has been noted at painful sites (Charkes et al, 1972). 
This finding was interpreted as evidence of bone 
infraction. Overt pathological fracture is very common 
in myeloma, being noted in 60 per cent of the 824 
patients reviewed by Kyle (1975). The spine is the site 
most frequently involved, with consequent pain, loss of 
Chapter 1 INTRODUCTION Page 45 
height and the development of kyphosis. Other common 
fracture sites are the ribs and the proximal ends of 
humerus and femur. 
Studies of fracture incidence in association 
with solid tumours have shown this complication to be 
surprisingly uncommon. Fracture occurred in 6 per cent 
of autopsied patients with skeletal metastases reviewed 
by Johnston (1970), but Galasko (1972) reported 
pathological fracture in less than 1 per cent of patients 
with advanced carcinoma. Carcinoma of the breast 
accounts for approximately 60 per cent of fractures 
associated with solid tumours (Galasko, 1974; Fitts et 
al, 1953). Once fracture of a long bone has occurred it 
may be very difficult to treat as the surrounding bone 
may be grossly abnormal, making fixation difficult, and 
fracture healing may be impaired particularly in femoral 
transcervical or subcapital fractures (Galasko, 1974). 
Pathological fracture is often considered as a near 
terminal event in patients with malignant disease. 
However, almost half the patients survive for at least 
one year from the time of first fracture (Galasko, 1974) 
and appropriate orthopaedic surgery may be very valuable 
in reducing morbidity. 
The clinical effects of hypercalcaemia in 
general will be considered following an account of 
primary hyperparathyroidism, which is the most common 
cause of hypercalcaemia amongst the general population 
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(Heath et al, 1980; Mundy et al, 1980). 
Primary hyperparathyroidism 
Primary hyperparathyroidism is a common 
condition which is characterised by chronic 
hypercalcaemia. It is primarily a disease of 
postmenopausal women although both sexes and all age 
groups may be affected (Heath et al, 1980; Mundy et al, 
1980). Surveys of the incidence of primary 
hyperparathyroidism show an apparent increase over the 
last 10 to 15 years. This phenomenon has generally been 
attributed to the routine use of multi-channel serum 
autoanalysers for patient screening. Thus, in a study of 
the resident population of Rochester, Minnesota between 
1965 and 1976, Heath and colleagues (1980) reported the 
apparent incidence during the initial 9.5 years to be 
only around 8 per 100,000 population per year. 
Immediately following the introduction of routine serum 
calcium measurement in 1974 the apparent incidence rose 
to 51 per 100,000 per year. This was presumed to be due 
to a catch-up effect whereby patients who had the disease 
for in excess of one year, but who may not have had 
specific symptoms, were diagnosed on routine biochemical 
screening. Subsequently, this effect appears to have 
abated as the average annual incidence fell to 27.7 per 
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100,000 for the last 18 months of this study (Heath et 
al, 1980). This incidence is similar to that reported by 
Mundy and colleagues (1980) for the population of 
Birmingham, England of 22.2 per 100,000 per year. From 
such estimates of incidence it can be inferred that 
approximately 10,000 new cases of primary 
'hyperparathyroidism will be diagnosed in England each 
year (Anonymous, 1980). Other studies have produced even 
higher incidence figures for this disease, ranging fom 50 
per 100,000 (Haff et al, 1970) to 100 per 100,000 per 
year (Boonstra & Jackson, 1970). 
With the apparent change in incidence there has 
been a marked change in the mode of presentation of this 
disease. Whereas, before 1975 renal stones or 
nephrocalcinosis were the most common presenting features 
and bone disease was also relatively common (McGeown, 
1969; Watson 1974) in more recent studies the majority of 
patients have had no symptoms which can be related to 
primary hyperparathyroidism and bone disease has become 
distictly uncommon (Mundy et all 1980; Heath et all 
1980). This could reflect a true change in the nature of 
the disorder. However, it is more likely that the 
improved ability to diagnose mild, more benign forms of 
primary hyperparathyroidism together with earlier 
diagnosis and treatment of the subpopulation of patients 
that would have developed specific symptoms is 
responsible for the observed change in the patterns of 
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clinical presentation. 
Many of the symptoms of primary 
hyperparathyroidism result from the effects of 
hypercalcaemia and are thus similar to the symptoms in 
other forms of hypercalcaemia including hypercalcaemia of 
malignancy. The clinical effects of hypercalcaemia will 
be discussed below. 
The frequency with which asymptomatic patients 
with primary hyperparathyroidism are being diagnosed 
raises several important questions regarding the 
indications for treatment of this condition. This 
question will be addressed later in this chapter. The 
possible role of active medical treatment of primary 
hyperparathyroidism will also be considered. It is 
pertinent, however, to first review the mechanisms of 
hypercalcaemia in primary hyperparathyroidism as an 
understanding of these is likely to lead to a more 
rational approach towards medical treatment. 
Mechanisms of hypercalcaemia in primary 
hyperparathyroidism 
It was noted in the section on regulation of 
plasma calcium that PTH has actions on all three major 
organs involved in calcium homeostasis (i. e. gut, bone 
and kidney). The importance of the contributions of each 
of these mechanisms to the development of hypercalcaemia 
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in primary hyperparathyroidism will now be discussed. 
Studies which have measured serum concentrations 
of 1,25(OH)2D3 and intestinal absorption of calcium in 
patients with primary hyperparathyroidism have found 
these to be increased (Peacock 1975, Broadus et al, 
1980). However, there is considerable interindividual 
variation and in a proportion of patients these indices 
are normal. Thus, calcium absorption, as judged by the 
increase in urinary calcium excretion following an oral 
calcium load, was found to be normal in 20 of 50 
unselected patients with primary hyperparathyroidism 
studied by Broadus and colleagues (1980). This index of 
calcium absorption correlated strongly and positively 
with concentrations of 1,25(OH)2D3 in these patients. 
Thus, they divided their patients into a "non-absorptive" 
group (normal calcium absorption) in which the mean value 
for 1,25(OH) 
2D3 was within the normal range, and an 
"absorptive" group in which 1,25(OH)2D3 concentrations 
were markedly increased. 24 hour urinary excretion of 
calcium on a lg calcium diet was normal or near normal in 
the "non-absorptive" group and was consistently high in 
the "absorptive" group. In spite of these differences 
there were no significant differences in serum calcium, 
phosphate or iPTH between the two groups. These findings 
indicate that, although intestinal calcium absorption is 
increased in a proportion of patients, hypercalcaemia can 
exist in patients with primary hyperparathyroidism in the 
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absence of any increase in calcium absorption. Even in 
patients in whom intestinal calcium absorption is 
increased, this mechanism alone would be unlikely to be 
sufficient to cause hypercalcaemia if other homeostatic 
mechanisms for regulating plasma calcium remained intact. 
Both PTH and 1,25(OH)2D3 remain sensitive to 
variations in dietary intake of calcium which, partly as 
a consequence, have little effect on the serum calcium in 
patients with primary hyperparathyroidism (Insogna et al, 
1985). 
The skeletal effects of PTH in patients with 
primary hyperparathyroidism, like those on the gut, are 
variable. As indicated above PTH stimulates both bone 
formation and bone resorption in vivo (Parsons, 1979). 
Hyperparathyroid patients in general have increased bone 
turnover, as judged by increased serum alkaline 
phosphatase although in most patients this index remains 
within the normal reference range (Dent, 1962; Marcus et 
al, 1984). Most patients with primary 
hyperparathyroidism are postmenopausal women in which 
group, even in the absence of parathyroid disease, 
osteoporosis is common (Melton & Riggs, 1983; Lewis, 
1981). Primary hyperparathyroidism appears to be a 
further risk factor for the development of osteoporosis 
as bone loss, predominantly from the axial skeleton, is 
accelerated (Seeman et al, 1982). However, although 
important for skeletal integrety, reduction in bone mass 
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occurs over a prolonged period and the short-term net 
losses of calcium, as judged by fasting urinary calcium 
excretion, remain within or just above the normal range 
in the majority of patients (Broadus et al, 1980; Peacock 
et al, 1969; also see Figure 1.3). Thus, although net 
bone loss may contribute to the development of 
hypercalcaemia in some patients, it seems unlikely that, 
overall, this is an important mechanism. 
At least theoretically the renal effects of PTH, 
in contrast to its effects on gut and bone, appear to be 
necessary for the maintenance of hypercalcaemia in 
primary hyperparathyroidism (peacock et al, 1969). The 
importance of this effect may be illustrated by a 
hypothetical example. Consider a patient in whom both 
the net fluxes of calcium entering the ECF (or calcium 
throughput) and the plasma calcium concentration were 
normal (around 5mmol/24h and 2.4mmol/l respectively). If 
this patient developed only the renal tubular effects of 
primary hyperparathyroidism initially the urinary calcium 
losses would fall to much less than 5mmol/24h (see Figure 
1.3). Consequently, the plasma calcium concentration, 
and thus the filtered calcium load, would rise. This 
process would stop once the filtered load had risen 
sufficiently to ensure that once again the net calcium 
entry into the ECF from gut and bone were matched by the 
urinary calcium losses and thus a new steady state was 
reached. Thus the renal tubular effect of PTH alone is 
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sufficient to produce hypercalcaemia. If, in addition, 
net entry of calcium into the ECF from gut and/or bone 
(calcium throughput) also occurred this would compound 
the hypercalcaemia by increasing the filtered load of 
calcium (and thus plasma calcium) required to reach a new 
steady state. However, because of the shape of the 
calcium excretion curve with increasing filtered load 
(Figure 1.3), the effects of increased calcium throughput 
are likely to be relatively minor in comparison with the 
effects of increased renal tubular reabsorption of 
calcium, at least for the majority of patients with 
primary hyperparathyroidism (Peacock et al, 1969). 
This concept of the primary importance of the 
renal mechanism for maintaining hypercalcaemia is 
supported by the relative failure of treatments aimed at 
reducing either intestinal calcium absorption or bone 
resorption to normalise serum calcium (see below). 
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Clinical effects of hypercalcaemia 
Although primary hyperparathyroidism is the 
commonest cause of hypercalcaemia among the population as 
a whole (Heath et al, 1980), within hospital populations 
malignancy is a more frequent cause (Fisken et al, 1981). 
As both primary hyperparathyroidism and maligant 
disorders are common it is not surprising that these 
conditions occasionally coexist (Francis et al, 1982; 
Stone et al, 1982). Patients with hypercalcaemia of 
malignancy usually have clinical or laboratory evidence 
of their neoplasia. However, the differential diagnosis 
between these two conditions, and other less common forms 
of hypercalcaemia, can be difficult. (For review see 
Habener & Potts, 1979). 
Hypercalcaemia, regardless of aetiology, is 
associated with a complex range of largely nonspecific 
symptoms which are mainly the result of effects on the 
kidney, nervous system and gastrointestinal tract. 
Although in health the kidney has an important role in 
the regulation of the concentration of calcium in the ECF 
(see above), hypercalcaemia itself may offset this 
sparing mechanism by its renal effects (Lins, 1979; 
Benabe & Martinez-Maldonado, 1978). Thus, hypercalcaemia 
impairs the ability to form concentrated urine, and 
experimentally a renal resistance to the action of 
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vasopressin has been found (Levi et al, 1983). 
Clinically this results in excess thirst, polyuria, 
polydipsia and clinical signs of dehydration. The fall 
in ECF volume is associated with a reduced glomerular 
filtration rate (GFR) as is hypercalcaemia itself, which 
may induce calcium precipitation particularly in the 
renal medulla. The ability of the kidney to eliminate 
large loads of calcium falls in proportion to the fall in 
GFR. 
A further consequence of volume depletion is an 
effect to increase the renal tubular reabsorption of 
calcium. There is a common co-transport mechanism for 
sodium and calcium in the proximal convoluted tubule, and 
when sodium delivery is decreased a greater fraction of 
both sodium and calcium is reabsorbed. In dehydrated 
patients this effect to increase renal tubular 
reabsorption of calcium will tend to offset the renal 
sparing effect of a homeostatic suppression of PTH 
secretion. 
Differences in the underlying mechanisms of 
hypercalcaemia are important determinants of the natural 
history of this abnormality. Thus, as discussed above, 
in primary hyperparathyroidism hypercalcaemia is 
sustained largely due to the PTH-induced increase in 
tubular calcium reabsorption. The ability of the kidney 
to eliminate more calcium in response to an increase in 
the filtered load (a function of plasma calcium) is 
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preserved (peacock et al, 1969). Thus, these patients 
generally remain in a steady state and serum calcium may 
remain elevated, but largely unchanged, for many years. 
In contrast, where fluxes of calcium into the ECF are 
very large, as in many cases of malignant hypercalcaemia, 
the impaired renal handling of calcium due to the 
mechanisms discussed above will produce a non-steady 
state situation with a progressive increase in the 
concentration of ECF calcium (Parfitt, 1979). Thus 
patients with primary hyperparathyroidism often report 
mild hypercalcaemic symptoms lasting for many months or 
years, but in contrast those with malignant 
hypercalcaemia usually have an acute onset of symptoms 
which are rapidly progressive and become severe. 
Neurological complications range from inability 
to concentrate or mild confusion to coma. Occasionally 
patients present with altered behaviour or psychosis and 
rarely focal neurological signs may be produced. The 
severity of these complications does not correlate well 
with the concentration of plasma calcium and other 
factors, such as the rate of rise of the calcium, may be 
important. Reversal of these neurological sequelae may 
take several days after normalisation of plasma calcium. 
Gastrointestinal effects of hypercalcaemia 
include anorexia, nausea, vomiting and constipation. It 
is probable that these are partly mediated by impairment 
of autonomic function. Pancreatitis is an occasional, 
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but serious, complication. Its aetiology is 
multifactorial, but probably includes dehydration, 
altered coagulation, activation of trypsinogen and focal 
deposition of calcium within pancreatic tissue. 
Other clinical changes include 
electrocardiographic changes with shortening of the Q-T 
interval and deposition of calcium in the limbus of the 
eye, particularly when the hypercalcaemia has been 
long-standing. 
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DIPHOSPHONATES IN THE TREATMENT OF DISORDERS OF BONE 
TURNOVER 
Diphosphonates, calcitonin and mithramycin are 
each inhibitors of bone resorption and each of these 
drugs has been used both in the treatment of Paget's 
disease and in hypercalcaemia of malignancy. Other forms 
of therapy may also be of value in the treatment of 
skeletal disorders. However, in view of the potential 
importance of the diphosphonates as therapeutic agents 
and their central role in the studies reported in this 
thesis it is appropriate to consider this group of drugs 
in some detail here. In the following section the 
discussion of treatment of skeletal disorders will mainly 
centre around the use of diphosphonates, although mention 
will be made of the role of other treatments. 
DIPHOSPHONATES 
Historical perspective 
Extensive studies on inorganic pyrophosphate 
have formed the basis of the development of the 
diphosphonates over the past 20 years (Russell & Fleisch, 
1976; Fleisch, 1983; Fleisch & Felix, 1979). The theory 
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put forward originally was that constituents of the 
inorganic matrix of bone played a crucial role in the 
process of calcification by inducing calcium phosphate 
precipitation (Neuman & Neuman, 1958). Thus, it became 
important to explain why the extracellular matrix of soft 
tissues does not normally mineralise. From this it was 
postulated that inhibitors of calcification might exist 
which would be broken down locally at sites of 
mineralisation. 
In the search for factors which might counteract 
the initiation of the crystal phase in bone and cartilage 
matrix, a serum factor was found to inhibit calcium 
phosphate precipitation from solution (Fleisch & Neuman, 
1961). The activity of this factor could be destroyed, 
in part, by alkaline phosphatase which was subsequently 
shown to possess pyrophosphatase activity. Urine was 
found to contain even higher amounts of crystal 
inhibitory activity than serum, and using this source the 
factor was identified as inorganic pyrophosphate (PPi), a 
compound not previously isolated from biological fluids 
(Fleisch & Bisaz, 1962a). Subsequently, PPi was isolated 
from serum (Fleisch & Bisaz, 1962b), synovial fluid 
(Russell et al, 1970) and saliva (Hausmann et al, 1970). 
Further studies on the physico-chemical effects of PPi 
revealed that inhibition of calcium phosphate 
precipitation occurred both in solution and in the solid 
phase of hydroxyapatite crystals (Hansen et al, 1976). 
Chapter 1 INTRODUCTION Page 59 
Also the conversion of amorphous calcium phosphate into 
crystalline hydroxyapatite was slowed by PPi (Fleisch et 
al, 1968), although it had no effect on the amorphous 
phase. PPi was further found to inhibit dissolution of 
hydroxyapatite crystals (Fleisch et al, 1966a). These 
effects appear to be related to the high affinity of PPi 
for hydroxyapatite (Jung et al, 1973). 
The pronounced effects of PPi on calcium 
phosphates in vitro at concentrations found in biological 
fluids suggested that it could be of significance in both 
normal and disease states. PPi might protect soft 
tissues from mineralisation, and in bone it could 
influence the calcification process as well as the 
distribution of the mineral phase (Russell & Fleisch, 
1976). Parenteral, but not oral, administration of PPi 
was found to inhibit the calcification of tissues in vivo 
(Fleisch et al, 1966b; Schibler et al, 1968; Schibler & 
Fleisch, 1966), but no effect was observed on the 
calcification or resorption of bone. Further studies of 
PPi effects were hampered by the finding that PPi was not 
absorbed intact from the gut and was rapidly destroyed 
enzymatically when given parenterally. This led to a 
search for PPi analogues which would be stable to both 
chemical and enzymatic degradation and effective when 
given by mouth. Among the analogues which turned out to 
be effective were the diphosphonates, some of which had 
previously been synthesised and studied as potential 
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additives to detergents. A large number of 
diphosphonates have now been synthesised and a few of 
these have been used clinically. These include 
dichloromethylene diphosphonate (clodronate; C12MDP), 
ethane-l-hydroxy-1, l diphosphonate (etidronate; EHDP; 
Didronel), aminopropylidine diphosphonate (APD), 
aminohexylidine diphosphonate (AHDP) and aminobutylidine 
diphosphonate (ABUDP). The structures of the 
diphosphonates studied in this thesis and of PPi are 
shown in Figure 1.5. 
Effects of diphosphonates in experimental systems 
Like PPi, the diphosphonates inhibit 
precipitation of calcium and phosphate from solution 
(Fleisch et all 1970), and antagonise the transformation 
of the amorphous form of calcium phosphate into 
hydroxyapatite (Francis, 1969). They retard aggregation 
of hydroxyapatite crystals (Hansen et all 1976) and 
disaggregate crystal clusters (Bisaz et all 1976). They 
also delay the dissolution of hydroxyapatite crystals in 
vitro (Jung et all 1973). These properties of 
diphosphonates probably relate to their adsorption onto 
the surfaces of hydroxyapatite crystals for which they 
have a high affinity (Jung et all 1973). In vivo 
diphosphonates inhibit a variety of forms of 
experimentally induced soft tissue calcification 
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Figure 1.5 Molecular structures of inorganic 
pyrophosphate and of the three diphosphonates studied in 
this thesis. 
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(Fleisch, 1983) and there is a close relationship between 
these in vivo effects and the ability of the various 
diphosphonates in vitro to inhibit crystal formation and 
growth (Fleisch et al, 1970). This suggests that the in 
vivo actions might be primarily explained by 
physico-chemical mechanisms. Diphosphonates possessing a 
1-alpha hydroxy group, such as etidronate, appear to be 
the most effective inhibitors of mineralisation. 
However, unlike PPi, several diphosphonates, 
including etidronate, prevent the normal calcification of 
bone and cartilage (Rosenblum, 1974; Russell et al, 
1973). The impaired mineralisation does not appear to be 
related to abnormalities in vitamin D metabolism as 
production of 1,25(OH) 2D3 in experimental animals 
is 
normal or increased unless very large doses of etidronate 
are given (Baxter et al, 1974). Such doses are 
associated with hypercalcaemia in growing animals (Gasser 
et al, 1972) which acting both directly and through 
reduced secretion of PTH would inhibit 1-alpha 
hydroxylation of 25(OH)D3. Of the diphosphonates in 
clinical use, etidronate is by far the most potent 
inhibitor of mineralisation in vivo. For example, 
following subcutaneous administration to rats, APD is 
about 50 times less potent than etidronate in this 
respect (Reitsma et al, 1980). Such differences in 
relative potency of various diphosphonates to inhibit 
mineralisation may have important implications for their 
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clinical use which are examined in this thesis (Chapters 
4,5 and 6). 
Experiments in vitro, for example in cultured 
calvaria, indicate that various diphosphonates inhibit 
basal bone resorption as well as resorption stimulated by 
a variety of agents, including PTH, prostaglandins and 
1,25(OH)2D3 (Fleisch et al, 1969; Fleisch, 1983; Gebauer 
& Fleisch, 1980). When diphosphonates are administered 
to growing animals, remodelling of long bones is blocked 
in the metaphysis leading to a club shaped appearance 
(Schenk et al, 1973). The inhibition of bone resorption 
gives rise to appearances which resemble osteopetrosis 
(Reynolds et al, 1973). This effect, seen with 
clodronate, APD and other alkyl-amino compounds, is less 
marked with etidronate (Schenk et al, 1973; Trechsel et 
al 1977; Reitsma, 1982). Although the architectural 
consequences are similar in animals given etidronate, the 
amount of mineralised bone does not increase since, at 
these doses, inhibition of mineralisation as well as 
inhibition of bone resorption are prominent features 
(Schenk et al, 1973). clodronate, APD and AHDP, unlike 
etidronate, have very little effect on skeletal 
mineralisation (Flora et al, 1980; Reitsma et al, 1980; 
Felix et al, 1982). 
There is little correlation between the activity 
of diphosphonates to inhibit bone resorption in vivo and 
their ability to inhibit the dissolution of 
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hydroxyapatite in vitro (Shinoda et al, 1979). This 
suggests that the action of diphosphonates to inhibit 
bone resorption may involve mechanisms other than their 
physico-chemical effects on hydroxyapatite. Potencies 
vary considerably and, for instance, on a molar basis APD 
is approximately 10 times more potent than etidronate in 
vivo in inhibiting bone resorption when given 
subcutaneously. 
Diphosphonates adsorb strongly onto 
hydroxyapatite and are localised in vivo to sites of 
mineral deposition such as the calcification front (Kahn 
et al, 1979). It is likely that this activity is related 
to their basic P-C-P configuration (compare with the 
P-O-P configuration of PPi shown in Figure 1.5) since 
there are no differences in gross distribution of these 
agents (Larsson, 1982). Pharmacokinetics of the 
diphosphonates are difficult to study, in part owing to 
the unavailability of sufficiently sensitive and specific 
assays for these agents. Also it is likely that 
concentrations in the ECF may not reflect concentrations 
at target tissues which may be much higher. The 
disposition of diphosphonates within bone is uneven (the 
basis of bone scanning which utilises 99Tc-tagged 
diphosphonates), so that the concentration of 
diphosphonate presented to particular cells is largely a 
matter of conjecture (Larsson & Rohlin, 1980). 
Diphosphonates are internalised within some cells (Fast 
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et al, 1978), and an example of this may be the renal 
secretion of diphosphonates, which has been documented in 
the case of etidronate and clodronate (Trohler et al, 
1975). However, the degree to which different 
diphosphonates are internalised by different skeletal 
cell types in vivo is largely unknown, so that it becomes 
difficult to relate any differences in effect observed in 
vitro to different cellular activity. 
A variety of biochemical actions of the 
diphosphonates have been described (Felix et al, 1982a). 
Of possible relevance to their ability to inhibit bone 
resorption is that they inhibit in vitro the activity of 
various lysosomal enzymes, including acid phosphatase and 
pyrophosphatase (Felix et al, 1976). They also inhibit 
the release of these enzymes stimulated by PTH in vitro 
(Morgan et al, 1973) and in vivo (Doty et al, 1972). 
Several of the diphosphonates, including etidronate, 
appear to inhibit the production of prostaglandins by 
bone cells in vitro (Felix et al, 1981). However, APD 
has been shown to increase prostaglandin synthesis, and 
thus the relevance of this effect to bone resorption is 
unclear (McGuire et al, 1982). Both clodronate and 
etidronate appear to decrease glycolytic activity in bone 
cells in vitro as judged by glucose consumption and 
lactate production (Fast et al, 1978; Shinoda et al, 
1979). 
It should be noted, however that many of the in 
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vitro studies were performed on osteoblast-like cells. 
Moreover, cell separation techniques suggest that 
osteoclast-like, rather than osteoblast-like, cells are 
sensitive to clodronate (Guenther et al, 1982) and thus 
the relevance of these effects in vivo is not clear. In 
this respect it is interesting that cells with phagocytic 
properties may engulf diphosphonates with avidity, 
particularly if they are bound to hydroxyapatite. Since 
osteoclasts are derived from potentially phagocytic cells 
(of the monocyte series), it is possible that 
diphosphonates influence not only osteoclast metabolism, 
but also their differentiation. 
Macrophages and monocytes are able to 
phagocytose and digest bone particles in vitro (Kahn et 
al, 1978) and several diphosphonates inhibit the 
proliferation of macrophages (Cecchini et al, 1984). The 
attachment of macrophages to bone particles coated with 
APD or clodronate is not affected, but resorption is 
inhibited (Reitsma et al, 1982). However, resorption of 
bone particles is not inhibited when clodronate is added 
after macrophage attachment indicating that this 
diphosphonate acts before cell attachment. In contrast, 
APD activity is not solely dependent on prior adsorption 
onto bone suggesting an additional mechanism of action. 
Such differences in effects, and thus in mechanisms of 
action, of the various diphosphonates may prove important 
in the clinical use of these agents. 
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Effects of diphosphonates in man 
Etidronate is the only commercially available 
diphosphonate in this country, although clodronate has 
recently been licenced for use in Finland and Italy and 
may soon be available in the rest of Europe. The 
therapeutic uses of these two agents have been widely 
investigated whereas clinical studies on the other 
diphosphonates (APD, AHDP and ABUDP) have been less 
extensive and confined to fewer centres. Etidronate has 
been most used in the medical management of Paget's 
disease and in the prevention of heterotopic 
calcification (Finerman & Stover, 1981). Experience with 
this drug is more limited in other disorders, including 
skeletal complications of malignancy, osteoporosis, 
hyperparathyroidism and other disorders associated with 
increased bone resorption. In contrast, the other 
diphosphonates, including clodronate, have been widely 
used in these latter disorders, as well as in Paget's 
disease, with encouraging results. 
General pharmacology 
Diphosphonates in general are poorly absorbed 
from the gastrointestinal tract. In the case of 
etidronate, absorption is between 1 and 10 per cent, but 
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this is reduced to zero in the presence of 
calcium-containing foods which chelate the diphosphonate 
(Fogelman et al, 1984). Oral clodronate bioavailability 
has been estimated to be around 1 to 2 per cent (Yakatan 
et al, 1982). It appears that geographical factors 
affect the degree of absorption as etidronate absorption 
was found to be much higher in Glasgow than in Madison 
for normal individuals (Fogelman et al, 1984). This may 
be one of the reasons for disparate observations of 
effects of etidronate between different centres (Kanis, 
1984). 
Diphosphonates are avidly retained by the 
skeleton, and the fraction appearing in the urine is 
related to skeletal turnover. This forms the basis for 
the use of 99Tc-tagged diphosphonate retention to monitor 
bone metabolism (Fogelman et al, 1978). The 24 hour 
whole body retention may be considerably increased in 
disorders such as Paget's disease and metastatic bone 
disease and correlates well with biochemical indices of 
bone turnover (Fogelman et al, 1978; Smith et al, 1984). 
It is thought that diphosphonates are excreted unchanged 
in the urine, although the possibility that some is 
metabolised has not been satisfactorily resolved. As 
previously mentioned, there is evidence for renal tubular 
secretion of diphosphonates since renal clearance may 
exceed the glomerular filtration rate (Trohler et al, 
1975). 
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Even in health, skeletal uptake of 
diphosphonates is not uniform, and in bone disorders such 
as Paget"s disease or metastatic bone disease the patchy 
distribution is even more marked. This may have 
important therapeutic implications since a 
proportionately greater dose of diphosphonate is 
delivered to the site of the disorder than elsewhere in 
the skeleton. This targeting effect may have obvious 
advantages in sparing non-affected sites, but also causes 
problems in assessing the adequacy of effect of a 
particular dose on skeletal metabolism. Thus, in very 
extensive Paget"s disease a given dose of diphosphonate 
will deliver less diphosphonate to any one site of 
disease activity than the same dose delivered to a 
patient with limited skeletal involvement. In support of 
this suggestion a study of the use of etidronate in 
Paget's disease by Fromm and co-workers (1979) has 
suggested that moderate to high doses may be associated 
with a greater incidence of side effects in patients with 
"oligostotic" Paget"s than in those with more widespread 
disease. 
Once incorporated into the skeleton the half 
life of diphosphonates may be very long. Prolonged 
treatment may lead to cumulative uptake which could 
account for the sustained biochemical suppression of 
pagetic activity that is observed with these agents even 
following withdrawal of treatment. Thus in the process 
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of bone resorption osteoclasts may cause local release of 
diphosphonate previously accreted in bone mineral. Such 
a mechanism might account for the highly specific effects 
of diphosphonates on bone resorbing cells. However, in 
other disorders associated with increased turnover, such 
as hypercalcaemia of malignancy, relapse may be rapid 
once treatment has been stopped (Chapter 5). 
Treatment of Paget's disease 
As recently as 15 years ago there were no 
generally available specific treatments for Paget's 
disease which therefore remained as something of a 
medical curiosity. However, since the discovery of 
calcitonin and its earliest use in Paget's disease 
(Bijvoet et al, 1967) and the development of etidronate, 
first used in oxford in 1969 (Smith et al, 1971) there 
has been a very rapid increase in the availability of 
specific treatments for this disorder. In addition to 
etidronate the newer diphosphonates, particularly 
clodronate and APD have been reasonably extensively 
evaluated in the treatment of Paget's disease. 
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Indications for treatment 
It is generally agreed that the use of specific 
anti-pagetic treatment is indicated in patients with bone 
pain. However, as mentioned previously, it may be 
difficult to distinguish between pain of pagetic origin 
and pain from an osteoarthritic joint. Intra-articular 
lignocaine may be useful in deciding the source of the 
pain but in many patients this remains uncertain and a 
trial of treatment is often justified. Furthermore, if 
patients with osteoarthrosis associated with Paget's 
disease require orthopaedic surgery, prior anti-pagetic 
treatment may be indicated to reduce bone vascularity and 
thus improve the ease and safety of operation (Bowie & 
Kanis, 1976; Meyers & Singer, 1978). A further 
indication for medical treatment is spinal cord 
dysfunction in Paget"s disease where results are as good 
as, or better than, those obtained by surgical 
decompression (Douglas et al, 1981). 
However, in the majority of individuals with 
Paget's disease (approximately 90 per cent) the disorder 
is not associated with significant symptoms and the risk 
of development of clinically important complications is 
small. Therefore the finding of Paget's disease per se 
is not an indication for treatment. Nonetheless, where 
pagetic involvement is extensive, particularly in a 
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relatively young patient, or in cases of Paget's 
involving the skull or thoracic or cervical spine, the 
risk of development of complications may justify 
treatment even in the absence of symptoms. 
Use of calcitonin 
This 32 amino acid polypeptide hormone displays 
considerable interspecies differences in amino acid 
sequence and potency. Pharmacologically, its major 
action is to specifically inhibit osteoclastic bone 
resorption (Maclntyre, 1983). To be effective as a 
therapeutic agent calcitonin has to be given 
parenterally, usuplly as daily or thrice weekly 
subcutaneous injections. More recently the possible use 
of salmon calcitonin given by nasal spray has been 
investigated, albeit in very small numbers of patients 
(Nagant de Deuxchaisnes et al, 1985b; Reginster et al, 
1985). These preliminary studies have suggested that 
pagetic activity can be significantly suppressed with 
this mode of administration and, moreover, that this 
route may be associated with fewer side effects than is 
subcutaneous administration. Certainly nasal 
insufflation would seem likely to be more acceptable than 
subcutaneous injections for many patients. 
Porcine, salmon and human calcitonin, given by 
subcutaneous injection, have all been shown to be 
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effective agents in the short term treatment of Paget's 
disease (DeRose et al, 1974; Evans et al, 1977). Effects 
include relief of bone pain, suppression of the indirect 
biochemical markers of bone resorption and a reduction in 
blood flow through pagetic bone (Wootton et al, 1981). 
However it is usual for serum alkaline phosphatase and 
urinary hydroxyproline to fall only to about half of the 
pretreatment values. Thus, whereas normal values may be 
achieved in patients with mild pagetic activity this is 
seldom the case in patients with more active disease. In 
careful radiological studies treatment with calcitonin 
has been shown to prevent the advance of osteolytic 
fronts and produce an increase in radiodensity at lytic 
sites (Nagant de Deuxchaisnes et al, 1980). 
A proportion of patients develop resistance to 
treatment with biochemical and/or symptomatic relapse 
despite continued administration of the drug. Various 
explanations for this resistance have been proposed, 
including secondary hyperparathyroidism (Burckhardt et 
al, 1973), development of neutralising antibodies (Haddad 
& Caldwell, 1972) and down-regulation of calcitonin 
receptors (Tashjian et al, 1978). The first of these 
mechanisms is unlikely as although PTH concentrations 
increase following acute administration of calcitonin 
they do not change significantly following long-term 
treatment (DeRose et al, 1974). The development of 
antibodies which block binding of calcitonin to its 
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receptor may be responsible in some patients, 
particularly those treated with salmon calcitonin. 
However, many patients possess antibodies but remain 
responsive, whereas others become calcitonin resistant in 
the absence antibodies (Singer & Mills, 1983; Tashjian et 
al, 1978). That down-regulation of calcitonin receptors 
may occur is evidenced in patients with medullary 
carcinoma of thyroid who, despite often massively raised 
concentrations of circulating calcitonin, continue to 
have a normal or even increased rate of bone turnover, 
possibly due to associated hyperparathyroidism (Saad et 
al, 1984). It is likely that this mechanism is 
responsible for aquired resistance in some patients. 
A further problem with the use of calcitonin is 
the relatively rapid rate of biochemical relapse (within 
months) that follows cessation of treatment (Avramides, 
1977; Evans et al, 1980). Symptomatic response may, 
however, outlast the biochemical response and in many 
patients intermittent treatment for a few months at a 
time may be satisfactory. 
Side effects of calcitonin, which occur in about 
30 per cent of patients, include nausea, facial flushing, 
tingling in the extremities, febrile reactions and a 
metallic taste in the mouth. These may subside after 
several weeks of therapy but in some patients demand 
withdrawal of treatment. A further consideration is that 
the calcitonins are relatively expensive and this is 
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especially true if a district nurse is required to give 
the injections. 
Diphosphonates in Paget's disease 
Despite poor intestinal absorption the 
diphosphonates that have been investigated clinically 
have all been demonstrated to be effective when given by 
mouth. In general they are capable of inducing a more 
marked suppression of the biochemical markers of bone 
turnover than is seen following calcitonin. Furthermore, 
the suppression is sustained not only during a period of 
treatment but often for in excess of one year thereafter. 
As indicated previously, however, important differences 
exist in the spectra of effects of the various 
diphosphonates, and some may be more suitable than others 
for the treatment of Paget's disease. The greatest 
volume of experience has been gained with the use of 
etidronate. 
Etidronate has been used at doses of between 1 
and 20mg/kg body weight/day. A dose dependent reduction 
in the biochemical markers of pagetic activity is seen 
throughout this dose range with the highest dose 
achieving a 70 to 80 per cent fall in serum alkaline 
phosphatase and urinary hydroxyproline excretion 
(Canfield et al, 1977). The recommended dose 
(5mg/kg/day) induces approximately a 50 per cent 
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reduction in disease activity although the response of 
individual patients is very variable (Johnston et al, 
1980; Russell et al, 1974; Altman et al, 1973). The 
biochemical suppression of disease activity is associated 
with pain relief which may occur in a dose dependent 
manner (Altman et al, 1973). 
As with calcitonin, the treatment of Paget's 
disease with etidronate is associated with a reduction in 
skeletal blood flow and in cardiac output (Walton et al, 
1983). However, whereas significant reductions in blood 
flow occur after only 2 weeks from the start of 
calcitonin treatment, no such effect is observed with 
etidronate treatment at this time, although by 3 to 4 
months from the start of treatment the effects on blood 
flow of the two treatments are similar (Walton et al, 
1985). 
Suppression of disease activity with low dose 
etidronate (5mg/kg/day) is also associated with the 
formation of lamellar rather than woven bone, a reduction 
of the calcification rate from high to normal or 
subnormal and a reduction in the number of osteoblasts 
and osteoclasts (Alexandre et al, 1981). When doses 
higher than 5mg/kg/day are used, mineralisation of 
osteoid is impaired and this gives rise to the 
histological appearance of osteomalacia in both pagetic 
and normal bone (Meunier et al, 1975) . Even at the 
recommended 5mg/kg/day for 6 months a recent study from 
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Glasgow demonstrated a high frequency of focal 
osteomalacia in pagetic bone (Boyce et al, 1984). It is 
notable, however, that many of these patients became 
hyperphosphataemic, an effect usually only seen at higher 
doses, suggesting that increased bioavailability of the 
drug may have been a major factor. Indeed, as previously 
mentioned, studies from the same centre have shown that 
the absorption of etidronate is on average two-fold 
higher in normal subjects from Glasgow than in normal 
subjects in Madison (Fogelman et al, 1984). Such 
differences in bioavailability probably account for much 
of the observed interindividual variability in response 
as well as differences in the general experience of 
different centres. In our own experience treatment with 
low dose (5mg/kg) etidronate has produced inconsistent 
results; some patients having responded well whereas in 
others treatment was ineffective (Preston et al, 1986; 
see Chapter 3). 
It is important to know whether the impairment 
of bone mineralisation is of any clinical relevance. 
There are reports of increased bone pain with the use of 
etidronate, particularly when given in high doses 
(Canfield et al, 1977), and there are concerns that the 
risk from fracture may be increased (Krane, 1982; 
Kantrowitz et al, 1975). It has been suggested that the 
recommended dose of etidronate is not associated with 
increased fracture prevalence (Johnston et al, 1983). 
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Eleven per cent of the 737 etidronate treated pagetic 
patients reviewed by these authors sustained at least 1 
fracture. Although this prevalence was comparable to 
retrospective data of untreated patients, no untreated 
controls were included in this study. Such comparisons 
may not be valid as there are likely to have been 
important differences in patient selection in the 
intervening years. Higher doses of etidronate were 
associated with a higher fracture incidence (Johnston et 
al, 1983). Recently Nagant de Deuxchaisnes and 
colleagues (1985) have reported a very low fracture 
incidence in untreated pagetic patients and suggested 
that the figures obtained in Johnston's study represent a 
real increase in fracture frequency due to etidronate. 
It is generally considered that rapidly advancing 
osteolytic Paget's in the appendicular skeleton is a 
relative contra-indication to the use of etidronate. 
Thus, for a given patient there is either a 
narrow therapeutic range or perhaps there is no dose of 
etidronate which will maximally suppress pagetic activity 
while having no significant effect on mineralisation of 
bone. Because of the inter-individual variability in 
drug absorption and in extent of pagetic involvement it 
is evident that no single dose will be appropriate for 
the entire population of Paget"s patients. This suggests 
that, if oral etidronate is to be used, some form of 
monitoring may be required to prevent overdosing or 
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underdosing of individual patients. 
One possibility is to use the hyperphosphataemic 
effect of etidronate as a guide to the systemic 
availability of etidronate (Kanis, 1984). Etidronate 
induces hyperphosphataemia via a dose dependent effect to 
increase renal tubular reabsorption of phosphate which 
becomes maximal at about 2 weeks from the start of 
treatment (Walton et al, 1975a). The mechanism by which 
this interesting effect occurs is unknown but appears to 
be unrelated to changes either in PTH or in renal 
sensitivity to PTH (Walton et al, 1975; Recker et al, 
1973). Treatment with other diphosphonates is generally 
associated with a fall rather than a rise in serum 
phosphate. However, in a study by Nagant de Deuxchaisnes 
and colleagues (1982) using high oral doses of APD 
(600mg/day) significant, albeit transient, increases in 
serum phosphate and TmP/GFR were observed. Moreover, 
radiological evidence in this study suggested a degree of 
impairment of skeletal mineralisation. Thus, there may 
be a relationship between the effects of diphosphonates 
in general on renal phosphate transport and their effects 
on bone mineralisation. Whether this relationship is 
causal, or whether these effects are unrelated 
epiphenomena is unknown. This question is addressed in 
Chapter 4 in which the effects of very high intravenous 
doses of etidronate and other diphosphonates on mineral 
metabolism are examined. Whatever the association, 
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monitoring of serum phosphate may enable titration of the 
dose of etidronate to more appropriate levels for 
individual patients. Etidronate induced 
hyperphosphataemia does not appear to be associated with 
any important clinical consequences and in particular, 
calcium phosphate precipitation within soft tissues does 
not occur. 
Some authors have advocated the use of low doses 
of etidronate combined with human or salmon calcitonin 
(Hosking et al, 1981; Bijvoet et al, 1978). Studies with 
this combination have suggested a more marked and/or a 
more consistent suppression of pagetic activity than may 
be achieved with either calcitonin or low-dose etidronate 
used alone. 
Both clodronate at doses of between 400mg and 
3,200mg per day and APD at doses of 50 to 600mg per day 
induce a dose-dependent rapid suppression of urinary 
hydroxyproline excretion with a later fall in serum 
alkaline phosphatase similar to that observed with 
etidronate treatment (Douglas et all 1980; Frijlink et 
all 1979; Heynen et all 1982). A transient positive 
skeletal calcium balance is thus produced and these 
treatments are associated with hypocalcaemia and a 
secondary increase in serum iPTH (Harris et all 1982). 
In contrast, treatment with oral etidronate is not 
associated with any significant change in serum calcium 
(Russell et all 1974; Canfield et all 1977). Clodronate 
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and APD, like etidronate are associated with a reduction 
in numbers of osteoclasts and osteoblasts seen on bone 
histology towards normal (Meunier et al, 1979; Bijvoet et 
al, 1980). However, in contrast to the observations with 
etidronate, patients do not develop histological evidence 
of osteomalacia and, at least with clodronate, the rate 
of bone mineralisation, as judged by double tetracycline 
labelling techniques, remains normal (Meunier et al, 
1979). 
The lack of significant impairment of 
mineralisation may give these newer agents a major 
advantage over etidronate. However, it should be noted 
that very high doses of both etidronate and clodronate 
given to dogs are associated with fracture, and in the 
case of clodronate this is likely to be solely due to 
impaired bone remodelling and thus impaired healing of 
bone microdamage (Flora et al, 1980). This phenomenon 
has not been observed with the use of therapeutic doses 
in man. 
It is difficult to compare the the relative 
efficacies of these diphosphonates as, with one 
exception, direct comparative studies have not been made. 
Dewis and colleagues (1985) in a small study, found that 
the clinical and biochemical effects of etidronate 
20mg/kg/day and APD 4.5mg/kg/day for three months were 
indistinguishable. 
Apart from osteomalacia induced by etidronate, 
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side effects of diphosphonates are generally minor. All 
three diphosphonates are associated with some 
gastrointestinal side effects (Nagant de Deuxchaisnes et 
al, 1982; Mautalen et al, 1984, Douglas et al, 1980). In 
the case of etidronate or clodronate these consist of 
nausea, abdominal discomfort and diarrhoea which may be 
troublesome, particularly when high doses are used. In 
clinical trials with clodronate 3 cases of leukaemia 
emerged from a total of around 900 patients which caused 
some concern over the safety of this agent. However, one 
of these patients had been exposed to benzene 20 years 
earlier, another patient had myeloma and the third came 
from an area in which the incidence of leukaemia is 
several times the average. Thus all 3 had predisposing 
factors for the development of leukaemia. No 
leukaemogenic or carcinogenic effects of clodronate were 
observed in animal studies with this agent and with 
continued patient follow-up no new cases of leukaemia 
have emerged. Thus, although continued vigilence is 
required, the association was probably fortuitous. The 
use of APD has been associated with severe 
gastrointestinal upset and oral ulceration although this 
may be a result of inadequate formulation of the drug 
(Mautalen, personal communication). 
Treatment with APD may also be associated with a 
pyrexia persisting for several days, transient leukopenia 
and the release of acute phase proteins (Bijvoet et al, 
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1980; Nagant de Deuxchaisnes et al, 1982). This appears 
to be a dose dependent effect, since when doses of 250mg 
per day or less have been used fever has not been 
reported (Heynen et al, 1982). The mechanism of the 
pyrogenic reaction is not clear but would be consistent 
with the release of IL-1 (endogenous pyrogen). Despite 
the fall in total white cell count, monocytes increase 
transiently (Nagant de Deuxchaisnes et al, 1982). These 
immunomodulatory effects of APD could confer either 
therapeutic advantages or disadvantages. Comparable 
effects with either etidronate or clodronate have not 
been observed. 
Other treatments 
Mithramycin is a cytotoxic antibiotic which also 
inhibits osteoclastic bone resorption, although this 
action is not specific (Ryan, 1977). It is effective in 
producing both a symptomatic and biochemical response. 
However its usefulness is severely limited by the nature 
of the side effects which include hepatic and renal 
dysfunction and bone marrow suppression which may result 
in thrombocytopenia. Although these effects are uncommon 
at the low doses used to treat Paget's disease, in view 
of the availability of safer drugs mithramycin is 
probably only rarely, if ever, indicated for the 
treatment of this disorder. Actinomycin D is another RNA 
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inhibitor which has been used to treat Paget's disease 
but which suffers from similar disadvantages (Fennelly & 
Groarke, 1971). An alternative approach has been to 
attempt to stimulate endogenous calcitonin secretion 
using glucagon or calcium and thiazides. The latter form 
of therapy was reported to be effective in reducing bone 
pain and causing a sustained suppression of alkaline 
phosphatase in a small group of pagetic patients (Evans, 
1977). 
Apart from specific treatment, general measures 
such as the use of analgesic and non-steroidal 
anti-inflammatory drugs, orthopaedic appliances and 
supports can often be helpful. 
Treatment of hypercalcaemia of malignancy 
The most important aspect of the acute 
management of hypercalcaemia is adequate restoration of 
extracellular volume. This is normally achieved with the 
use of physiological saline. An adequate saline load 
decreases renal tubular reabsorption of calcium and 
increases GFR both factors combining to allow more 
efficient elimination of calcium and thus a fall in serum 
calcium (Hosking et al, 1981). Some patients, 
particularly those with myeloma, may have marked renal 
impairment and care should be taken not to overload the 
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cardiovascular system with saline. it may be necessary 
to give supplements of potassium or magnesium as these 
cations may become depleted during prolonged saline 
administration (Sleeboom et al, 1983). Loop diuretics 
are sometimes used since they increase the excretion of 
both sodium and calcium (Reimold, 1972). However, in 
patients who are not adequately volume expanded the 
effects of diuretics to increase dehydration will offset 
any beneficial effect (Parfitt, 1979) and thus these 
agents should be used cautiously if at all. Thiazides 
should be avoided as they increase renal tubular 
reabsorption of calcium, and occasionally may be the sole 
cause of hypercalcaemia. Only a minority of patients 
become normocalcaemic following treatment with saline 
alone (Hosking et al, 1981; Sleeboom et al, 1983). Even 
in these patients, if the cause for the increased load of 
calcium is not treated the hypercalcaemia is likely to 
recur (Parfitt, 1979). 
Corticosteroids are frequently used in 
conjunction with saline rehydration. In myeloma they 
have effects both on the disease process and on the 
activity of bone resorbing factors (Strumpf et al, 1978). 
However, we have recently shown that their use with 
saline in hypercalcaemia associated with solid tumours 
does not confer any additional benefit over saline alone 
(Percival, 1984). Moreover, because treatment with high 
doses of steroids inhibit bone formation (Avioli et al, 
Chapter 1 INTRODUCTION Page 85 
1984) it is possible that in some cases their use may 
limit rather than enhance the hypocalcaemic effect of 
other agents. The hypocalcaemic effects of specific 
forms of chemotherapy tend to be of slow onset although 
such treatment may help to prevent recurrence of 
hypercalcaemia. Thus, specific additional treatment for 
hypercalcaemia is often required. 
A reduction in serum calcium may be achieved 
with the use of inorganic phosphate, which may be given 
either orally or intravenously. The mechanism of action 
of oral phosphate may in part be related to decreased 
bone resorption (Mundy & Raisz, 1974). Increasing 
concentrations of phosphate inhibit bone resorption in 
vitro and the administration of phosphate by mouth to 
immobilised normal subjects decreases calcium losses from 
the skeleton (Hulley et all 1971). In contrast, the 
major mechanism of action of intravenously administered 
phosphate is the formation of calcium phosphates in the 
ECF and their subsequent clearance by the 
reticulo-endothelial system. This treatment is 
associated with a risk of renal failure particularly in 
those with pre-existing renal impairment. With the 
development of specific inhibitors of bone resorption the 
use of this agent is probably no longer indicated. 
The calcitonins, mithramycin and the 
diphosphonates have all proved useful in the management 
of malignant hypercalcaemia. Apart from inhibiting 
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osteoclastic bone resorption calcitonin also inhibits 
renal tubular reabsorption of calcium; both of these 
mechanisms contributing to the overall hypocalcaemic 
effect (Hosking & Gilson, 1984). Flushing and nausea 
occur in a proportion of patients treated with calcitonin 
which is, however, free from major side effects and 
produces a prompt hypocalcaemic response. Unfortunately, 
this effect is often incomplete and is short-lived with 
maximal hypocalcaemia being seen at 4 to 6 hours after a 
single injection (Behn & West, 1977). Thus injections 
need to be repeated frequently. When calcitonin is given 
repeatedly its effects diminish progressively. This may 
be due to down-regulation of receptors but, if so it 
occurs very much more quickly than in patients with 
Paget's disease. The combination of corticosteroids with 
calcitonin may decrease the rapidity with which this 
resistance occurs (Binstock & Mundy, 1980; Ralston et al, 
1985). 
Infusion of mithramycin in lower doses than 
those used for tumour chemotherapy (around 25ug per kg of 
body weight) lowers plasma calcium concentrations (Stamp 
et al, 1975; Smith et al, 1975; Ralston et al, 1985). 
However, the effect is relatively slow and responses in 
serum calcium may not be seen for one to two days 
(Ralston et al, 1985; Mundy & Martin, 1982). Moreover, 
at these doses mithramycin may induce hepatic damage and 
thrombocytopenia. 
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There has been much recent interest in the use 
of diphosphonates in the treatment of malignant 
hypercalcaemia. However, perhaps surprisingly, there has 
only been one small study of the use of oral etidronate, 
the only commercially available form, in the management 
this complication (Mundy et al, 1983). These authors 
found that only 1 of 4 hypercalcaemic patients responded 
to treatment with oral etidronate. Two studies on the 
use of intravenous etidronate have demonstrated 
hypocalcaemic responses in the majority of patients 
(Jung, 1982; Ryzen et al, 1985) although the mean serum 
calcium for the entire etidronate treated group remained 
above normal in the second of these studies. Other 
diphosphonates, particularly clodronate and APD have been 
successfully employed in the treatment of malignant 
hypercalcaemia (van Breukelen et al, 1979; Paterson et 
al, 1983; Jacobs et al, 1981) but, with one exception 
(Jung et al, 1982) direct comparative studies between 
diphosphonates have not been performed. Jung and 
colleagues (1982), treated patients with either 
intravenous clodronate or etidronate. They noted a delay 
in the fall of serum calcium in the etidronate group 
although there was no difference in the hypocalcaemic 
response after 10 days. However, known differences in 
the mechanisms of action of the various diphosphonates 
may be expected to affect their suitability as 
hypocalcaemic agents and thus such comparisons are of 
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considerable importance. In my own studies, reported in 
this thesis, I have compared the effects of three 
diphosphonates (etidronate, clodronate and AHDP) given 
intravenously in the treatment of malignant 
hypercalcaemia (Chapter 5). In addition, I have compared 
the hypocalcaemic effects of etidronate and clodronate 
given by mouth to patients with primary 
hyperparathyroidism (Chapter 6). 
High-dose bolus intravenous injection of 
diphosphonates may impair renal function in dogs and this 
effect has also been reported in man (Bounameaux et all 
1983). However, as we have previously reported, these 
renal effects may be avoided by the use of slow 
intravenous infusion rather than bolus injection (Kanis 
et all 1983b). 
Long-term management of skeletal involvement in 
malignancy 
In many patients with skeletal metastases the 
value of chemotherapy is questionable and even in hormone 
responsive tumours the effects of hormonal manipulation 
are usually only short-lived. Bone pain, fractures and 
hypercalcaemic episodes are a major cause of morbidity 
and account for some of the mortality of malignant 
diseases. Although, as previously reviewed, different 
forms of malignant disease affect the skeleton by 
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different mechanisms, they all induce an increase in 
osteoclastic bone resorption. Thus if specific 
inhibitors of osteoclast activity, such as the 
diphosphonates, are capable of producing effects 
regardless of the mechanism of osteoclast activation then 
they may have a role in the prevention of skeletal 
complications. 
There are anecdotal reports of the relief of 
bone pain following etidronate treatment (Schnur, 1984; 
Zalcberg personal communication) but this agent is 
probably not suitable for long-term control of osteolysis 
because of the associated mineralisation defect. Several 
short-term studies with the newer diphosphonates (APD and 
clodronate) have shown encouraging results with reduced 
calcium release from the skeleton and suppression of 
hypercalcaemia (Siris et all 1980; Chapuy et all 1980; 
Douglas et all 1980; van Breukelen et all 1979; Delmas et 
all 1982; Siris et all 1983). Recently Elomaa and her 
colleagues (1983) have performed a placebo controlled 
trial of longer-term oral clodronate in the treatment of 
women with carcinoma of the breast and multiple 
osteolytic metastases. Bone pain, new bone metastases 
and development of hypercalcaemia as well as bone 
resorption, as judged by urinary hydroxyproline 
excretion, were suppressed in the treatment group. 
Further follow-up of these patients has shown a 
significantly increased survival of clodronate treated 
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patients compared to placebo controls (Elomaa et al, 
1984). It seems very likely that such treatments will 
become a useful addition to currently employed methods 
for control of malignant disease. 
Treatment of primary hyperparathyroidism 
In the presence of specific symptoms or 
complications referable to primary hyperparathyroidism, 
such as renal stones, bone disease, thirst and polyuria, 
there is general agreement that parathyroidectomy is 
required. Worsening renal function or an increase in 
serum calcium to above 3.0mmol/l are also usually 
accepted as sufficient justification for surgery. 
However, as discussed above, the widespread availability 
of routine serum calcium measurement, and the consequent 
change in the pattern of clinical presentation has 
produced a situation in which over 50% of patients with 
proven primary hyperparathyroidism are asymptomatic or at 
least have no specific symptoms (Mundy et all 1980; Heath 
et all 1980). The most appropriate management of these 
patients (i. e. those that fill none of the above 
criteria) has been a topic of much recent debate (Coe & 
Favus, 1980; Anonymous, 1984). 
The two major alternative approaches are, on the 
one hand, early parathyroidectomy and, on the other, 
simple observation with subsequent referral for 
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parathyroidectomy if the patient becomes symptomatic or 
develops other evidence of significant disease. A third 
alternative, that of active medical treatment (rather 
than just observation), is discussed below. The decision 
for or against surgery for asymptomatic patients should 
be based on three principal considerations. Firstly, 
what is the natural history of the disease in mildly 
hypercalcaemic asymptomatic individuals? Secondly, what 
are the risks and benefits of parathyroidectomy? 
Finally, what is the relative acceptability of either 
surgery or long-term medical follow-up to the patient? 
The question of the natural history of 
asymptomatic patients has most extensively investigated 
in a prospective 5 year study by Purnell and co-workers 
(1974) which included 147 such patients. Six patients 
died of causes unrelated to primary hyperparathyroidism 
and 27 were lost to follow-up. Of the remainder, 29 
required parathyroidectomy by the end of 5 years. 
Reasons for parathyroidectomy included deteriorating 
renal function in 5 patients, psychological problems in 4 
patients, increasing hypercalcaemia in 2 patients, 
osteitis fibrosa in 1 patient and preparation for hip 
surgery in 1 patient. Thus, over one third of the 
original study group (56 of 147 patients) were either 
lost to follow-up or eventually required surgery anyway 
and might be considered as failures of the conservative 
medical approach. 
Chapter 1 INTRODUCTION Page 92 
In a smaller study, Van't Hoff and colleagues 
(1983) followed 32 untreated asymptomatic patients for a 
mean period of 4.2 years. One patient was referred for 
surgery because of increasing serum calcium and 
hypertension and 2 patients were operated on because they 
were relatively young although they had no complications. 
Operation was advised, but refused, in another patient 
who subsequently developed pancreatitis followed by 
diabetes mellitus. Three patients died through unrelated 
causes. These authors also studied a control group of 60 
patients who underwent successful parathyroidectomy. 
Neither serum creatinine nor blood pressure changed 
significantly in either group of patients. However, 5 
patients (of 21 non-hypertensive patients) in the medical 
management group became hypertensive during the study 
period compared with only 3 (of 42 non-hypertensive 
patients) in the surgically treated group. The numbers 
are too small to be able to exclude a significant risk of 
developing hypertension due to primary 
hyperparathyroidism. Thus larger numbers of patients are 
required to determine the relative risks for the 
development of hypertension in conservatively managed 
versus parathroidectomised patients. 
In experienced hands the outcome of 
parathyroidectomy in asymptomatic patients is generally 
excellent, with very high cure rates (over 98%) and 
minimal morbidity (Taylor, 1980; Attie & Khafit, 1976; 
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Gaz & Wang, 1984). Persistant postoperative 
hypoparathyroidism and recurrent laryngeal nerve damage 
are currently rare, at least in interested centres 
(Taylor, 1980; Gaz & Wang, 1984). However, the 
importance of choosing a surgeon with considerable 
experience in neck explorations to achieve such good 
results has been stressed (Cope, 1966). Recently surgery 
has been facilitated by improved imaging techniques for 
parathyroid tissue including thallium/technetium 
subtraction scanning, ultrasound and computerised 
tomography. As confidence in these techniques has 
improved some surgeons have adopted the practice of 
initially only exploring the side of the neck in which a 
single adenoma has been localised. If the surgical 
findings conform to those predicted by the imaging 
techniques (i. e. one normal and one adenomatous gland) 
then the contralateral side may not need to be explored 
(Gaz & Wang, 1984). 
Although the main reason for surgery in 
asymtomatic patients is prophylactic, some patients 
notice an improvement in their general well-being after 
successful parathyroidectomy even though no specific 
symptoms were noted beforehand. However, despite the 
safety and high rate of success of parathyroidectomy many 
patients are understandably reluctant to submit 
themselves to surgery, and this is particularly so when 
patients are asymptomatic. Most patients will, however, 
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consent to operation if they are strongly advised to do 
so by their doctor. Thus, the clinician has a difficult 
role in trying to balance the best interests of the 
patient in these circumstances. In some cases surgery 
will be clearly inappropriate, either because of a short 
life expectancy or because the patient is unfit for 
anaesthesia. 
The reluctance of patients to have surgery must 
be balanced against the problems of long-term follow-up, 
particularly if they are seen in a routine clinic where 
mechanisms for ensuring continued surveillance may be 
inadequate. Even within the prospective study of Purnell 
and colleagues (1974), despite "heroic efforts", 27 of 
the original 147 patients (18%) were lost to follow-up. 
A further consideration noted by these authors, and 
emphasised by Heath and colleagues (1980), is the 
relative cost of the two approaches to management. The 
latter authors estimated that, in the USA, the costs of 
surgery would be outweighed by the costs of follow-up for 
5.5 years. 
On balance the risks of conservative medical 
management of asymptomatic patients with primary 
hyperparathyroidism, though probably small, appear to be 
greater than the risks of surgery for the majority of 
asymptomatic patients with primary hyperparathyroidism. 
However, these relative risks need to be further 
evaluated with a prospective controlled study as 
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advocated by Coe & Favus (1980). At present there can be 
no rigid rules and the decision to advise 
parathyroidectomy must be made on an individual basis. 
The role of medical treatment of primary 
hyperparathyroidism obviously depends on the efficacy, 
acceptability and side effects of the treatment. Several 
different forms of treatment have been proposed including 
oral phosphate, cimetidine, beta-adrenergic blockade, 
oestrogens, progestagens, and the diphosphonates. Oral 
phosphate, which may act partly by limiting intestinal 
calcium absorption and partly by inhibiting bone 
resorption (Hulley et al, 1971), was the first form of 
medical treatment to be used (Albright et al, 1932). 
Although this form of therapy might have a minor role in 
treatment of a subgroup of patients with hyperabsorption 
of calcium its effects on serum calcium are generally 
small and side effects, including diarrhoea and possibly 
renal impairment, preclude its general use (Broadus et 
al, 1983; Purnell et al, 1974). 
Bearing in mind the multiple mechanisms by which 
PTH acts to produce hypercalcaemia in primary 
hyperparathyroidism, the most rational medical approach 
would be at the level of the parathyroid gland itself to 
inhibit PTH secretion. An initial report on 12 patients 
by Sherwood and colleagues (1980) suggested that 
treatment with cimetidine 1.2g/day may result in 
consistent falls in iPTH. In addition, these authors 
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stated that serum calcium was reduced in all patients, 
although data was not shown to confirm this. Subsequent 
studies, however, have failed to substantiate any 
significant response to cimetidine treatment either in 
terms of iPTH concentration or serum calcium (Wiske et 
al, 1983; Fisken et al, 1982). Similarly, although the 
use of beta-adrenergic blocking agents has theoretical 
potential to reduce PTH secretion these drugs have not be 
found to have any significant effects on serum calcium in 
patients with primary hyperparathyroidism (Ljunghall et 
al, 1982). 
Recent studies with the use of an organic 
thiophosphate compound, WR-2721, are of interest. 
WR-2721 is a radioprotective and chemoprotective agent of 
potential use in patients with malignant disease 
undergoing treatment with ionising radiation or 
alkylating agents. In a phase 1 clinical trial this 
drug was discovered to induce reversible hypocalcaemia 
and at the same time reduce serum iPTH concentrations in 
previously normocalcaemic patients with malignant 
disorders (Glover et al, 1983). The hypocalcaemia 
appeared to result purely from an acute inhibition of PTH 
secretion. Furthermore, in in vitro studies by these 
authors, WR-2721 produced consistent inhibition of 
release of iPTH from dispersed bovine parathyroid cells 
The mechanism of action of this agent on the parathyroid 
glands is unknown. Side effects of this treatment, which 
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was administered by slow intravenous infusion, were 
reported to be minor, and thus a possible role of this 
agent in the management of parathyroid disorders was 
suggested (Glover et al, 1983). 
Treatment with ethinyloestradiol 50ug/day 
significantly reduced the serum calcium in 10 women with 
primary hyperparathyroidism, although in none of these 
patients did serum calcium return to within the normal 
range (Gallagher & Nordin, 1972). In a more recent study 
of 6 patients treated with ethinyloestradiol, Selby & 
Peacock (1986) reported a fall in the mean serum calcium 
to the upper end of the normal range. Similar results 
have been achieved with the use of the conjugated 
oestrogen, Premarin, at an average dose of 1.25mg/day 
although 4 of the 14 patients studied failed to respond 
to this treatment (Marcus et all 1984). In these various 
studies treatment with oestrogens produced falls in 
urinary hydroxyproline excretion and both fasting and 24h 
urinary calcium excretion. Neither intestinal calcium 
absorption nor concentrations of free 1,25(0H)2D3 were 
affected by oestrogen treatment (Gallagher & Wilkinson, 
1973; Selby & Peacock, 1986). Thus these studies suggest 
that the primary effect of oestrogens is to inhibit bone 
resorption. Such an effect is probably mediated 
indirectly as no oestrogen receptors have yet been 
localised within bone cells (Yoshioka et all 1980). 
Treatment with norethisterone, appears to have effects 
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similar to those of oestragens, producing significant, 
but incomplete, reductions in serum calcium (Selby & 
Peacock, 1986; Horowitz et al, 1986). 
In a small study of the use of high-dose oral 
etidronate (20mg/kg/day) there was no significant change 
in serum calcium (Kaplan et al, 1977). However, a report 
of a single case suggested that treatment with low-dose 
etidronate (400mg/day) may be more effective (Licata & 
O'Hanlon, 1983). This suggestion has been examined in 
the studies reported in Chapter 6. There have been two 
studies of the use of oral clodronate (Douglas et al, 
1983; Shane et al, 1981). In both studies serum calcium 
fell significantly but mean values remained above the 
normal range. 
The hypocalcaemic effects of oestrogens, 
norethisterone, and the diphosphonates in primary 
hyperparathyroidism each appear to mediated, at least 
principally, by their effects to inhibit bone resorption. 
From a consideration of the mechanisms of hypercalcaemia, 
outlined previously, it would seem likely that inhibition 
of bone resorption, alone, would only be partially 
effective in reducing plasma calcium as both the gut and 
the renal mechanisms of hypercalcaemia would be 
unchecked. The studies of the use of gonadal steroids 
and diphosphonates quoted above appear to conform to this 
expectation. 
Perhaps more surprising than the lack of 
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complete response is the fact that hypocalcaemic 
responses can be so consistently observed following 
treatment with these agents. However, bone turnover is 
generally increased in primary hyperparathyroidism and 
part of the observed hypocalcaemic response may be a 
transient effect due to dissociation of the rates of bone 
formation and bone resorption. This phenomenon is well 
demonstrated in patients with Paget's disease treated 
with clodronate (see Figure 1.6). Acute inhibition of 
bone resorption in this disorder is only later followed 
by a reduction in the rate of bone formation, as 
indicated by the delayed fall in serum alkaline 
phosphatase. During this period of dissociation, bone 
formation exceeds bone resorption and the net entry of 
calcium into bone results in hypocalcaemic and 
hypocalciuric effects. However, after several months the 
rates of bone resorption and formation again become 
matched and the hypocalcaemic and hypocalciuric effects 
gradually become attenuated. Such a sequence might be 
predicted in patients with primary hyperparathyroidism 
treated with inhibitors of bone resorption. Indeed, 
attenuation of the hypocalcaemic response has been 
observed in a single patient treated with clodronate for 
several months (Douglas et al, 1983) although 
resposiveness to oestrogens has been reported to be 
sustained for up to 2 years (Marcus et al, 1984). Thus, 
in order to examine the importance of the dissociation 
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Figure 1.6 Effect of diphosphonate treatment on 
skeletal calcium balance. Rapid suppression of bone 
resorption is associated with a transient phase of net 
bone formation and calcium accretion. Due to the coupled 
remodelling process the rate of bone formation 
subsequently decreases to match the rate of resorption 
and skeletal balance is restored. The transient 
dissociation of resorption from formation causes 
significant hypocalcaemic and hypocalciuric effects. 
(Kanis et al, unpublished observations). 
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mechanism and the duration of hypocalcaemic responses I 
have studied the long-term effects of clodronate in 
patients with primary hyperparathyroidism (Chapter 6). 
CHAPTER TWO 
OBJECTIVES AND METHODS 
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OBJECTIVES 
The clinical uses of diphosphonates have not yet 
been widely investigated. However, the published studies 
that are available clearly suggest that they may be of 
considerable benefit in the treatment of Paget's disease 
of bone and in the treatment of hypercalcaemia associated 
with malignancy. The role of diphosphonates in other 
disorders in which bone resorption is excessive, such as 
hyperparathyroidism, remains to be established. 
Several questions regarding the use of 
diphosphonates remain. As discussed above, structural 
differences between the various diphosphonates result in 
marked differences in their effects both in vitro and in 
vivo. Even the mechanisms by which these drugs inhibit 
osteoclast function appear to differ depending on which 
analogue is used. In addition, at least some 
diphosphonates have actions at sites other than bone. 
These include effects on renal tubular reabsorption of 
inorganic phosphate and immunomodulatory effects. Such 
differences in action are likely to have important 
consequences for their use in disease and it is for this 
reason that direct comparisons of the clinical effects of 
different diphosphonates are required. Furthermore, the 
pharmacokinetics of diphosphonates have proved difficult 
to study. Because of these uncertainties and the limited 
number of clinical studies so far performed with these 
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agents, in no disorder has the optimum diphosphonate 
treatment regimen been established. Studies of 
alternative modes of administration might not only 
provide more effective ways in which to employ these 
agents but also shed further light on differences between 
the effects of different diphosphonates and their 
mechanisms of action. 
Interest lies, not only in the use of 
diphosphonates in treatment, but also in their role as 
tools for investigating the physiological regulation of 
bone turnover and the mechanisms of bone disease. This 
thesis attempts to examine many of these questions in the 
light of original clinical studies of the use of 
diphosphonates in disorders of bone turnover. Thus, 
there were several objectives at the inception of these 
studies :- 
1) To study the differences between the effects of 
different diphosphonates. The therapeutic effects of 
different diphosphonates were compared directly. In 
addition, other actions of the diphosphonates, in 
particular their effects on the mineralisation of newly 
formed bone and effects on calcium and phosphate 
metabolism were examined. The mineralisation effects of 
diphosphonates, if prolonged, might cause a significant 
reduction in skeletal integrity, and their effects on 
calcium homeostasis are relevant to their use as 
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hypocalcaemic agents. 
2) To compare effects of diphosphonates in different 
disorders. Thus, although Paget"s disease, 
hypercalcaemia of malignancy and primary 
hyperparathyroidism are each characterised by increased 
bone resorption there are important differences in terms 
of skeletal balance and effects on calcium metabolism. 
Potentially, a study of responses to diphosphoanates in 
one disorder, such as Paget"s disease, might provide 
insights into probable responses in other disorders, such 
as hypercalcaemia of malignancy, which are inherently 
less susceptible to controlled study. The validity of 
the use of such disease models was assessed. 
3) To investigate the use of novel treatment regimens. 
Previous diphosphonate regimens for Paget's disease have 
consisted of continuous oral treatment with these drugs 
for a duration of three months or longer. However, the 
bioavailability of orally administered diphosphonates is 
very low and variable. By using the intravenous route of 
administration systemic loading with diphosphonate 
similar to that achieved following several months of oral 
diphosphonate therapy might be achieved within days. 
Thus, one aim was to investigate the relative effects of 
acute pulses of high-dose diphosphonates compared with 
the much lower, but more sustained, systemic dosing 
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achieved with continuous oral diphosphonate treatment. 
4) To study the assessment of biochemical response in 
Paget's disease. Existing methods for assessment of 
response are relatively crude, either utilising 
percentage change in serum alkaline phosphatase with 
treatment or numbers of patients in whom values enter a 
"normal" range. Little attention has been paid to the 
potential importance of factors such as the the initial 
degree of pagetic activity or of previous treatment with 
diphosphonates which have been studied in this work. 
5) Some of the variability in response to diphosphonates 
may be due to differences in bioavailability or drug 
compliance between patients. These differences would be 
eliminated by the use of intravenous administration 
leading to more accurate dosing. This might enable a 
clearer assessment of dose-response relationships which 
were studied in the case of treatment of Paget"s disease 
with intravenous clodronate. 
6) To examine mechanisms of disease. The pathogeneses 
of hypercalcaemia, both in malignancy and in primary 
hyperparathyroidism, are complex and involve renal as 
well as skeletal mechanisms. Because of the selective 
effect of diphosphonates to inhibit bone resorption, 
responses to these drugs may be useful as a tool for 
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dissecting out the mechanisms of hypercalcaemia in 
individual patients. 
7) To investigate new clinical uses for diphosphonates. 
The use of the diphosphonates in the treatment of 
immobilisation hypercalcaemia had not previously been 
described and was studied in two patients reported in 
this thesis. 
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METHODS 
Several different patient groups with disorders 
of bone or calcium metabolism were studied. Details of 
patients are provided either in the appropriate chapters 
or, in the case of patients with Paget"s disease of bone, 
within the Appendix. The majority of patients were 
studied on the metabolic Unit of the Royal Hallamshire 
Hospital, Sheffield either as inpatients or on a regular 
outpatient basis. However, a proportion of patients, 
particularly those with hypercalcaemia of malignancy, 
were studied in other wards either in the Royal 
Hallamshire Hospital or at Western Park Hospital by 
courtesy of the consultants in charge of their primary 
care. All patients gave informed consent and all studies 
had been approved by the local Ethics Committee. 
Diagnostic criteria 
Paget's disease was diagnosed on the basis of 
typical radiographic features. This was supported in all 
but a few cases, in whom the extent of Pagetic 
involvement was very limited, by increased serum alkaline 
phosphatase (>105U/1) in the absence of evidence of liver 
dysfunction and increased urinary hydroxyproline 
excretion (>30mmol/mol creatinine). Skeletal 
scintigraphy was performed in the majority of patients. 
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A typical distribution of areas of increased uptake of 
the 99Tc-tagged diphosphonate provided further support 
for the diagnosis. 
Hypercalcaemia of malignancy was characterised 
as hypercalcaemia (calcium >2.63mmol/1) in the presence 
of proven malignant disease (haematological or solid 
tumour). Concomitant primary hyperparathyroidism was 
excluded either on the basis of recent normocalcaemia 
with a return of serum calcium into the normal range 
following therapy or on the presence of low or 
undetectable values of iPTH during the period of 
hypercalcaemia. 
Primary hyperparathyroidism was diagnosed when 
persistent elevation of serum calcium occurred in 
patients with high or inappropriately normal values of 
iPTH and no evidence of malignancy or other causes of 
hypercalcaemia. 
Serum and urine sample collection 
All samples were collected after an overnight 
fast, patients having had water only since the previous 
evening. Approximately 40m1 of blood was obtained using 
a "Vacutainer" system (Becton Dickenson). 10ml was sent 
to the department of clinical Chemistry for routine 
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biochemical measurements on serum including calcium, 
phosphate, albumin, creatinine, alkaline phosphatase and 
hepatic transaminases. The remaining blood was allowed 
to clot, centrifuged and the serum separated and stored 
at -2000 for later analyses. Patients were asked to void 
urine at around 0700h. A fasting urine sample was then 
collected approximately 2 hours later and stored in a 
200m1 bottle containing lml of 0.1 normal hydrochloric 
acid to prevent precipitation of calcium phosphate 
crystals. Urine analyses, which were performed by the 
Department of Clinical Chemistry, were for calcium, 
phosphate, creatinine and hydroxyproline. During periods 
of inpatient admission to the Metabolic Ward urine 
collection continued for the remaining 22 hours of each 
day. 22 hour urine samples were analysed separately for 
calcium, phosphate and creatinine and the results were 
expressed as excretion per 24 hours (i. e. multiplied by 
24/22). 
Biochemical measurements 
Serum measurements 
Serum calcium, inorganic phosphate, creatinine, 
albumin, alkaline phosphatase and liver transaminases 
were measured using a Technicon SMAC multichannel 
analyser by standard methods. Serum alkaline phosphatase 
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was used as an index of the rate of bone formation. The 
coefficient of variation for this measurement in patients 
with Paget's disease both in untreated patients and in 
the plateau phase following diphosphonate treatment was 
approximately 10%. As discussed in chapter 3, alkaline 
phosphatase is a useful marker of bone formation, 
particularly when this is greatly increased. Nearer the 
normal range, however, the variable contribution of 
liver-derived alkaline phosphatase is proportionately 
greater and thus the usefulness of this enzyme as a 
marker of bone formation becomes more limited. 
Immunoreactive parathyroid hormone (iPTH) in 
stored samples was measured using an antiserum 
cross-reacting predominantly with the mid-molecule region 
of human parathyroid hormone (amino acid numbers 44-68) 
using a kit supplied by Immuno Nuclear Corporation Ltd. 
The characteristics of this sensitive assay have been 
described by Mallette and colleagues (1982). In common 
with other immunoassays for PTH, values are increased in 
patients with recent renal impairment (3-4 times normal 
in patients with non-hyperparathyroid hypercalcaemia and 
serum creatinine above 440umol/1) due to altered 
peripheral metabolism of PTH. Chronic renal failure is 
associated with very high concentrations of iPTH (up to 
100 fold higher than normal) due both to altered 
degradation and to true hyperparathyroidism (Mallette et 
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al, 1982) 
1,25-dihydroxy-vitamin D3 (1,25(OH)2D3) was 
measured by the method previously described by Clayton 
and colleagues (1982). Using this measurement, together 
with measurements of other metabolites of vitamin D, we 
have previously been able to describe disturbances of 
vitamin D metabolism in a variety of disorders including 
myeloma and Paget"s disease (Lawson-Matthew et al, 1985; 
Yates et al, 1985) as well as to investigate seasonal 
trends in normal individuals (Clayton et al, 1982). 
Thus, in hypercalcaemic myeloma patients serum 
concentrations of 1,25(OH) 2D3 were low whereas 
normocalcaemic myeloma patients had values which were in 
the lower end of the normal range (Lawson-Matthew et al, 
1985; Yates et al, 1985). 
Urine measurements 
Urinary calcium, creatinine and phosphate were 
measured using a Technicon II AutoAnalyser. 
Total urinary hydroxyproline was measured by the 
method of Stegeman and Stalder (1967). The principle of 
this method depends on the neutralisation of the 
hydrolysate, prepared by hydrolysing urine samples at 
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100'C with 50% hydrochloric acid, prior to oxidation of 
hydroxyproline to pyrrole and pyrrole-2-carboxylic acid 
by chloramine T. Both products form red complexes on 
addition of P-amino-dimethylbenzaldehyde (Erlich"s 
reagent). The dialysable fraction of hydroxyproline 
(about 90% of total) is related to bone resorption 
whereas the non-dialysable component is related to bone 
formation (Krane, 1980). However, total rather than 
dialsable hydroxyproline was measured as the former 
measurement is more convenient and provides an adequate 
index of bone resorption (Russell et al, 1981). 
Derived measurements 
Total Serum calcium concentrations were adjusted 
for changes in 
0.02mmol/1 for 
similar subtrai 
(Payne, 1973). 
referred to in 
total calcium. 
serum albumin with the addition of 
each lg/l of albumin below 42g/1 and a 
-tion for albumin values above 42g/l 
Unless otherwise stated the values 
this thesis are of adjusted rather than 
Fasting urinary excretion of calcium was 
expressed as a ratio to urinary creatinine (Ca/Cr). 
Under steady-state conditions the net amount of calcium 
entering the ECF pool from bone and gut is equal to the 
amount leaving this pool by urinary excretion. After an 
Chapter 2 OBJECTIVES AND METHODS Page 112 
overnight fast the net contribution of intestinal 
absorption of calcium is negligible and thus at least the 
greater part of a net calcium flux into the ECF is likely 
to be bone derived. Thus fasting Ca/Cr provides an index 
of net calcium loss from bone and hence, where skeletal 
mineralisation is unimpaired, an index of net bone 
resorption. The Ca/Cr has been previously used as an 
index of bone resorption in several disorders including 
primary hyperparathyroidism and osteoporosis (Gallagher & 
Wilkinson 1973; Selby & Peacock, 1986). 
In order to study renal tubular handling of 
calcium, excretion was also expressed per unit of 
glomerular filtrate (CaE of Peacock & Nordin, 1968). 
This may be calculated simply by multiplying the Ca/Cr by 
the serum creatinine concentration. Thus: - 
Ca/Cr x serum creatinine = calcium excretion (CaE) 
(mmol/mmol) (mmol/1) (mmol/1 GF) 
Urinary hydroxyproline excretion in fasting 
urine was expressed as a ratio to urinary creatinine 
(OHP/cr). Previous studies have found very close 
correlations between OHP/Cr from fasting urine samples 
and OHP/Cr from 24 hour collections as shown in figure 
1.4 (Russell et al, 1981). Inhibition of bone resorption 
with diphosphonates results in a rapid suppression of 
OHP/Cr which becomes significant as early as 1 day from 
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the start of treatment (Chapter 3). Bone formation does 
not become suppressed within the first week or so from 
the start of treatment and thus the fall in OHP/Cr is due 
to changes in bone resorption rather than bone formation. 
As discussed in Chapter 1, close correlations between 
this measurement and the level of bone formation, as 
judged by serum alkaline phosphatase, in patients with 
Paget's disease suggest that it is a reliable marker of 
bone turnover. 
Renal tubular reabsorption of phosphate was 
expressed as the maximal tubular reabsorption of 
phosphate per litre of glomerular filtrate (TmP/GFR) and 
was derived from the equation of Bijvoet (1977) for 
measurement of TmP/GFR without phosphate infusion. This 
measurement was used in preference to the fractional 
tubular phosphate reabsorption (TRP) as the latter index 
is highly dependent on the filtered load of phosphate per 
nephron and thus on the plasma phosphate concentration. 
Creatinine clearance, expressed as ml/min, was 
calculated using the equation: - 
Clcr = Ucr x V/SCr 
where UCr is the urinary concentration of creatinine v 
is the urinary volume (average per minute from a 22 hour 
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sample) and SCr is the serum creatinine concentration. 
Histomorphometric techniques 
Bone biopsies were taken from patients with 
Paget's disease treated with intravenous diphosphonates. 
These patients had each previously received 3 courses of 
tetracycline for labelling bone surfaces undergoing 
mineralisation. To aid distinction of the labels 
ledermycin 600mg/day was for given for 4 days for the 
first label and oxytetracycline lg/day for 2 days was 
used for the two subsequent labels. In all but 3 
patients successive labels were each separated by a 10 
day interval and intravenous diphosphonate infusions 
started on the first day following completion of the 
second tetracycline label. In 2 clodronate treated 
patients, however, the final label was given during the 
last 2 days of the treatment period and in one patient 
the final label was given 30 days from the start of 
etidronate treatment (Chapter 4). At between 2 and 5 
days after completion of all labels patients underwent a 
bicortical trans-iliac biopsy using an 8mm Meunier 
trephine. All patients gave informed consent for the 
procedure which was carried out after valium 
premedication and local infiltration with lignocaine 2% 
of the standardised biopsy site 2-3cm below the iliac 
crest. Samples were fixed in 80% ethanol before being 
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embedded undecalcified in methyl methacrylate. Bone 
histomorphometry was performed on 7u sections. 
Measurements were made with polarised light microscopy 
using a Kettle MOP AMO 3 digitising table with a Leitz 
orthoplan microscope at a final magnification of x 300. 
Trabecular bone was examined utilising at least 2 
sections and 5 contiguous fields per section. The 
mineral apposition rate (MiAR) was derived from the 
distance between midpoints of two tetracycline labels, 
corrected for obliquity, divided by the time interval 
between the labels (Merz & Schenk, 1970). The 
administration of three tetracycline labels permitted two 
separate assessments of MiAR for each biopsy sample. 
Thus the distance between the first label (identified by 
the colour difference between labels as well as the 
relationship to the trabecular surface) and the second 
label was used to measure the MiAR before diphosphonate 
treatment whereas the distance between second and third 
labels was used to measure the MiAR following the start 
of treatment. Using this triple label technique acute 
changes in the rate of mineralisation could be determined 
from a single biopsy. 
Other techniques 
Bone scintigraphy and skeletal radiography were 
used extensively for the detection of skeletal metastases 
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in patients with hypercalcaemia of malignancy. Other 
hospital investigative facilities were used where 
appropriate. 
Statistical methods 
Some of the variables studied, in particular 
serum alkaline phosphatase and urinary OHP/Cr, conformed 
to a log-normal rather than a normal distribution as 
determined by probit analysis. Thus for the purpose of 
statistical analysis of change in these measurements the 
data were log-transformed. Other measurements, such as 
serum calcium and serum phosphate, were distributed in a 
Gaussian manner and therefore the significance of changes 
were analysed directly (Armitage, 1971). 
Where an approximately Gaussian distribution 
could be achieved comparisons were made using a 2-tailed 
Student's t-test for either paired or non-paired data as 
appropriate. Data which did not conform to a Gaussian 
distribution was analysed using nonparametric tests 
including Wilcoxon and Fishers exact tests. Correlation 
coefficients were determined by the method of least 
squares. Other statistical methods are detailed where 
used. 
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Reference ranges Range 
Serum measurements 
Calcium 2.12-2.63 mmol/1 
Phosphate 0.6-1.5mmol/l 
Creatinine 60-120umol/l 
Albumin 35-53g/1 
Alkaline phosphatase 35-105U/1 
iPTH (midmolecule assay) <130pg/ml 
1,25(OH)2D3 20-60pg/ml 
Derived measurements 
Urinary Ca/Cr 0.1-0.4mol/mol 
Urinary OHP/cr 9-30mmol/mol 
TmP/GFR 0.80-1.35mmol/1GF 
Mineral apposition rate (MiAR) 0.5-0.8um/day 
Normal ranges (+/- 2SD) for iPTH, 1,25(OH)2D3, urinary 
Ca/Cr and OHP/Cr are derived from a combined group of 30 
healthy hospital staff member and 32 elderly healthy 
individuals (mostly spouses accompanying clinic 
patients). The normal range given for MiAR is derived 
from published data for normal subjects (Merz & Schenk, 
1970). Other ranges are those quoted by the routine 
hospital laboratory. 
CHAPTER THREE 
THE USE OF NOVEL DIPHOSPHONATE REGIMENS IN THE TREATMENT 
OF PAGET'S DISEASE OF BONE 
SECTION TWO 
EFFECTS OF DIPHOSPHONATES IN PAGET'S DISEASE OF BONE 
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THE USE OF NOVEL DIPHOSPHONATE REGIMENS IN THE TREATMENT 
OF PAGET'S DISEASE OF BONE 
Introduction 
Etidronate, in tablet form, is the only 
commercially available diphosphonate, but when given in 
maximally effective doses this drug is associated with 
impaired mineralisation of bone (Meunier et al, 1975). 
In the recommended regimens treatment is continued for 3 
to 6 months. High-dose treatment (20mg/kg/day) for this 
length of time produces reliable suppression in pagetic 
activity, but at a cost of clinically significant 
osteomalacia in a proportion of patients (Krane, 1982), 
whereas low doses are ineffective in some and may produce 
osteomalacia in others due to variable bioavailability 
(Boyce et al, 1984; Fogelman et al, 1984). However, as 
the mineralisation defect is reversible on stopping 
etidronate treatment, shorter courses, even of very high 
doses, of etidronate might not be expected to induce 
clinically significant osteomalacia as the amount of 
unmineralised osteoid is proportional to the duration of 
treatment. In addition, by far the greatest fall in bone 
resorption, as judged by urinary OHP/cr, occurs within 
the first month of etidronate treatment and the later 
fall in alkaline phosphatase may be a consequence of the 
coupling process rather than of continued treatment. 
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These considerations suggested that short 
courses of high-dose treatment with etidronate might 
prove both effective and relatively safe. In a previous 
study we have shown that, over a period of 6 months, 1 
month of high-dose oral etidronate (20mg/kg/day) produces 
a degree of biochemical suppression comparable to that 
seen with the same dose for 6 months (Preston et al, 
1986). Moreover, the response to the 1 month regimen was 
more marked and more consistent than that achieved with 
low-dose treatment (5mg/kg/day) for 6 months despite a 
higher total dose in the latter regimen (see Figure 3.1). 
Similarly, Delmas and colleagues (1982) found 
that a1 month course of high-dose oral clodronate 
treatment produced suppression of bone resorption 
comparable to that seen with 6 months treatment at the 
same dose (1.6g/day). Thus continued biochemical 
suppression was not dependent on patients receiving 
long-term treatment and might possibly be related to 
early treatment effects on the remodelling process. The 
question thus arose as to whether even shorter courses of 
treatment with higher doses may prove effective in the 
treatment of Paget"s disease. 
Major problems with the oral route are the 
inconvenience of having to take tablets away from food 
and poor and variable intestinal absorption of 
diphosphonates. Bioavailability has been estimated at 
1-10 per cent for etidronate and 1-2 per cent for 
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Figure 3.1 Comparison of the effects of 3 different 
etidronate treatment regimens in patients with Paget's 
disease of bone. Mean suppression of serum alkaline 
phosphatase was least marked in the low-dose group in 
which responses were very variable. Responses to 1 month 
and those to 6 months of high-dose etidronate were 
similar. THP = total 24h hydroxyproline excretion. 
80umo1/kg/day is equivalent to 20mg/kg/day. (Data from 
Preston et al, 1986). 
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clodronate (Fogelman et al, 1984; Yakatan et al, 1982). 
In addition gastrointestinal side effects are frequently 
encountered with high oral doses. Much higher and more 
consistent systemic loading can be achieved with 
parenteral administration of diphosphonates. Thus, 
assuming 2 per cent bioavailability, a1 month course of 
oral clodronate 1.6g/day would result in a total systemic 
delivery of only around lg of the drug. Using the 
intravenous route the same systemic loading may be 
achieved within a few days. However, with reduced 
duration of treatment uptake of the diphosphonate might 
be expected to be concentrated at more focal sites within 
the skeleton which may potentially affect its skeletal 
actions. 
Thus, in the present study the use of short 
intravenous treatments with diphosphonates (clodronate 
and etidronate) was investigated. The results were 
compared with those obtained using high-dose long-term 
oral clodronate treatment. The aims of the study were 
not only to examine the effects of treatment on skeletal 
turnover in Paget's disease (this chapter) but also to 
investigate the effects of these agents on mineral 
metabolism (Chapter 4). 
Aminohexane diphosphonate (AHDP) is a new 
diphosphonate which in animal studies has been shown to 
be a more potent inhibitor of bone resorption than either 
clodronate or etidronate and, like clodronate and APD, 
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appears to have little effect to impair mineralisation of 
osteoid (Felix et all 1982b). This agent therefore shows 
promise as a treatment for Paget's disease and thus the 
effects of AHDP in this disorder were examined in the 
present study. 
Patients and methods 
45 patients were treated with clodronate 1.6g 
daily by mouth for 6 months. None of this group had 
received previous treatment with diphosphonates. Data 
from some of these patients have been previously reported 
(Douglas et all 1980). 
31 patients received clodronate 300mg/day by 
intravenous infusion. 15 of these patients had been 
previously treated with diphosphonates. 
7 patients (5 previously treated) were given 
clodronate 100mg/day i. v. 
16 patients (13 previously treated) received 
clodronate 600mg/day i. v. 
21 patients received intravenous etidronate 
either at a dose of 300mg/day (n=7) or 7.5mg/kg/day 
(n=14; dose range 410 to 700mg/day). 
17 patients (8 previously treated with 
diphosphonates) were treated with intravenous AHDP at a 
dose of 25mg/day. A further 16 patients received AHDP 
400mg daily by mouth for 1 month. 
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Details of all patients who received intravenous 
diphosphonates are given in the appendix. All 
intravenous treatments were given as 3 hour infusions of 
the drug in 500ml of 0.9% saline repeated daily for 5 
days. All patients gave informed consent for study which 
was approved by the local Ethics Committee. 
Methods for study were as outlined in Chapter 2. 
Patients given oral clodronate were reviewed monthly as 
outpatients. Intravenously treated patients were 
admitted 3 days before the start of treatment for 
collection of baseline samples of blood and urine. These 
were continued daily during the 5 day infusion period and 
patients were seen regularly as outpatients thereafter. 
Results 
Comparison of oral clodronate and clodronate 300mg i. v. 
The effects of these two treatments on 
biochemical markers of Pagetic activity are shown in 
Figure 3.2. There was a marked progressive fall in 
urinary OHP/Cr during the 5 days of intravenous treatment 
but this effect rapidly became attenuated on stopping 
treatment. Although at 1 month the degree of biochemical 
suppression induced by the two treatments was broadly 
comparable, by 6 months the response in the oral 
treatment group was clearly the more marked. 
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Figure 3.2 Comparison of changes in indirect markers of 
bone turnover (as a percentage of immediate pretreatment 
values for individuals) in pagetic patients treated with 
clodronate either by mouth 1.6g/day for 6 months or 
intravenously 300mg/day for 5 days. 
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However, there was a striking difference in the 
degree of biochemical suppression between the 16 
previously untreated patients and the 15 patients who had 
already received at least 1 course of diphosphonate 
treatment. Thus there was no significant difference in 
terms of suppression of alkaline phosphatase between 
previously untreated patients and those given oral 
clodronate (also previously untreated), although the fall 
in urinary OHP/Cr was not as complete in the 
intravenously treated group (Figure 3.3). In contrast, 
patients who had previously received diphosphonates had a 
much attenuated biochemical response after intravenous 
treatment (Figure 3.3). This suggested that previous 
treatment with diphosphonates might render patients 
relatively resistant to subsequent treatments. However, 
although these patients had relapsed as judged by 
biochemical criteria, the majority had not attained the 
degree of Pagetic activity observed before their first 
course of treatment (mean 50% and 61% of initial alkaline 
phosphatase and OHP/Cr respectively). It should be 
noted, however, that the mean original pretreatment 
alkaline phosphatase was higher in the retreatment group 
than in either the previously untreated intravenous group 
or the oral treatment group (Table 3.1). 
The effect of incomplete relapse on response to 
further treatment is illustrated by one patient who 
received oral clodronate for 6 months and, following 
300mg 
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Figure 3.3 Effects of clodronate on biochemical markers 
of bone turnover. Patients who received intravenous 
clodronate 300mg/day were separated into previously 
treated (n=15) and previously untreated (n=16) groups. 
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partial relapse, was retreated with intravenous 
clodronate (Figure 3.4). The percentage fall in 
biochemical markers upon retreatment appeared to depend 
to a great extent on the degree of biochemical relapse. 
This source of artefact was circumvented by replotting 
values as a proportion of biochemical values observed 
before the original diphosphonate treatment for each 
patient. The differences in final degree of biochemical 
suppression between previously untreated and previously 
treated patients disappeared (Figure 3.5). 
Clinical observations 
Bone pain improved in 20 of the 31 patients 
given intravenous clodronate (77% of those with bone 
pain) and improvement was substantial in 17. Patients 
reported no side effects related to intravenous treatment 
although transient proteinuria (<24 h) was observed in 4 
patients following each infusion. There were no 
significant changes in serum creatinine with either 
regimen. 
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Figure 3.4 Responses to 2 successive diphosphonate 
treatments in one patient (JC). A reduced, percentage 
fall on retreatment is largely due to incomplete 
biochemical relapse. 
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Figure 3.5 Biochemical markers of bone turnover 
expressed as a percentage of original pretreatment values 
in previously treated and previously untreated patients 
given clodronate 300mg/day for 5 days. 
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Duration of biochemical remission 
Actuarial survival analysis (Kaplan & Meier, 
1958) was used to examine the duration of biochemical 
remission following treatment with either oral or 
intravenous clodronate. The coefficient of variation for 
serial measurements of alkaline phosphatase taken either 
from the plateau response phase or before treatment was 
found to be approximately 10 per cent. On this basis 
response and relapse were defined as a fall or an 
increase respectively of at least 25% (2.5 x coefficient 
of variation) from previous mean values of alkaline 
phosphatase. The results (Figure 3.6) show that the 
duration of remission is significantly shorter following 
intravenous treatment than following 6 months of oral 
clodronate (p<0.0001 using Gehan's test; Gehan, 1965). 
The difference remained highly significant even when 
duration of remission is taken from the end rather than 
the beginning of treatment (p<0.001). 
Dose response relationship with i. v. clodronate 
With each of the three doses studied (100mg, 
300mg and 600mg) the treatment groups contained both 
previously treated and previously untreated patients. 
Thus, in order to facilitate comparisons values were 
Duration of biochemical remission 
c 
clodronate 
20 300mg 5d 
0 
0 200 400 600 800 1000 
time since start of treatment (days) 
N 
Figure 3.6 Duration of biochemical remission following 
treatment with clodronate either as 1.6g/day by mouth for 
6 months or as 300mg/day intravenously for 5 days. 
Biochemical relapse (25% increase from minimum values) 
occurred in the majority of intravenously treated 
patients at around 1 year. 
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expressed as percentage of values seen before the initial 
course of diphosphonate treatment. The results of this 
comparison are shown in Figure 3.7. This appears to 
confirm a dose/response relationship with 100mg having no 
significant effect whereas 600mg induced a significantly 
more marked suppression in alkaline phosphatase at 3 
months than did the 300mg dose (p<0.01 on non-paired 
t-testing of percentage values). 
However, general experience with treatment of 
Paget's disease has indicated that in patients with only 
minimally increased biochemical markers of pagetic 
activity only a small percentage fall can be expected 
even after maximally effective treatment. Conversely, in 
some patients with very active Paget's disease effective 
treatment can result in suppression of alkaline 
phosphatase to a very small percentage of the 
pretreatment values. This relationship is well 
demonstrated in the 6 month oral clodronate group by 
Figure 3.8. Thus, in order for a direct comparison 
between percentage falls in different groups to be valid 
it is important to match patients for the degree of 
Pagetic activity. 
In fact, the three dose/response groups were 
poorly matched. Mean original pretreatment values for 
alkaline phosphatase (derived from log-transformed data) 
were 351U/1 (266-704), 485U/1 (356-699) and 760 
(494-1170) U/1 respectively for the 100mg, 300mg and 
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Figure 3.7 Dose/response relationship in pagetic 
patients treated with intravenous clodronate. Values for 
alkaline phosphatase are expressed as a percentage of 
values observed before the original course of 
diphosphonate treatment for each patient. * p<0.05 
** p<0.01 on non-paired t-testing. 
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Figure 3.8 Relationship between original level of 
pagetic activity (pretreatment alkaline phosphatase) and 
the percentage of this value reached after 6 months of 
treatment with clodronate 1.6g/day by mouth. The lines, 
which were drawn by eye, approximate to mean values and 
the upper confidence estimate and are used for comparison 
of responses in other treatment groups (figure 3.9 and 
3.13). 
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600mg groups (95% confidence estimates for the mean in 
parentheses). Thus much of the apparent dose/response 
relationship might be due to an artefact caused by 
differences in Pagetic activity between the groups. An 
alternative method is to compare response (in terms of 
percentage of original pretreatment values) against the 
curvilinear relationship seen in the oral treatment group 
(Figure 3.9). Values at 3 months for each group were 
used in this comparison as suppression was near maximal 
for all three dose groups at this time point and some 
patients relapsed rapidly thereafter. Exhibited in this 
way, all but 2 of the 600mg treated patients suppressed 
to values comparable to the oral treatment group, whereas 
half of the 300mg group and all of the 100mg group lie 
outside this range. This appears to confirm the 
existence of a dose/response relationship although other 
factors, in particular whether patients had been 
previously treated, may still be influential. 
A further attempt to demonstrate a dose/response 
relationship is shown in Figure 3.10. In retreated 
patients, both immediate pretreatment and original 
pretreatment values of alkaline phosphatase are shown. 
From this analysis it can be seen that the 100mg dose did 
not cause significant further suppression in serum 
alkaline phosphatase in either previously treated or the 
2 previously untreated patients. Treatment with 300mg 
induced a marked suppression in the majority of 
i. v. clodronate 
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Figure 3.9 Serum alkaline phosphatase values at 3 
months as a percentage of original pretreatment values in 
patients treated with intravenous clodronate at doses of 
100mg, 300mg or 600mg/day. The continuous and dashed 
lines are derived from the relationship for the oral 
clodronate group shown in figure 3.8. 
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log scale) in individual patients treated with 
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the start of intravenous treatment. 
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previously untreated patients but this occurred in less 
than half of the retreated patients. The 600mg dose 
induced marked suppression in alkaline phosphatase in all 
but one (previously treated) patient. Thus, although the 
methods of analysis are, of necessity, somewhat 
arbitrary, there does appear to be a genuine 
dose/response relationship for intravenous clodronate at 
doses of between 100 and 600mg per day. 
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Effects of treatment with intravenous etidronate 
The effects of intravenous etidronate on 
alkaline phosphatase and urinary OHP/Cr are shown in 
Figure 3.11. Only 7 of the 21 patients had been 
previously treated with diphosphonates and relapse was 
near completion in 5 of these patients. The fall in 
urinary OHP/Cr for the whole group was comparable to that 
observed following clodronate treatment but the 
suppression of alkaline phosphatase appeared to be less 
marked in the etidronate treated group (Figure 3.11). 
Thus there was a mean fall to 62.5% of original 
pretreatment at 3 months in the etidronate group compared 
with 44.1% at 3 months following clodronate 300mg (p<0.02 
on non-paired t-testing of percentage values). 7 
(previously untreated) patients had each received 300mg 
etidronate whereas the remaining 14 patients received a 
dose of 7.5mg/kg body weight to give a mean dose of 
523mg/day. The group who received the higher dose had a 
greater degree of suppression in serum alkaline 
phosphatase than the lower dose group (Figure 3.12). 
Further evidence of a dose/response relationship to 
intravenous etidronate is shown in Figure 3.13 in which 
responses at 3 months were compared against the 
curvilinear relationship derived from the resposes in the 
oral treatment group. 6 of the 10 patients treated with 
the higher dose for whom data was available at 3 months 
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e 
biochemical markers of bone turnover. 
"1 
i. v. etidronate dose/response 
120 
100 
80 
0 t a 
12 
Co 60 
40 
days months 
300mg 
7.5mg/kg 
N 
Figure 3.12 Comparison of the effects of high-dose 
(7.5mg/kg/day) and low-dose (300mg/day) intravenous 
etidronate to suppress alkaline phosphatase (expressed as 
a percentage of original pretreatment values) in pagetic 
patients. 
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Figure 3.13 percentage of original pretreatment 
alkaline phosphatase at 3 months from the start of 
etidronate treatment in patients given either 300mg/day 
or 7.5mg/kg/day. Solid and dashed lines are derived from 
the relationship in oral clodronate treated patients 
shown in figure 3.8. 
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had a degree of biochemical suppression comparable to the 
group treated with oral clodronate whereas responses were 
less marked in the lower dose group. 
3 of the 21 patients (all of whom received the 
7.5mg/kg dose) noted altered taste sensation during the 
treatment period. This feature was noticed shortly after 
the start of etidronate infusion and resolved within 
hours of the end of the infusion. Altered taste was not 
reported by any of the patients treated with the other 
diphosphonates studied. Transient proteinuria occurred 
in 1 patient treated with etidronate but this was not 
associated with any change in renal function as judged by 
serum creatinine. 
Effects of treatment with AHDP 
When given by mouth for 1 month, AHDP 400mg 
daily produced consistent suppression of both alkaline 
phosphatase and OHP/cr to less than 50 per cent of 
pretreatment values (Figure 3.14). Intravenous AHDP 25 
mg/day (Figure 3.15) or 50mg/day (not shown) also 
effectivly suppressed pagetic activity producing 
responses similar to that seen following the 300mg dose 
of intravenous clodronate. Thus, AHDP appears to be at 
least 6 times more potent than clodronate when given by 
the intravenous route. 
There was no increase in body temperature in any 
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Figure 3.14 Effects of treatment with oral AHDP 
400mg/day for 1 month on biochemical markers of pagetic 
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of the intravenously treated patients and no effect on 
lymphocyte numbers was noted. As yet few data are 
available on the rate of biochemical relapse following 
AHDP treatment. 
Discussion 
Our previous experience with the successful use 
of 1 month high dose oral etidronate (Preston et all 
1986), and that of Delmas and colleagues (1982) with 1 
month courses of oral clodronate, suggest that use of the 
currently recommended lengthy regimens of 3 to 6 months 
of treatment by mouth may be unnecessary. Skeletal 
uptake of diphosphonates, as shown by whole body 
retention of 99Tc-tagged diphosphonate, is proportional 
to the prevailing rate of skeletal turnover, being 
greatest during the early phase of treatment and 
diminishing thereafter as turnover decreases (Smith et 
all 1984). This may explain, in part, why the effects of 
shorter courses of oral diphosphonate treatment appear to 
be similar to those of more prolonged treatments. 
The present studies demonstrate that even very 
short courses of diphosphonate treatment may have 
profound and sustained effects to reduce bone turnover in 
Paget's disease. The inhibition of bone resorption is 
rapid (within days) but the fall in bone formation as 
judged by alkaline phosphatase, occurs over 3 months and 
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only commences after the end of intravenous treatment. A 
short delay in suppression of alkaline phosphatase might 
be expected as this enzyme has a half life in plasma of 
around 2 days (Walton et al, 1975b), but this could not 
account for the time course observed in these studies. 
The findings support the notion that the suppression of 
alkaline phosphatase is a consequence of the coupling 
mechanism, which is maintained in Paget"s disease, rather 
than a direct result of the treatment per se. 
The time course of the biochemical response to 
intravenous diphosphonates is of interest. Maximal 
suppression of OHP/Cr is achieved at the end of the 
treatment period, but it is impossible to predict whether 
a further fall would have occurred had intravenous 
treatment continued. Within weeks of stopping treatment 
there was a secondary increase in OHP/Cr suggesting 
either that reactivation of some osteoclasts occurred or 
that there was new recruitment of osteoclasts. At around 
1 month from the end of treatment a new plateau for 
OHP/Cr was reached. The fall in alkaline phosphatase 
following treatment with intravenous clodronate 300mg may 
be slightly more rapid than that following oral therapy 
but by 3 months the degree of suppression was identical 
for the two groups. 
In the intravenously treated groups in general 
no further suppression of mean values occurred after 3 
months and after 6 months (data not shown) there is a 
Chapter 3 DIPHOSPHONATES IN PAGET'S DISEASE Page 133 
gradual increase due to biochemical relapse in a 
proportion of patients. In contrast, during 6 months 
oral treatment both OHP/Cr and alkaline phosphatase 
continue to fall. One possibility is that continued 
treatment prevents the secondary recruitment or 
activation of osteoclasts. 
The actuarial survival analysis data on the 
duration of remission indicate that although intravenous 
clodronate 300mg has prolonged effects (median relapse 
free interval approximately 1 year) the length of 
remission is significantly shorter than that following 
long-term oral clodronate. Thus, although the ideal 
would be to be able to achieve reliable and complete 
suppression of disease activity which would last for many 
years following short intravenous courses of 
diphosphonate treatment this has not been fulfilled in 
practice. It is possible that some form of maintenance 
therapy, perhaps with intermittent intravenous doses of 
diphosphonate, could be used in order to prevent 
biochemical relapse. However the duration of remission 
following intravenous clodronate 300mg is comparable to 
that which we have observed following high dose oral 
etidronate for 3 to 6 months where only 58% remain in 
remission at 1 year (Gray et al, 1984). Thus, in real 
terms the duration of effect of intravenous clodronate 
treatment is comparable to that induced by the only 
generally available form of diphosphonate therapy. 
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The present study highlights several hitherto 
unresolved difficulties in the assessment of response to 
anti-pagetic treatment. Although previous treatment may 
be allowed for by always comparing values with those 
observed before the initial treatment (or highest 
observed), interpretation remains difficult in patients 
in whom the degrees of relapse, and subsequent response 
to re-treatment, are slight. Also the use of original 
pretreatment values assumes a lack of progression of the 
pagetic process, whereas this is probably not always so 
particularly if disease activity is incompletely 
suppressed (Woodard, 1959). 
The possibility that a degree of resistance to 
retreatment with diphosphonates has not been entirely 
excluded by the present study as the mean value of 
original alkaline phosphatase was higher in the 
previously treated group than in untreated patients. 
Furthermore, many patients retreated with clodronate 
300mg, unlike those given the 600mg dose, failed to show 
further biochemical suppression. This suggests that 
there may have been partial resistance which could be 
overcome with the use of the higher dose of clodronate. 
Apparent resistance might also be, in part, a consequence 
of patient selection. Responses to diphosphonates are 
heterogeneous and poor responders are likely to present 
for retreatment more often than good responders thus 
introducing a bias against retreated groups. 
Chapter 3 DIPHOSPHONATES IN PAGET'S DISEASE Page 135 
The extent to which the original pretreatment 
alkaline phosphatase is increased is clearly an important 
determinant of the percentage fall that may be expected. 
The observed relationship is to be expected as at least a 
proportion of total alkaline phosphatase (liver-derived) 
is not amenable to suppression with inhibitors of bone 
resorption. Thus the nearer the pretreatment value is to 
the value of the non-suppressible component of alkaline 
phosphatase the lower the percentage fall that can be 
expected. The position is complicated by the fact that 
patients with very high initial values of serum alkaline 
phosphatase often fail to suppress into the normal range 
even following prolonged effective treatment (Figure 
3.16). This indicates that even the fraction of serum 
alkaline phosphatase which is derived from pagetic bone 
is not completely suppressed by treatment. 
The concept of suppressible and non-suppressible 
alkaline phosphatase may be used as a simple 
bi-compartmental model. An equation may be formulated 
which approximates the observed percentage of 
pretreatment value achieved following treatment. 
Thus :- 
AP% _ 
APns + (k x APs) x 100 
APtotal 
Where AP% is the predicted percentage fall, APns and APs 
are the non-suppressible and suppressible components of 
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Figure 3.16 Relationship between pretreatment alkaline 
phosphatase and minimum values achieved in pagetic 
patients treated with clodronate 1.6g/day by mouth for 6 
months (P < 0.0001). In general, patients with the most 
active disease failed to suppress into the normal range 
following treatment. However, there was considerable 
heterogeneity of response. 
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alkaline phosphatase respectively and k is the factor by 
which APs is reduced following treatment. 
From an examination of Figure 3.8 it can be seen 
that for very high pretreatment values for alkaline 
phosphatase, where the contribution of the 
non-suppressible alkaline phosphatase is minimal, the 
values at 6 months are around 10% of the pretreatment 
values. Figure 3.17 shows this theoretical relationship 
and the effect of differences in the APns component on 
the percentage fall achieved. Note that at low values of 
pretreatment alkaline phosphatase quite small differences 
in the value of the Apns component would result in large 
differences in percentage fall. In fact the line drawn 
by eye from Figure 3.8 approximates very closely to the 
theoretical line assuming a non-suppressible alkaline 
phosphatase of 60 U/1 and a value for k of 0.1. 
In reality there may be a spectrum of 
suppressibility of skeletal alkaline phosphatase with the 
fraction derived from non-involved bone being more 
resistant to suppression than that derived from pagetic 
bone where a very high concentrations of diphosphonate 
may be achieved. However, in terms of mathematical 
expression this is probably unimportant and a theoretical 
single non-suppressible component would remain valid in 
the same way that one can usefully consider a single 
"physiological dead space" in the lungs even though in 
reality there is a continuous spectrum between 
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Figure 3.17 Theoretical relationship between 
pretreatment alkaline phosphatase and percentage achieved 
following treatment assuming a fall in the suppressible 
component of alkaline phosphatase to 10% of pretreatment 
(see text). The 3 lines represent predicted 
relationships for patients in whom the non-suppressible 
component of alkaline phosphatase is 70,50 or 30U/1. 
The effect of these differences is greater at lower 
values of total pretreatment alkaline phosphatase. 
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functionless and fully functioning alveoli (West, 1977). 
Using this relationship it may be possible to construct 
an algorithm which could give an index of the adequacy of 
response for individual patients. However, this is 
unlikely to be useful in patients with pretreatment 
alkaline phosphatase values of less than 200 U/1 as both 
the increased slope of the curve and the larger effect of 
interindividual variations in the non-suppressible 
component of alkaline phosphatase at lower values of 
total alkaline phosphatase will tend to reduce the 
predictive value (Figure 3.17). 
Ideally, comparison of responses between 
treatment groups should be done on pairs of patients who 
are matched for both original pretreatment alkaline 
phosphatase and, if previously treated, patients should 
also be matched for alkaline phosphatase values 
immediately before retreatment. Although randomised 
controlled trials would also produce unbiased results, in 
order to ensure comparability of pagetic activity between 
groups larger numbers of patients would be required than 
in a study of matched pairs. In practice such matching 
is difficult. Furthermore, it is often desirable to be 
able to make retrospective comparisons in order to judge 
responses to new treatments against those of existing 
treatments and also to be able to compare treatment 
responses between two or more different studies. 
Therefore a more important use of the relationship 
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between pretreatment alkaline phosphatase and expected 
fall may be that it enables a more valid comparison of 
imperfectly matched treatment groups. This use has been 
demonstrated with regard to the dose/response 
relationship to intravenous clodronate. 
Practical difficulties with oral diphosphonate 
treatment include the inconvenience of having to take 
tablets, often in considerable quantities, away from food 
(which impairs drug absorption) for prolonged periods. 
These problems are greater in patients who develop 
gastrointestinal intolerance and in those who have 
difficulty with drug compliance for other reasons. Thus 
the use of an intravenous regimen provides an attractive 
alternative to oral treatment. However, the relatively 
short duration of remission (at least in the clodronate 
300mg group) suggests that a5 day regimen may not be 
optimal. 
Treatment of Paget's disease with AHDP either by 
mouth or intravenously effectively suppresses the disease 
activity using doses considerably lower than those 
required with etidronate or clodronate treatment. It 
therefore shows promise as a treatment for this disorder. 
Apart from higher potency the effects of AHDP to suppress 
bone turnover appear to be very similar to those of 
clodronate. Biochemical relapse has occurred in some 
AHDP treated patients and although the follow-up interval 
on most patients is very short the duration of remission 
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appears to be similar to that following clodronate 
treatment. This treatment appears to be free from side 
effects and in particular, unlike APD, no 
immunomodulatory effects, either pyrexia or leucocyte 
suppression, were noted in the present study. Further 
studies are required to confirm this lack of effect of 
AHDP on the immune system. The effects of these agents 
on the mineralisation of newly formed osteoid is 
discussed in the next chapter. 
The suppression of alkaline phosphatase 
following intravenous etidronate treatment appears to be 
less marked than that seen following treatment with 
intravenous clodronate or AHDP despite a similar degree 
of suppression of OHP/Cr. Thus, biochemically it appears 
that intravenous etidronate might produce a more 
sustained "uncoupling" effect than does clodronate. If 
this is a true reflection of events in terms of turnover 
of bone matrix then this might imply that etidronate is 
capable of producing a greater incremental increase in 
bone mass than clodronate and thus may be potentially 
useful in the treatment of bone loss. However, it is 
difficult to envisage a mechanism whereby differences in 
the degree of dissociation of bone formation and bone 
resorption lasting for several months may be produced by 
such short courses of treatment. It is possible that the 
apparent difference in the degree of "uncoupling" is 
artefactual. Further studies are required to examine 
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this point. 
Future studies are planned, and have been 
initiated, to investigate the importance of the timing of 
intravenous diphosphonate administration and the possible 
role of a combined intravenous/oral approach. Thus, as a 
direct comparison to the 5 day intravenous regimens, some 
patients are receiving a once monthly intravenous 
infusion of clodronate 300mg or 600mg to be continued for 
5 months. In other patients a5 day intravenous course 
of clodronate will immediately be followed by a1 month 
course of oral clodronate 1.6g daily. It will be 
interesting to see if either of these approaches results 
in more complete or more sustained responses than those 
obtained with 5 consecutive days of intravenous treatment 
alone. 
The present studies have shed some light on the 
problem of optimising diphosphonate treatment and 
comparing treatment responses in Paget's disease of bone. 
In addition, by confining treatment to such a short 
period, the biochemical effects of intravenous treatment 
provide information on bone turnover and the coupling 
mechanism in this disorder. Clearly there is much scope 
for further work in this area and it will be some time 
before optimal regimens will be known with confidence. 
Changes in bone turnover at a cellular or bone matrix 
level are inevitably associated with changes in calcium 
and phosphate homeostasis. The changes in mineral 
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metabolism observed following the short intravenous 
diphosphonate treatments described here are discussed in 
the next chapter. 
Summary 
1. We and others have previously shown that short courses 
(1 month) of high dose oral diphosphonate treatment 
induce biochemical suppression of pagetic activity 
comparable to that seen following 6 months treatment. 
2. Thus the effects of very short (5 day), high dose, 
intravenous courses of diphosphonates to suppress pagetic 
activity were studied and compared with responses to 
long-term oral diphosphonate treatment. 
3. Intravenous clodronate induced a marked and sustained 
suppression in the biochemical indices of pagetic 
activity. There appears to be a dose/response 
relationship; 600mg/day was almost universally effective, 
100mg/day has very little effect whereas the response to 
300mg/day was intermediate between the two. 
4. Previous diphosphonate treatment caused an apparent 
resistance to intravenous clodronate which was, at least 
in part, an artefact due to incomplete biochemical 
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relapse before retreatment. 
5. The percentage fall in biochemical markers following 
effective treatment for Paget's disease is highly 
dependent on the degree of pagetic involvement as judged 
by values of alkaline phosphatase observed before 
diphosphonate treatment. This relationship should be 
considered in order to facilitate comparisons between 
treatment groups. 
6. The duration of biochemical remission following 
intravenous clodronate therapy was significantly shorter 
than that following 6 months oral clodronate treatment 
but similar to that observed following oral etidronate 
treatment. 
7. Treatment of Paget"s disease with the novel 
diphosphonate AHDP, given either orally or intravenously 
effectively suppressed pagetic activity when given by 
either route and when given intravenously has a potency 
of approximately 6 to 12 times greater than that of 
clodronate. 
S. Intravenous etidronate was also effective in 
suppressing bone resorption although preliminary results 
suggest a less marked suppression of bone formation, as 
judged by alkaline phosphatase, than that seen with 
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either clodronate or AHDP. 
9. Short intravenous courses of diphosphonates offer an 
attractive alternative form of treatment to the currently 
used long-term oral diphosphonate regimens. 
CHAPTER FOUR 
EFFECTS OF INTRAVENOUS DIPHOSPHONATES ON CALCIUM AND 
PHOSPHATE METABOLISM AND SKELETAL MINERALISATION IN 
PAGET'S DISEASE OF BONE 
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EFFECTS OF INTRAVENOUS DIPHOSPHONATES ON CALCIUM AND 
PHOSPHATE METABOLISM AND SKELETAL MINERALISATION IN 
PAGET'S DISEASE OF BONE 
Introduction 
The potent effects of diphosphonates on bone 
turnover in Paget's disease, discussed in Chapter 3, may 
be expected to result in changes in skeletal calcium 
balance and thus calcium homeostasis. While alterations 
in calcium homeostasis may be of little consequence in 
this disorder, Paget's disease forms a useful model for 
the study of the use of diphosphonates in treatment of 
hypercalcaemia of malignancy where conditions are less 
controlled. The known effects of etidronate at high 
dosage to impair mineralisation of bone may have 
important consequences for skeletal calcium homeostasis. 
Although diphosphonates other than etidronate given by 
mouth are not generally associated with impaired 
mineralisation, their effects when given intravenously, 
where very much higher systemic delivery may be achieved, 
have not previously been investigated. Thus the effects 
of intravenous diphosphonates on bone mineralisation as 
well as possible interrelationships between 
mineralisation effects and effects on calcium and 
phosphate homeostasis were investigated in these studies. 
Several studies on the use of etidronate in the 
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treatment of Paget"s disease of bone have noted a 
consistent hyperphosphataemic response in patients taking 
high oral doses (Altman et all 1973; Russell et all 
1974). This effect, which becomes maximal at about 2 
weeks from the start of treatment, has been shown to be 
mediated via an increase in renal tubular reabsorption of 
phosphate, expressed as TmP/GFR (Walton et all 1975a). 
Clinical studies with other diphosphonates, including 
clodronate and APD, given by mouth have generally shown a 
decrease rather than an increase in serum phosphate and 
thus hyperphosphataemia is generally assumed to be an 
idiosyncratic effect of etidronate (van Breukelen et all 
1979; Douglas et all 1980). However, using high doses of 
APD (600mg by mouth daily) Nagant de Deuxchaisnes and 
colleagues (1982) noted a small and transient increase in 
phosphate and TmP/GFR in pagetic patients. The question 
arose as to whether the hyperphosphataemic response might 
be a general property of all diphosphonates if given in 
sufficient dosage. Thus a further aim of the present 
study was to explore this possibility using the very high 
systemic doses of three diphosphonates which are achieved 
by intravenous infusion. Changes in TmP/GFR following 
diphosphonate treatment may be influenced by changes in 
calcium homeostasis and thus in PTH status. In order to 
investigate effects of diphosphonates on TmP/GFR 
independently from changes in PTH a small number of 
patients with hypoparathyroidism were also studied. 
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The studies on calcium and phosphate metabolism 
in Paget's disease were of the same patients and 
treatments with intravenous diphosphonates as reported in 
the last chapter except that an additional 9 patients who 
were treated with intravenous AHDP 50mg/day are included 
here. Quantitative histology of bone was studied in 29 
patients with Paget's disease (8 given etidronate, 13 
given clodronate and 8 given AHDP) using methods outlined 
in Chapter 2. In a further 3 patients the timing of the 
tetracycline labelling was altered to investigate 
mineralisation either during clodronate treatment (2 
patients) or 1 month following the end of etidronate 
therapy (1 patient) as described in Chapter 2. 
Two of the pagetic patients receiving their 
fifth day of etidronate were infused with 200U of human 
PTH (1-84) for 30 minutes during a period of half hourly 
blood and urine sampling for the detection of acute 
changes in renal tubular reabsorption of phosphate 
measured as TmP/GFR. 
A further 4 patients (all female) with 
hypoparathyroidism were studied. Three received 
clodronate 300mg/day whereas the remaining patient was 
given AHDP 50mg/day. Each was treated for 5 days. All 
patients gave informed consent for study which had been 
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approved by the local Ethics Committee. 
Results 
Effects on calcium metabolism 
The comparative effects of intravenous 
clodronate (300mg/day), etidronate (300-700mg/day) and 
AHDP (25mg/day) on serum calcium, fasting Ca/Cr and 
urinary OHP/Cr are shown in Figure 4.1. There was an 
initial slight but significant (p<0.01) increase in serum 
calcium in the etidronate treated group by day 1 which 
was sustained (apart from the drop at day 4) for at least 
19 days. Urinary Ca/Cr also increased significantly on 
day 1 (p<0.05) but overall changed very little from 
pretreatment values. As in the etidronate treated group, 
significant, albeit modest, increases in calcium and 
Ca/Cr occurred at day 1 in the clodronate group (p<0.01 
and p<0.05 respectively). However, the predominant 
effects in both clodronate and AHDP treated patients were 
of marked and consistent hypocalcaemia and hypocalciuria. 
These effects were maximal at 5 to 12 days from the start 
of treatment, both indices gradually returning to 
pretreatment values at around 3 months (data not shown). 
The similarity of changes in calcium and changes in Ca/Cr 
in all three groups suggests that calcaemic changes were 
not due to primary changes in renal tubular reabsorption 
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Figure 4.1 Effects of treatment with 3 diphosphonates 
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of calcium. All three diphosphonates induced a similar 
degree of suppression of bone resorption as judged by 
urinary OHP/Cr. 
The most likely explanation for the observed 
hypocalcaemic responses to clodronate and AHDP was that 
the rapid suppression of bone resorption with a delayed 
fall in bone formation, described in chapter 3, would 
lead to a transient phase of net bone formation with 
calcium accretion and consequent hypocalcaemia. If this 
was the case the degree of the hypocalcaemic effect 
should be a function of the degree of suppression of bone 
resorption. Figure 4.2 shows that such a relationship 
did indeed exist among patients treated with clodronate 
300mg/day but not among the 7 patients given etidronate 
300mg/day. Moreover, in patients treated with clodronate 
100mg/day, in whom suppression of bone resorption was 
minimal, no significant hypocalcaemic effect was 
observed, whereas the 600mg dose, which induced the 
greatest suppression of bone resorption, was also 
associated with the most marked hypocalcaemic effect 
(Figure 4.3). 
Changes in iPTH in the different treatment 
groups were appropriate homeostatic responses to the 
observed changes in serum calcium for each group (Figure 
4.4). Thus, there were marked increases in iPTH in both 
clodronate and AHDP treated patients due to a secondary 
hyperparathyroid effect whereas there was no significant 
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Figure 4.2 Relationship between the mean change in 
serum calcium and the mean fall in OHP/Cr by 4 days to 2 
weeks from the start of treatment in patients treated 
with either intravenous clodronate 300mg/day or 
intravenous etidronate 300mg/day. Correlation 
coefficient and P value for clodronate treated patients 
only. No significant correlation in etidronate treated 
group. 
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three doses of intravenous clodronate in patients with 
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Figure 4.4 Changes in concentrations of immunoreactive 
PTH (as percentage of pretreatment values; mean +/- SEM) 
in response to intravenous treatment with etidronate 
(squares), clodronate (closed circles) or AHDP (open 
circles). 
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change in iPTH in the etidronate group. 
Effects on mineralisation of bone 
Mineral apposition rates (MiAR) before the start 
of diphosphonate treatment and for the 10 days after this 
point, determined from the triple tetracycline labelling 
technique, are shown in Figure 4.5. Rates before 
treatment were similar for etidronate, clodronate and 
AHDP treated patients. Intravenous treatment was 
associated with a consistent and highly significant fall 
in MiAR in all three groups. However, whereas mean 
values fell by 30% and 25% in clodronate and etidronate 
treated patients respectively, there was complete loss of 
uptake of the final tetracycline label (commenced 5 days 
after the end of intravenous treatment) in all 8 of the 
etidronate treated patients (Figure 4.5). This finding 
suggests that etidronate induced a complete inhibition of 
mineralisation and that this effect was sustained for at 
least 7 days from the end of the treatment period (i. e. 
to the end of the third label). In the one patient given 
the final tetracycline label 30 days from the start of 
etidronate treatment uptake of this label was present, 
but diminished, indicating that reversal of the 
mineralisation defect was occurring at around that time. 
Changes in MiAR in clodronate treated patients 
given either 100mg (n=2) or 600mg (n=2) were also 
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Figure 4.5 Effects of intravenous diphosphonate 
treatments of Paget's disease on mineral apposition rate 
(MiAR) determined by a triple tetracycline labelling 
technique. Both intravenous clodronate and intravenous 
etidronate produced a significant suppression of MiAR on 
paired t-testing. Uptake of the final label was 
completely absent in all etidronate treated patients. 
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examined and are compared with the individual responses 
of 300mg clodronate treated patients in Figure 4.6. 
These results suggest that a dose/response relationship 
exists so that 100mg has little or no effect on 
mineralisation 600mg produces a very marked suppression 
(mean fall of 66%). However, no such dose-dependence 
could be detected in AHDP treated patients. In fact the 
5 patients given 25mg had a slightly greater mean 
reduction (29%) than did the 3 given 50mg/day (19%). 
The reduced MiAR following clodronate or AHDP 
treatment might have resulted either from a transient but 
complete inhibition of mineralisation during the 
treatment period or from an incomplete but more sustained 
suppression of mineralisation. in order to examine these 
possibilities 2 patients were studied. Both patients, 
who received clodronate (300mg/day), were given their 
final tetracycline label during the last 2 days of the 
treatment period. In both cases uptake of this final was 
observed but separation between labels was markedly 
reduced suggesting that suppression but not complete 
inhibition of mineralisation occurred during the 
treatment period. 
Effects on phosphate metabolism 
Figures 4.7 and 4.8 show the changes in serum 
phosphate and TmP/GFR in response to intravenous 
Effects of clodronate on mineralisation 
., 
1.2 
1.0 
ýv 
0.8 
0.6 
0, . 
0.4 
U 
Pre 
13 100mg " 300mg 
0 
Post 
o 600mg 
Figure 4.6 Changes in MiAR in individual clodronate 
treated patients. Marked decreases were observed in 2 
patients who were treated with the 600mg dose whereas a 
fall in MiAR occurred in only 1 of the 2 patients treated 
with clodronate 100mg/day. 
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Figure 4.7 Effects of daily 3h intravenous infusions 
with etidronate (squares), clodronate (closed circles) or 
AHDP 50mg/day (open circles) for 5 days on serum 
phosphate in patients with Paget"s disease. Early 
increases were significant in all three groups (at day 1 
only in the AHDP group). 
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Figure 4.8 Effects of daily 3h intravenous infusions 
with etidronate (squares), clodronate (closed circles) or 
AHDP 50mg/day (open circles) on TmP/GFR. * p<0.05 
** p<0.01 *** p<0.0001 on paired t-testing. 
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treatment with the three diphosphonates (data shown for 
AHDP 50mg/day dose). Etidronate treatment induced a 
rapidly progressive increase in both of these indices to 
reach a maximum at between 6 and 14 days from the start 
of treatment with a gradual fall thereafter. Values for 
both phosphate and TmP/GFR remained significantly 
increased until 5 weeks from the start of treatment. 
Significant, although less marked, increases in 
serum phosphate and TmP/GFR were seen in patients treated 
with the other two diphosphonates (although this failed 
to reach significance in the AHDP 25mg group). Increases 
in those given clodronate were sustained for the period 
of treatment whereas these effects were seen only for the 
first few days following treatment with AHDP 50 mg/day. 
In both the clodronate group and the AHDP group a highly 
significant hypophosphataemic effect was observed 
following the end of treatment which gradually diminished 
over 2 to 3 months. The time courses of changes in iPTH 
and of the secondary hypophosphataemic responses seen in 
these two groups were similar suggesting that the fall in 
phosphate was likely to be due to a PTH mediated fall in 
TmP/GFR. 
The hyperphosphataemic response to clodronate 
did not appear to be dose dependent as the degree of the 
hyperphosphataemia was indistinguishable for the three 
doses (Figure 4.9). However, a dose/response 
relationship was apparent for the subsequent 
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Figure 4.9 Mean values for serum phosphate in pagetic 
patients treated with either 100mg, 300mg or 600mg of 
clodronate per day for 5 days. 
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hypophosphataemia which is likely to reflect the 
different degrees of hypocalcaemia and consequent 
secondary hyperparathyroidism for the three dosage 
groups. 
Effects of exogenous PTH on TmP/GFR 
The fall in TmP/GFR induced by exogenous 
administration of human PTH in 2 etidronate treated 
patients is shown in Figure 4.10. The presence of this 
continued renal tubular responsiveness to PTH, even 
following very high intravenous doses of diphosphonates, 
indicates that at least part of the hyperphosphataemic 
response to clodronate and AHDP may be masked by the 
observed concomitant secondary hyperparathyroidism. In 
order to examine the effects of these agents given 
intravenously in the absence of changes in PTH status 4 
patients with hypoparathyroidism were studied. 
Effects in hypoparathyroid subjects 
In all 3 hypoparathyroid patients treated with 
clodronate 300mg/day for 5 days serum phosphate and 
TmP/GFR became markedly increased during treatment 
(Figure 4.11). The extent of these increases was 
comparable to that seen following etidronate treatment 
and much greater than that observed in pagetic patients 
PTH 
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Figure 4.10 Acute changes in TmP/GFR in 2 patients with 
hyperphosphataemia due to treatment with intravenous 
etidronate 7.5mg/kg in response to exogenous PTH 200U. 
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Figure 4.11 Changes in serum phosphate and TmP/GFR in 4 
hypoparathyroid subjects treated with daily 3h 
intravenous infusions of either clodronate 300mg/day 
(closed circles) or AHDP 50mg/day (open circles) for 5 
days. 
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given the same dose of intravenous clodronate. The 
single hypoparathyroid subject treated with intravenous 
AHDP also had increases in both phosphate and TmP/GFR 
although these changes were less marked than those seen 
in the other 3 patients. However, both from the increase 
in iPTH observed in this subject (Figure 4.12) and the 
initial serum phosphate, which was within the normal 
range, it seems likely that she possessed some residual 
parathyroid function which may have partially offset the 
effect of AHDP on TmP/GFR. 
Discussion 
This study demonstrates major differences in 
calcaemic and calciuric effects of intravenous etidronate 
treatment compared with those of the other diphosphonates 
studied. These findings are similar to those of previous 
studies using oral diphosphonates in pagetic patients in 
which no change in serum calcium has been noted following 
etidronate treatment (Khairi et al, 1974; Russell et al, 
1974) but both clodronate and APD treatments have 
hypocalcaemic effects (Frijlink et a1,1979; Douglas et 
al, 1980). Such marked differences between 
diphosphonates could have important implications when 
these drugs are being used for their hypocalcaemic 
effects, for example in the treatment of hypercalcaemia 
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Figure 4.12 
. Serum concentrations of 
iPTH before and at 
the end of diphosphonate treatment in 4 hypoparathyroid 
subjects. The pretreatment value was in the mid- normal 
range in the 1 patient treated with AHDP (open circles) 
and increased following treatment suggesting that there 
was at least some parathyroid activity. 
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of malignancy which is examined in Chapter 5. 
In the present study changes in urinary calcium 
excretion were in the same direction as changes in serum 
calcium in all groups. Thus, although renal tubular 
transport of calcium has not been studied directly, it is 
unlikely that differences in calcaemic response were 
caused by differences in diphosphonate effects on renal 
handling of calcium. All three diphosphonates studied 
produced a marked early suppression of bone resorption 
followed by a later fall in bone formation (Chapter 3). 
These changes would be expected to result in a period of 
positive net bone balance and thus net entry of calcium 
into bone and a tendency towards hypocalcaemia. However, 
the present study indicates that etidronate treatment 
results in a profound and sustained inhibition of bone 
mineralisation, and thus calcium entry into bone, and 
this probably accounts for the lack of hypocalcaemic 
response and the slight tendency towards hypercalcaemia 
in this group. Figure 4.13 represents diagramatically 
the changes in calcium fluxes between bone and the ECF 
that are likely to occur in response to these treatments. 
The measurements of MiAR show that both 
clodronate and AHDP can also induce significant 
impairment of bone mineralisation, a finding which has 
not previously been reported in man. In the case of 
clodronate, this appears to be a dose-dependent effect. 
Such an effect may account for the significant increases 
p. 
Bone calcium fluxes in Paget's 
untreated Paget 's 
Ca 
unchanged 
etidronate 
CaO 
ciodronate or AHOP 
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Figure 4.13 Schematic diagram of changes in calcium 
fluxes following diphosphonate treatment of Paget"s 
disease. Inhibition of bone resorption results in net 
calcium entry into bone following clodronate or AHDP 
whereas this net flux is reversed following etidronate 
due to complete inhibition of mineralisation. 
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in serum calcium and urinary Ca/Cr at day 1 noted in the 
clodronate 300mg and 600mg groups. Thus it may be 
inadvisable to give very high intravenous doses of 
clodronate in the treatment of patients with 
hypercalcaemia of malignancy as impaired skeletal uptake 
of mineral at such doses may potentially offset the 
hypocalcaemic effect. 
The presence of a tetracycline label 
administered during treatment with clodronate indicated 
that mineral accretion into bone continued throughout the 
treatment period albeit at a reduced rate. This notion 
is supported by the hypocalcaemic response to clodronate 
treatment which suggests that there was a net flux of 
calcium entering bone. Although not studied directly, in 
view of the early hypocalcaemic response to AHDP 
continued mineralisation would also be expected in 
patients treated with this agent. These findings suggest 
that urinary Ca/Cr is insufficiently sensitive to be used 
as a screen to detect modest degrees of impairment of 
mineralisation following diphosphonates. 
The present study demonstrates that 
hyperphosphataemia is not a unique feature of etidronate 
treatment but occurs when other diphosphonates are given 
in sufficient dosage. As previously mentioned, mild and 
transient increases in serum phosphate and TmP/GFR have 
been observed following the use of a high oral dose of 
APD (600mg/day) in the treatment of Paget's disease 
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(Nagant de Deuxchaisnes et al, 1982). In that study 
there was some radiographic evidence for treatment 
induced focal impairment of mineralisation. 
Recker and colleagues (1973) have previously 
demonstrated unimpaired phosphaturic and urinary CAMP 
responses to exogenously administered PTH during oral 
etidronate-induced hyperphosphataemia in normal subjects. 
This observation has been extended in the present study 
to patients on intravenous etidronate treatment in whom 
the systemic dose may be as much as 20 times higher. 
These data suggest that a competitive mechanism, blocking 
the PTH mediated effect to reduce renal tubular 
reabsorption of phosphate, to cause the observed increase 
in TmP/GFR must be unlikely. In view of this continued 
responsiveness of renal tubular phosphate transport to 
PTH, much of the difference in degree of 
hyperphosphataemia between diphosphonates may be 
accounted for by the observed differences in calcaemic 
and PTH responses. When the effects of changes in PTH 
were removed, as in the hypoparathyroid subjects and in 
etidronate treated patients in whom iPTH remained 
unchanged, the full hyperphosphataemic effects of the 
diphosphonates became apparent. 
However, despite similar increments in serum 
phosphate and TmP/GFR in the hypoparathyroid group 
compared with the etidronate treated Paget's patients 
there were marked differences in duration of responses. 
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Thus, serum phosphate and TmP/GFR had returned to normal 
within 1 week of stopping clodronate or AHDP, whereas 
these measurements remained maximally increased at 1 week 
following etidronate and only returned to pretreatment 
values after 1 month. It seems unlikely that the 
difference in time course is a result of fundamentally 
different mechanisms for the production of the 
hyperphosphataemic effect. The sustained effect 
following etidronate, which like other diphosphonates is 
rapidly taken up into bone or eliminated in the urine, in 
pagetic patients would appear to mitigate against a 
direct effect of the drug on the renal tubule to enhance 
phosphate transport. The time course of the 
hyperphosphataemic response to etidronate in 
hypoparathyroid patients has not been studied, but might 
be expected to be similar to that in pagetic patients in 
view of the lack of any significant change in PTH in the 
pagetic group. 
One possible explanation for the different 
TmP/GFR effects of the various diphosphonates is that 
there may be a causal relationship between the impaired 
mineralisation and the renal tubular effects. Thus, the 
short-lived impairment of mineralisation with intravenous 
clodronate or AHDP treatment coincides with the transient 
hyperphosphataemia whereas both effects are sustained 
following cessation of etidronate treatment. As further 
circumstantial evidence for this hypothesis, whereas 
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neither increased phosphate nor defective mineralisation 
are commonly observed in patients treated with low dose 
etidronate (5mg/kg/day), higher doses usually produce 
both features (Recker et al, 1973; Russell et al, 1974). 
Patients given the lower dose who have histological 
evidence for impaired mineralisation also develop 
hyperphosphataemia (Boyce et al, 1984). The relationship 
appears sufficiently close that the hyperphosphataemic 
response may in fact be a useful marker for measuring the 
dose requirements of etidronate for individual patients 
(Kanis, 1984b). 
From a teleological viewpoint the production in 
bone of a factor in response to changes in mineralisation 
which could regulate renal phosphate handling might be 
beneficial for the control of the mineralisation process. 
However, on present evidence the existence of such a 
factor must remain entirely speculative. 
Because of relatively wide fluctuations in serum 
phosphate in response to dietary phosphate loads it is 
often assumed that there is no specific homeostatic 
mechanism for the regulation of ECF phosphate 
concentrations. However, evidence from many studies 
using phosphate deprivation in both animals (Trohler et 
al, 1976) and man (Lotz et al, 1968; Dominguez et 
al, 1976) indicates the existence of a rapid and highly 
sensitive mechanism for near complete conservation of 
inorganic phosphate by the kidney prior to any 
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significant change in serum inorganic phosphate. 
Conversely, TmP/GFR has been shown to fall in response to 
a dietary phosphate challenge in man (Bijvoet & Morgan, 
1971). These homeostatic changes may result in part from 
a renal autoregulatory mechanism (Caverzasio et al, 
1985). However, it is likely that humoral regulatory 
mechanism(s) also exist (Altus & Garrick, 1984). Whereas 
acute responses to phosphate depletion appear not to 
involve new protein synthesis, more prolonged increases 
in phosphate transport in vitro is inhibited by 
actinomycin D, an inhibitor of protein synthesis (Dousa 
et al, 1980) suggesting the presence of more than one 
regulatory mechanism. 
Several hormones, including PTH, 1,25(OH)2D3, 
sex steroids, corticosteroids and growth hormone, are 
known to induce changes in TmP/GFR (Steele et all 1975). 
However, none of these appears to have a primary role in 
phosphate homeostasis, at least in the rat (Bonjour et 
all 1978). Thus the existence of a specific, as yet 
unknown, phosphate regulatory hormone or hormones may 
usefully be invoked to account for the observed 
homeostatic changes in renal handling of phosphate. 
A major difficulty in further study in this area 
arises because of wide interspecies variations in terms 
of phosphate responses to various probes. Thus whereas 
in man, and probably also in dogs and rabbits, etidronate 
induces an increase in inorganic phosphate the opposite 
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effect is observed in rats (Muhlbauer et al, 1981). 
There are also marked interspecies differences in 
calcaemic response to etidronate and in responses to 
phosphate deprivation. Studies to examine the effects of 
human bone cell culture media on phosphate transport in a 
pig renal epithelial cell line (LLC-PK1) are planned 
(Bevington, personal communication) but negative results 
in such a cross-species experiment obviously cannot 
exclude the presence of a bone derived phosphate 
regulatory factor in man. Whatever the mechanism 
responsible for diphosphonate-induced hyperphosphataemia, 
further investigation into this effect is likely to 
provide useful information about this poorly understood 
area of mineral metabolism. 
Summary 
1. The effects of daily intravenous infusions of three 
diphosphonates (etidronate, clodronate and AHDP for 5 
days) on calcium and phosphate homeostasis were studied 
in patients with Paget"s disease of bone. 
2. Treatment with clodronate (100-600mg/day) and AHDP 
(25-50mg/day) induced hypocalcaemia and secondary 
hyperparathyroidism (increased iPTH). These changes were 
not observed with etidronate (300-700mg/day) despite 
similar degrees of suppression of bone resorption with 
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each of the three treatments. 
3. The degree of the hypocalcaemic response in clodronate 
treated patients correlated significantly with the fall 
in urinary OHP/Cr suggesting that the fall in serum 
calcium was due to the inhibition of calcium efflux from 
bone. This relationship was not observed following 
etidronate treatment. 
4. A dose/response relationship was found for intravenous 
clodronate in terms of the hypocalcaemic response 
reflecting the greater suppression of bone resorption 
induced with higher doses. 
5. Intravenous etidronate induced marked increases in 
serum phosphate and TmP/GFR which remained significantly 
increased for 1 month after stopping intravenous 
treatment. Clodronate and AHDP induced smaller but 
significant increases in serum phosphate and TmP/GFR 
although these changes were ill-sustained and followed by 
decreases in both measurements. 
6. Normal phosphaturic responses to exogenously 
administered PTH occurred in 2 patients with etidronate 
induced hyperphosphataemia. 
7. In 4 hypoparathyroid subjects, intravenous clodronate 
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or AHDP produced increases in serum phosphate and TmP/GFR 
of comparable degree to, but shorter duration than, those 
seen following etidronate treatment. 
8. Bone mineral apposition rates (MiAR), obtained from 
triple tetracycline labelled bone biopsies, fell from 
high to normal values following intravenous clodronate or 
AHDP but consistently decreased to zero both during 
treatment with etidronate and for at least 7 days 
thereafter. 
9. In conclusion, clodronate and AHDP inhibit bone 
resorption with only minimal effects on mineralisation. 
These actions account for the hypocalcaemic response, 
secondary hyperparathyroidism and, in part, for changes 
in phosphate metabolism in pagetic patients. 
10. There is an apparent relationship between 
diphosphonates effects to impair mineralisation and their 
effects to increase TmP/GFR suggesting the possibility of 
a bone/kidney link for regulation of phosphate 
homeostasis. 
11. Despite similar effects on bone resorption, 
etidronate halts mineralisation, and this accounts for 
the attenuated effects on serum calcium. 
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12. Differences in the potencies of different 
diphosphonates to impair mineralisation relative to their 
effects on bone resorption may make etidronate less 
suitable than either clodronate or AHDP in the treatment 
of hypercalcaemic disorders. 
SECTION THREE 
THE USE OF DIPHOSPHONATES IN HYPERCALCAEMIC DISORDERS 
CHAPTER FIVE 
INTRAVENOUS DIPHOSPHONATES IN THE TREATMENT OF 
HYPERCALCAEMIA OF MALIGNANCY 
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INTRAVENOUS DIPHOSPHONATES IN THE TREATMENT OF 
HYPERCALCAEMIA OF MALIGNANCY 
Introduction 
The hypercalcaemia of malignancy is often 
marked, rapidly progressive and may be associated with 
severe symptoms. Treatment with intravenous saline, 
which increases renal elimination of calcium, is usually 
sufficient to halt the rise in serum calcium, but used 
alone saline treatment often fails to reduce serum 
calcium to normal (Hosking et al, 1981). Excessive bone 
resorption is the major mechanism responsible for 
hypercalcaemia in the majority of patients (see Chapter 
1) and, therefore, inhibitors of bone resorption may be 
useful. Of the available agents calcitonin is often only 
partially effective and the usefulness of mithramycin is 
limited by liver and bone marrow toxicity caused by this 
agent. Diphosphonates, because of their potent and 
specific effects to inhibit bone resorption and their 
general lack of toxicity, may be very useful in the 
treatment of malignant hypercalcaemia. A small study of 
the effects of oral etidronate, the only generally 
available form of diphosphonate, in malignant 
hypercalcaemia found this agent to be effective in only 1 
of the 4 patients treated (Mundy et al, 1983). 
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Similarly, oral etidronate was found to be ineffective in 
reducing calcium in patients with primary 
hyperparathyroidism (Kaplan et al, 1977; see chapter 6). 
Treatment with clodronate or APD by mouth has 
been shown to be effective in normalising serum calcium 
(Chapuy et al, 1980; Douglas et al, 1980; Paterson et al, 
1983; van Breukelen et al, 1979) or reducing net bone 
loss in patients with malignant disorders (Jung et al, 
1983; Siris et al, 1980). However, the high doses 
required to ensure sufficient absorption are commonly 
associated with gastrointestinal side effects and thus 
may be poorly tolerated by some patients. Impaired 
absorption of diphosphonates from the intestine might 
also occur particularly in dehydrated or cachectic 
patients or in those on chemotherapy. Use of the 
intravenous route of administration avoids such problems 
and the much higher systemic loading achieved by this 
route might be expected to result in a more rapid or a 
more consistent suppression of excess bone resorption 
than occurs with oral administration. 
Jacobs and colleagues (1981) using intravenous 
clodronate induced normocalcaemia in 11 of 12 treated 
hypercalcaemic patients. Intravenous APD has also been 
used with normalisation of calcium in 29 of 30 patients 
(Sleeboom et al, 1983). However, hypercalcaemia persisted 
in "about half" of the patients treated with APD studied 
by Ralston and colleagues (1985). In a comparative 
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study, Jung and coworkers (1982) noted no difference in 
ultimate hypocalcaemic effect between patients given 
intravenous treatment with either etidronate or 
clodronate at doses ranging from 100 to 500mg per day. 
However, they did observe a greater delay by several days 
in the hypocalcaemic effect of etidronate compared with 
the response to clodronate. More recently Ryzen et al 
(1985) have reported normalisation of serum calcium in 19 
of 26 patients treated with intravenous etidronate for 1 
to 4 days. However, the mean serum calcium for their 
patients remained above the normal range because of the 
poor response of some patients. Thus, the available 
evidence is insufficient to determine whether there are 
real differences in therapeutic efficacy between these 
agents. An intravenous preparation of etidronate may 
soon become commercially available and thus it is 
important to know how the efficacy of intravenous 
etidronate compares with that of other diphosphonates. 
Differences in the effects of the various 
diphosphonates in pagetic patients, examined in Chapters 
3 and 4, suggest that some may be more suiTable than 
others for the treatment of malignant hypercalcaemia. 
These studies indicated that the hypocalcaemic effect of 
intravenous etidronate was attenuated due to the 
associated impairment of mineralisation whereas both 
clodronate and AHDP induced significant hypocalcaemia. 
Therefore, the aim of the present study was to compare 
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directly the hypocalcaemic responses to the three 
diphosphonates, etidronate, clodronate and AHDP, given 
intravenously to patients with hypercalcaemia of 
malignancy. The doses used were those which had been 
found to suppress bone resorption in pagetic patients. 
In addition, control of serum calcium with the 
use of diphosphonates, which specifically inhibit bone 
resorption, facilitates an examination of the importance 
of renal tubular mechanisms in the genesis of 
hypercalcaemia in these patients. In particular, recent 
evidence has suggested that a humoral PTH-like mechanism 
to increase renal tubular reabsorption of calcium may be 
important in patients with solid tumours with or without 
metastases (Ralston et al, 1982,1984; Percival et al, 
1985b). For these reasons I have examined renal tubular 
reabsorption of calcium in patients with solid tumours 
and compared them with patients with haematological 
malignancies in order to investigate this mechanism. 
Methods 
48 hypercalcaemic episodes in 44 patients with 
malignant disease were studied. 17 patients had myeloma 
(20 episodes), 1 patient had a non-Hodgkins lymphoma (2 
episodes), 13 had carcinoma of the breast, 4 had 
bronchial carcinoma whereas the remaining 9 patients had 
a variety of solid tumours (see Table 5.1). All patients 
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remained hypercalcaemic following at least 48 hours of 
continuous intravenous infusion of saline. A further 7 
patients were excluded from the study on the basis of a 
fall in serum albumin concentration of more than 4g/l 
after the commencement of diphosphonate treatment 
suggesting that there was continued intravascular volume 
expansion. Informed consent was obtained either from the 
patient or, when their state of consciousness did not 
permit this, from a first degree relative. This study 
had prior approval of the local Ethics Committee. 
Fasting blood and urine samples were collected daily 
throughout the period of study and routine biochemical 
measurements were made as outlined in chapter 2. 
27 patients were treated with clodronate at 
doses of between 100 and 600mg daily for between 3 and 10 
days. 13 patients received etidronate 100-500mg daily. 
AHDP was given to 8 patients at a dose of either 25mg (2 
patients) or 50mg (6 patients) for 5 or 6 days (see Table 
5.1). These drugs were added to 0.51 of saline and 
infused over a minimum period of 3 hours. Continuous 
infusion of physiological saline 31 daily was maintained 
either until the patients became normocalcaemic or at 
least for the duration diphosphonate treatment. 
Results 
Comparison of diphosphonate treatments 
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Changes in serum albumin concentration provided 
a guide to the adequacy of intravascular volume 
expansion. Mean values for albumin for all patients 
combined fell by 2.0g/1 in the 48 hours preceding the 
start of diphosphonate infusion. No significant changes 
in serum albumin occurred following the start of 
diphosphonate treatment in any of the three treatment 
groups (Table 5.2) suggesting that intravascular volume 
expansion did not change markedly and was likely to be 
adequate in all groups. 
Figure 5.1 shows the fall in serum calcium in 
the 3 treatment groups. The groups were well matched for 
the degree of hypercalcaemia at the start of 
diphosphonate treatment and mean concentrations of serum 
calcium had been sTable over the preceding 48 hours in 
each group. This stability of calcium concentrations 
despite continuous intravenous saline suggests that the 
majority of patients had reached a new steady state for 
calcium. A significant hypocalcaemic response was 
achieved within 2 days of the start of diphosphonate 
treatment in all three groups. Mean values for serum 
calcium fell to normal within 5 days in clodronate and 
AHDP treatment groups but remained above normal following 
etidronate treatment. Thus, whereas 24 of the 27 
clodronate treatments (89%) and 6 of the 8 AHDP 
treatments (75%) resulted in normocalcaemia this was 
I 
rr N N A) N 
'd Gn (DD C 1. -+ 5 C 
D ä 
cl, ^ 51 m ºs 0x 50N 
5Nn 
G 
H- O 0 IL G 1-' N Aº 0 Cl) G ' 
0 (] 
r 
" r rr ýCf º- a L7 
.°° I- ä ä \ º- 5 º -' 
... w r* (D Vrr '-' 
at 0ý fD 
ºb CD 
Iv ro CD rs n 
CD 0 
o 
rr o 
(D 
~ : ro Cl Cii 
(n * I. - x x F- x x1 tz w W4 t 
N 
r 
(D * t7 N C7 C7 N0 0NU UN PC) ro tn U) ro Z to 1.0 ro ro M ro 
nn ro ro ºv td o0 
(t O 
Dl 0 
r" O 
r 
fD Mf ^N^F"^iý ^r^Fý^Fý O -w-w"-"w 
I 
I-" N CO PI-- WNW %0wF-+NI-a w O" O" O" Cl . O- 
O- N 
er O 01 CO -4ON I-'O JV1O1-4 C) C) " N. C) - %D " 
Fl " P- W 
:: ' E3 ". " -- 1 rn kc r ON 0 %D O o1 r 1.0 ºj v+ 
I-"' H 
cD rI1 to co * co OOw 
H 
ri to w I. 'ý r - V*- V-v 
r" 
rs Mw v+ 
m 
i! ) (D J . P. 
trier ,I Cl) 3" r- cu 
011) 
Nrr 1r !ý ^1+^ ww^W O 
0 
O (D O O 
" 0O W LA) " lD 
Q! O 
0%00L"POl--"N 
v" "- 
001001 1--A CD 
P %D 1 
t0 I-r- 0 
OOOWO t0 F-" OD O -4 I- JP N 
rt. 
. . u 
III kD co -4 Ov Fý 
rr 
Pl 
(D < P. N Cº 
r* ^ sv co j, p + 0 
O-G 
OI (D 
rr U) 
^ . N^N^W 
"OO" 
rr 
-j Pl O Liz 0 " L" t-a -" t) F-r 0% F-j W F--' Cº O"O"O" - 
O 
" G) " -A "0 fD r- 3 Q1 .P tp h+ co 1--" [J N 1-A 1"-a W F-A 
ý 
" CO " %0 "I 
PON 1- -1 I - F-a \C 
0N F- 0 A) fD 
II+ N 
-- ýt NJ*1 
1(1 
& - 
W CO W N*p* tu rr ` 
MI N 1-"" 1 VvV V*- 
* ý 
00 . .o * CN Ai L" co -4 rr CD r" vvv 
K 1--/ º""- 
vO CD 
O O' 
ýº N^N^N O" " 
Al 
F-'< r" PC IV NO i-+ v F-j w F-+ i-r O"O"O" O O 
" vi" m" to Pl rnoo0 -4 cn Li P. 1 . arn.. " ý" ý" r 
O r"t III W Co U' W* w*v* 
N (D HN Vv 
V 
hfi C. N (3) co 
0 C1 Cl w 
P1 vvv 
CD 
d 
er 
C. 
w cD 
n 
0 
ro 
0 
z 
0 
ro 
ro 
0 En ro 
0 z 
x 
ro 
rri 
rxj 
0 
ýTJ 
z 
rr 
rr 
Ea I'd 
0n50 
res wHm 
rt A ro r- 0\ r" \ tr re 
H. O0\H () H f G 
H C) ä1) \ Pl IL - 51 
0 I-' 
*H 
0ro P't A 
(D O 
Z 
rr o 
En* xxx k- x 
P- 
x 
(D ýE UN C7 VN0UNW 
:A ro ro ro ro 3 ro ED >F ro 
Oro 
Cl ro ro 
00 
r* o 
No 
ro 
fD M^ 01 01 ^ 01 iº O "ý f-+ ý-. F'' ^W^W^N 
r"rs U70UI W Ui O" O. O" l-"'0 I- L, )I. _. a Co 
cr0 'p. . C) . 0) 0" tn" v, " &. 1 
5I co IAI Ui W0) 0101I- 0oN01C (A)W 
fD Cl co * co Ol CO * "P 
hl v"rv 
än CD 
Pl 
CD 
Pl 
rCr ---m--rn ý H. -, H, _. N --W-W- N 5 0) , 0- -N0ný, o o" C) - p" 1NHOº--0) N ýS (D O"P, . gyp .. p. -4. 
¢1 I C1 IWI -1 N'Aº_JW W 01-1HNN0 
4O l0 N `-' `- - 
(D C- . _.. ... 
H + 
\ I~ 
fD 
(n ý, W"", p-Ui ^W^W-N 
CrI 0 NNWOPJ O" O" O" FriPf'HHai 
IWI .oI Wo 
C) (D N) C) -j -4 J-1- w 0) ON 
t~1 I0O 00 -- *- 
0vvv 
r'i SU 
r" 
HH 
0 (D 
to a 
I-- (7) - 
CI- 'Cl WN 01 t -n 
P. N O. O. O. NPNW º- -4 
I-I tU N"N" 0). "W" 01 " ON """"" 
¢J M" I vi INIH I-' cc) HW I-+ at. WN kO I"' WD O 
Z3 rl Un co co 110 'A. 
U1 !D Ol H .P-- ý" v 
Ftf ý, - 
0 
rt 
cD 
SU 
fr 
A) 
H 
CY 
ýD 
Ln 
N 
n 
O 
rt 
r" 
r't G 
C fD 
Lß na 
i 
N 
H 
I-" 
fD 
Co 
U) 
rt 
rt 
O 
rn 
rr 
-Jn 
m 
ni 
rr 
5 
m 
rr 
a 
m 
. CI) 
Comparison of diphosphonates 
o etidronate 
1 wlw arwný4ý 
3.4 
0 
E 
E 3.0 
E 
C., 2.6 
E 
co r 2.2 
days from start of treatment 
Figure 5.1 Effects of three diphosphonates given 
intravenously for 3 to 10 days on serum calcium in 
patients with hypercalcaemia of malignancy. 
IIIAI 11 111Iº 
-2 0247 10 14 
Chapter 5 HYPERCALCAEMIA OF MALIGNANCY Page 170 
achieved in only 2 of the 13 episodes treated with 
etidronate (15%). This difference in response rate 
between etidronate and the other 2 treatments achieved 
statistical significance using Fisher's exact test 
(p<0.001). 
Serum calcium in the etidronate group remained 
high even at 14 days (mean 2.92mmol/1). Mean serum 
calcium remained suppressed in the AHDP treated group but 
showed a secondary increase by 14 days in the clodronate 
group. It is not clear whether this late difference 
reflects true differences between clodronate and AHDP in 
duration of effect or is merely due to differences in the 
patient populations. 
Changes in fasting urinary Ca/Cr were similar to 
those observed in serum calcium for each of the three 
groups (see Figure 5.2, Table 5.2). The lack of an early 
fall in Ca/Cr in the etidronate group suggests that net 
calcium release from bone remained high during etidronate 
treatment. In contrast, net calcium loss from bone, as 
judged by Ca/Cr, was decreased by both clodronate and 
AHDP treatment. However, the fall in Ca/Cr in the AHDP 
treated group did not reach statistical significance 
because of the low number of observations. Despite the 
difference in effects of the diphosphonates on calcium 
metabolism, bone resorption, as judged by urinary 0HP/Cr, 
decreased significantly and by similar amounts in all 
three treatment groups (Figure 5.3). 
w 
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Figure 5.2 Effects of intravenous treatment with 
etidronate, clodronate or AHDP on fasting urinary Ca/Cr 
in patients with hypercalcaemia of malignancy. 
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Figure 5.3 Effects of three diphosphonates on urinary 
OHP/Cr in patients with hypercalcaemia of malignancy. 
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Other biochemical changes are shown in Table 
5.2. There were no significant changes in serum 
phosphate in any group, although mean values increased 
following etidronate and decreased following the other 
two diphosphonates. Serum creatinine fell in all 3 
groups probably reflecting the fall in serum calcium with 
consequent increases in GFR in each group. The mean 
pretreatment serum creatinine concentration in the AHDP 
group was particularly high because of the inclusion of 
one patient with myeloma (No. 13) who had severe renal 
impairment (creatinine 688umo1/1 immediately before the 
start of diphosphonate treatment). 10 days after the 
start of treatment serum creatinine in this patient had 
fallen to 137umol/l. Although serum albumin did not 
change significantly following the start of treatment in 
any group, mean values were lowest in the etidronate 
group (Table 5.2). 
Comparison of responses in haematological malignancies 
and solid tumours 
Patients with haematological malignancy and 
those with solid tumours were well matched for the degree 
of hypercalcaemia before treatment. In response to 
treatment with either clodronate or AHDP highly 
comparable falls in serum calcium were seen in the two 
groups (Figure 5.4). In addition, both the mean 
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Figure 5.4 Comparison of changes in serum albumin and 
serum calcium between patients with haematological 
malignancy and those with solid tumours. 
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pretreatment values of urinary Ca/Cr and urinary OHP/Cr 
and the degree to which these measurements were 
suppressed following treatment was very similar in 
patients with haematological malignancy and in the solid 
tumour group (Table 5.3). 
Whereas in 4 of the solid tumour patients given 
clodronate or AHDP serum calcium remained above the 
normal range this also occurred in 3 patients with 
myeloma. Of the 4 patients with solid tumours but no 
evidence of metastases (see Table 5.1) only 1 failed to 
become normocalcaemic. Thus separation of patients with 
different types of malignancy or on the basis of presence 
or absence of metastases was not useful in predicting 
degree of response to treatment. 
Fasting urinary calcium excretion per unit of 
glomerular filtrate (CaE), both before treatment and 
after 5 to 10 days, were plotted against serum calcium 
for individual patients with haematological malignancy 
(Figure 5.5) or solid tumours (Figure 5.6). There was 
considerable heterogeneity, in terms of renal tubular 
reabsorption of calcium, present in both types of 
malignancy but this was greater in solid tumour patients 
4 of whom had markedly increased renal tubular 
reabsorption of calcium before the start of diphosphonate 
treatment. However, renal tubular reabsorption of 
calcium remained markedly increased in only one patient 
following treatment (Figure 5.6). This man, who had a 
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Figure 5.5 Effects of treatment with either clodronate 
or AHDP on caE and serum calcium in patients with 
hypercalcaemia due to haematological malignancy. In the 
majority of patients the relationship between these 
measurements was close to normal (denoted by the curved 
lines) both before and after diphosphonate treatment. 
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Figure 5.6 Changes in the relation hip between CaE and 
serum calcium in patients with hypercalcaemia due to 
solid tumours following treatment with clodronate or 
AHDP. In 3 of 4 patients with increased renal tubular 
reabsorption of calcium before treatment (indicated by a 
shift to the right from the normal relationship) this 
returned to normal following treatment. 
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parotid carcinoma without evidence of skeletal 
metastases, had a negligible response to clodronate 
treatment. Bone resorption in this man, as judged by 
urinary OHP/Cr, was within the normal range and thus the 
hypercalcaemia in this case appears to have been entirely 
due to a PTH-like effect to enhance renal tubular 
reabsorption of calcium. iPTH was undetecTable and it is 
thus assumed that his tumour was producing a PTH-like 
humoral factor. 
Mean responses (+/- SEM) for the two diagnostic 
groups are shown in Figure 5.7. Note that whereas renal 
tubular reabsorption of calcium is, on average, higher in 
the solid tumour group at the start of treatment, this 
difference is lost by the end of treatment when mean 
values for both groups fell within the reference limits. 
Other biochemical changes are shown in Table 
5.3. It is noteworthy that serum alkaline phosphatase 
increased in the solid tumour group following treatment. 
However, this is likely to reflect increasing liver 
dysfunction, rather than an increase in osteoblast 
activity, as it was accompanied by a rise in 
gamma-glutamyl transpeptidase from a mean of 115U/1 to 
172U/1 at 14 days. 
Clinical observations 
No side effects of diphosphonate treatment were 
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Figure 5.7 Mean values (+/- SEM) for CaE and serum 
calcium in patients with either solid tumours or 
haematological malignancy before and after treatment with 
diphosphonates. 
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noted in any of the treatment groups. Symptomatic 
improvement occurred in the majority of patients and was 
related to the reduction in serum calcium and improved 
hydration. 
Discussion 
In this study the efficacies of three 
diphosphonates were compared directly in well matched 
groups of patients with malignant hypercalcaemia. By 
ensuring a minimum period of 48 hours of rehydration and 
excluding 7 patients who had an excessive subsequent fall 
in serum albumin, differences between groups due to 
rehydration effects were minimised. The stable 
concentrations of serum calcium before the start of 
diphosphonate treatment and the time course of the 
hypocalcaemic response, which did not become marked until 
2 days after the start of treatment, suggest that the 
observed effects were predominantly related to the 
diphosphonate treatment rather than to the effects of 
saline. However, we have previously found that 
continuous saline treatment alone may be associated with 
a progressive fall in serum calcium over several days and 
thus may have accounted for part of the observed 
hypocalcaemic responses (Percival et all 1984). 
In the current study the hypocalcaemic effect of 
intravenous etidronate, either in terms of mean calcium 
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concentrations or in numbers of patients achieving 
normocalcaemia, was significantly less marked than that 
seen with the other two agents. This attenuated response 
was not due to a lesser effect to inhibit bone resorption 
as urinary OHP/Cr fell to a similar degree following all 
three treatments. By analogy to the differential effects 
of these three diphosphonates given intravenously to 
patients with Paget"s disease reported in Chapter 4, it 
is likely that the lesser hypocalcaemic response to 
etidronate is due to the impaired mineralisation and thus 
impaired entry of calcium into bone induced by this 
agent. This was not verified directly because of the 
difficulties in obtaining tetracycline labelled bone 
biopsies from patients with acute episodes of 
hypercalcaemia of malignancy. Further evidence that 
etidronate is a less effective hypocalcaemic agent than 
clodronate is provided by studies of the oral use of 
these agents in patients with primary hyperparathyroidism 
reported in Chapter 6. In this study oral clodronate, 
but not oral etidronate, induced a significant 
hypocalcaemic response. 
The time course of the hypocalcaemic responses 
to diphosphonates in the present study, in which little 
change had occurred at 1 day, contrasts with that 
observed in the study by Ryzen and colleagues (1985) in 
which there was an early marked fall in serum calcium 
following treatment with etidronate. in their study 
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normocalcaemia was achieved in 19 of the 26 patients 
studied which compares with only 2 of 13 patients 
etidronate treated patients in the present study. Such 
an early fall in calcium in their patients is likely to 
have been due to the effects of saline infusion rather 
than of the diphosphonate. Thus inadequate pretreatment 
with saline may have accounted for the apparent more 
marked hypocalcaemic response to etidronate in their 
study than was observed in the present study. 
We have recently reported continued increased 
tubular reabsorption of calcium and a low TmP/GFR in 
patients with hypercalcaemia due to carcinoma of the 
breast suggesting that a PTH-like renal effect may be 
important (Percival et all 1985b). Other authors have 
made similar observations (Ralston et all 1984) 
suggesting that even in patients with bony metastases, 
humorally mediated increases in renal tubular 
reabsorption of calcium may be an important mechanism for 
producing hypercalcaemia. Furthermore, biochemical 
studies of patients with sold tumours have noted 
increased excretion of CAMP in the urine suggesting the 
possible presence of a PTH-like factor (Rude et all 1981; 
Stewart et all 1980). However, if renal tubular 
reabsorption of calcium remained elevated serum calcium 
would be expected to fall only to around the upper end of 
the normal reference range after diphosphonate treatment 
as has been observed in patients with primary 
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hyperparathyroidism (Douglas et al, 1983; also see 
Chapter 6). In support of this hypothesis, in a separate 
study in which clodronate was given by mouth we observed 
only a partial hypocalcaemic response in solid tumour 
patients (Percival et al, 1985a). 
Thus the lack of any solid demonstrable 
differences in response between patients with 
haematological malignancies and those with solid tumours 
and also between patients with metastases and those with 
no evidence of metastases was unexpected. The reason for 
this is unclear but may be largely a result of patient 
selection. The present study demonstrates that patients 
with solid tumours in particular show highly 
heterogeneous responses with only a proportion having 
clearly increased renal tubular bone resorption after 48 
hours of rehydration with intravenous saline. in some 
cases tubular handling of calcium appears to have 
normalised after normocalcaemia had been induced by 
diphosphonate treatment. It may be that the nephrogenic 
diabetes insipidus that accompanies hypercalcaemia 
results in inadequate rehydration despite the precautions 
taken to try to ensure this. Following normalisation of 
serum calcium this tubular defect is likely to improve 
(Levi et al, 1983) and thus renal handling of calcium 
might also be expected to return to normal. 
Another factor of possible relevence is the 
tendency for greater impairment of renal glomerular 
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function in myeloma patients compared with patients with 
solid tumours. This is reflected by differences in serum 
creatinine in the two groups (Table 5.3). For a given 
fluid throughput an increased fluid load per nephron will 
occur in a patient with a reduced GFR and because of 
increased sodium delivery this might be expected to cause 
a relative reduction in renal tubular reabsorption of 
calcium. Such a mechanism may account, in part, for the 
observed differences in renal handling of calcium between 
the two groups before diphosphonate treatment. 
Only one of the patients in the present study 
appeared to have a true PTH-like effect to increase renal 
calcium reabsorption. The type of solid tumour studied 
appears to have some bearing on the degree to which renal 
tubular reabsorption of calcium is increased. Thus in 
the study of Ralston and colleagues (1984), in which 
nearly all patients had evidence of increased renal 
tubular reabsorption of calcium, the majority of tumours 
were either squamous carcinomata or cancers of the 
genito-urinary system. By contrast, Hosking and 
coworkers (1981), whose patient group contained mainly 
patients with breast cancer or myeloma, found CaE entered 
the normal range in the majority of cases following 
rehydration. A relationship between these differing 
effects on renal calcium transport and the production of 
factors which bind to PTH receptors (other than PTH) as 
described by Strewler (1983) would seem likely but 
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further work in this area is required. 
The results of this study suggest that both 
clodronate and AHDP are highly effective treatments for 
malignant hypercalcaemia when given intravenously in 
conjunction with saline rehydration. Their use appears 
to be problem free and either agent may be conveniently 
added to the standard intravenous saline rehydration 
regimen. The short duration of these diphosphonate 
effects would suggest that longer-term maintenance 
treatment with oral diphosphonates should be considered, 
particularly in patients in whom the underlying malignant 
disease is not amenable to treatment. A recent study has 
suggested that long-term oral clodronate significantly 
reduces the development of new metastases and 
hypercalcaemia in women with carcinoma of the breast 
(Elomaa et al, 1983). We are currently involved in the 
design of two multi-centre trials to assess the value of 
such long-term treatments in patients with myeloma and in 
those with carcinoma of breast. Using a combination of 
intravenous diphosphonates for the acute management of 
hypercalcaemic episodes and long-term oral treatment for 
prophylaxis of hypercalcaemia and pathological fracture 
it is hoped to be able to substantially reduce the 
morbidity due to skeletal involvement in malignancy. 
Sumay 
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1) The effects of three diphosphonates given 
intravenously to patients with hypercalcaemia of 
malignancy were studied. Comparisons were made between 
treatment groups and also between patients with 
haematological malignancies and those with solid tumours. 
2) Following at least 48 hours of treatment with 
intravenous physiological saline, patients were given 
etidronate (n=13), clodronate (n=27) or AHDP (n=8) by 
daily slow intravenous infusion for 3 to 10 days. 
3) Mean serum calcium fell to normal in both clodronate 
and AHDP treated groups (2.42mmol/l and 2.39mmo1/l 
respectively at 7 days) but remained elevated in the 
etidronate treated group (3.00mmol/1) despite comparable 
suppression of bone resorption, as judged by the fall in 
urinary OHP/Cr. Only 2 of the 13 etidronate treated 
patients became normocalcaemic compared with 24 of 27 
clodronate treatments and 6 of 8 treatments with AHDP. 
4) changes in urinary Ca/Cr were in the same direction as 
changes in serum calcium for each group indicating that 
differences in calcaemic response were unlikely to be due 
to differential effects of diphosphonates on renal 
tubular reabsorption of calcium. 
5) By analogy with the calcaemic responses in Pagetic 
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patients, the less marked hypocalcaemic response to 
etidronate is probably related to the associated 
impairment of mineralisation and thus of entry of calcium 
into bone. 
6) As was noted in Pagetic patients treated with 
intravenous diphosphonates, hypocalcaemic responses did 
not become marked until 2 days from the start of 
treatment suggesting that these were due to the 
diphosphonates rather than to the effects of intravenous 
saline. 
7) Before diphosphonate treatment a proportion of 
patients with solid tumours had increased renal tubular 
reabsorption of calcium. However, there were no 
significant differences in response between patients with 
haematological malignancies and those with solid tumours 
in the degree of suppression of serum calcium, urinary 
Ca/Cr or OHP/Cr or in renal tubular reabsorption of 
calcium following treatment with clodronate or AHDP. 
Thus a sustained PTH-like effect on renal tubular 
reabsorption of calcium in a substantial proportion of 
patients with solid tumours could not be confirmed. 
8) Both clodronate and AHDP given intravenously are 
effective treatments in the management of hypercalcaemia 
of malignancy. 
CHAPTER SIX 
COMPARATIVE STUDY OF CLODRONATE AND HIGH OR LOW DOSES OF 
ETIDRONATE BY MOUTH IN THE TREATMENT OF PRIMARY 
HYPERPAR. ATHYROIDISM 
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COMPARATIVE STUDY OF CLODRONATE AND HIGH OR LOW DOSES OF 
ETIDRONATE BY MOUTH IN THE TREATMENT OF PRIMARY 
HYPERPARATHYROIDISM 
Introduction 
Hypercalcaemia in patients with primary hyper- 
parathyroidism is a result of the effect of PTH on the 
three major organs involved in calcium homeostasis, i. e. 
bone, gut and kidney. As discussed in chapter 1, 
probably the most important mechanism for sustaining an 
increased serum calcium is the PTH-induced increased 
renal tubular reabsorption of calcium. Bone turnover is 
modestly increased in the majority of patients but marked 
bone loss is less common. Thus treatment with inhibitors 
of bone resorption might not be expected to completely 
normalise serum calcium in these patients. This is borne 
out by studies using oral clodronate in which mean serum 
calcium values fell close to, but not within, the normal 
range (Douglas et al, 1983; Shane et al, 1981). Similar 
effects have been observed with the use of APD (van 
Breukelen et al, 1982) although mean values did fall into 
the normal range with this treatment probably reflecting 
lower pretreatment values (mean calcium before treatment 
2.83mmol/1). 
In contrast, in a study by Kaplan and colleagues 
(1977) using etidronate 20mg/kg in 6 hyperparathyroid 
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patients no significant change in serum calcium was seen 
despite a significant fall in total urinary 
hydroxyproline excretion. However, the small number of 
patients in this study meant that a significant 
hypocalcaemic effect of etidronate in primary 
hyperparathyroidism could not be excluded. The lack of 
hypocalcaemic response to high-dose oral etidronate was 
ascribed to the likely mineralisation defect although 
this was not examined directly (Kaplan et al, 1977). In 
a report of a single case of primary hyperparathyroidism 
Licata and O"Hanlon (1983) found that low dose etidronate 
(400mg/day) induced a reproducible hypocalcaemic effect. 
Such a low dose of etidronate might suppress resorption 
while having only minimal effects to impair skeletal 
mineralisation and thus may produce a greater 
hypocalcaemic effect than higher doses of this agent. In 
the present study both high and low doses of etidronate 
by mouth have been used and effects on calcium metabolism 
compared with those following clodronate treatment. In 
addition, the effects of long-term treatment with oral 
clodronate were examined. 
Patients and methods 
A total of 29 patients with primary hyper- 
parathyroidism were studied. 5 patients received more 
than one course of treatment. 14 patients were treated 
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with a total of 15 courses of oral clodronate 
0.8-1.6g/day (1 patient was re-treated). 9 patients 
received etidronate 400mg/day whereas 10 patients were 
given etidronate l. 0-1.2g/day. Details of patients and 
treatment are given in Table 6.1. All patients gave 
informed consent. The study had been approved by the 
local Ethics Committee. All treatments were given 
continuously as a single daily dose taken on waking with 
water only. Routine biochemical measurements on fasting 
blood and urine samples were carried out as described in 
Chapter 2. 
Results 
Treatment with clodronate 
Serum calcium fell significantly from a mean of 
2.95mmol/1 before treatment to 2.77mmol/1 at 2 months 
from the start of clodronate treatment (Figure 6.1). A 
significant decrease was also observed in fasting urinary 
Ca/Cr which fell from initially high values (mean 
0.55mol/mol) to within the normal range (mean 0.27mo1/mol 
at 2 months: NR 0.1-0.4mol/mol). There was an early fall 
in urinary OHP/Cr which remained suppressed for the 
duration of clodronate treatment. In contrast, an 
apparent attenuation of both the hypocalcaemic and 
hypocalciuric effects of treatment occurred after 3 to 4 
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Figure 6.1 Changes in serum calcium, urinary Ca/Cr and 
OHP/Cr during treatment in patients with primary 
hyperparathyroidism treated continuously with oral 
clodronate. 
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months of treatment (Figure 6.1). This is further 
demonstrated in Figure 6.2 which shows the individual 
responses of the 6 patients treated for at least 5 
months. In 4 of these 6 patients (patients 8,9,12 and 15 
see Table 6.1) the maximum hypocalcaemic effect was 
achieved within 2 months and this was followed by a 
steady upward trend in calcium values. However, in the 
other 2 patients (Nos 2 and 7) serum calcium fell but no 
secondary increase was observed. 
These data would suggest that the hypocalcaemic 
effect resulted from the inhibition of bone resorption 
and transient net calcium accretion into bone similar to 
the effect observed in patients with Paget's disease of 
bone treated with diphosphonates (Chapter 4). The 
observed attenuation of the hypocalcaemic response could 
thus be explained by a "recoupling" of the rates of bone 
formation and resorption. However, only a modest fall in 
serum alkaline phosphatase occurred (pretreatment mean 
122U/1 to 103U/1 at 6 months; p>0.1) and thus 
"recoupling" could not be confirmed biochemically. 
However, in one patient with tertiary hyperparathyroidism 
due to chronic renal failure who was treated with AHDP 
for 20 weeks biochemical recoupling was clearly evident 
(Figure 6.3). In this patient attenuation of the 
hypocalcaemic response coincided with the secondary fall 
in serum alkaline phosphatase. 
Long-term responses to clodronate 
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Figure 6.2 Changes in serum calcium in 6 patients with 
primary hyperparathyroidism treated with oral clodronate 
for 5 months or longer. Attenuation of the hypocalcaemic 
response occurred after 2 months in 4 of the 6 patients. 
POST-TRANSPLANT HYPERCALCAEMA 
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Figure 6.3 Effects of continuous treatment with AHDP 
400mg/day by mouth in a patient with tertiary 
hyperparathyroidism following renal transplantation. 
Attenuation of the hypocalcaemic response coincides with 
a fall in alkaline phosphatase and thus with biochemical 
"recoupling". 
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Treatment with etidronate 
Responses to high-dose and low-dose etidronate 
treatment are shown in Figure 6.4. Neither dose induced 
a significant change in serum calcium although a downward 
trend was apparent with the higher dose. Little overall 
change in Ca/Cr occurred with the lower dose (although a 
significant fall was present at 8 weeks) whereas a 
sustained suppression was observed in the high-dose 
group. Even so, the absolute values of Ca/Cr remained 
raised at around the upper end of the normal range 
(0.4mol/mol). Perhaps surprisingly, OHP/Cr fell 
significantly and by a similar extent in the two groups. 
However, it is notable that a marked and significant 
increase in serum phosphate occurred in the low-dose 
etidronate group comparable to, or even greater than, 
that seen with the higher dose (Figure 6.5) suggesting a 
high drug bioavailability in both groups. Moreover, the 
hyperphosphataemic responses might indicate that 
impairment of skeletal mineralisation was occurring with 
both high and low-dose etidronate treatment. 
Unfortunately bone histological data was not available to 
support this hypothesis. 
Values before treatment and at 1 month were 
compared in all three groups (clodronate and high and 
low-dose etidronate) in Figure 6.6. Thus, despite 
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Figure 6.4 Comparison of the effects of low-dose and 
high-dose oral etidronate treatment in patients with 
primary hyperparathyroidism. 
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Figure 6.5 Changes in serum phosphate in response to 
low or high doses of oral etidronate in patients with 
primary hyperparathyroidism. 
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Figure 6.6 Comparison of effects of three diphosphonate 
regimes (clodronate and high-dose or 1ow-a6se etidronate 
by mouth) after 1 month of treatment in patients with 
primary hyperparathyroidism. 
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comparable suppression of bone resorption, as judged by 
urinary OHP/Cr, in all three groups, a significant 
hypocalcaemic effect occurred only in the clodronate 
treated group. 
Discussion 
The experience with clodronate treatment of 
primary hyperparathyroidism reported here is similar to 
that of previous authors (Douglas et al, 1983; Shane et 
al, 1981) in that mean serum calcium fell significantly, 
but remained above normal. However, in the present study 
the lowest mean values achieved were still substantially 
above normal (2.77mmol/1) whereas these more closely 
approximated to normal in the previous studies 
(2.63mmol/1 and 2.70mmol/1). In part this may be due to 
more marked initial hypercalcaemia in the present study 
(2.95mmol/l compared with 2.88mmol/1 and 2.87mmol/l 
respectively). In the study by Douglas and colleagues an 
attenuation of the hypocalcaemic response was documented 
in one patient given prolonged treatment. This effect 
has been confirmed in a larger number of patients in the 
present study and is likely to be a consequence of 
recoupling of bone formation and resorption at a reduced 
rate of bone turnover. 
The present study also confirms the relative 
lack of hypocalcaemic response to high-dose etidronate 
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treatment (Kaplan et al, 1977). Although mineralisation 
was not studied directly this lack of effect probably 
results from the mineralisation defect associated with 
these high oral doses (Meunier et al, 1975). The lack of 
hypocalcaemic effect of the lower dose of etidronate was 
surprising in view of the marked fall in bone resorption 
in this group. However, the hyperphosphataemic response 
in these patients was much larger than that expected with 
this low dose and suggests increased bioavailability. 
That such an effect may occur is suggested by the 
findings of Boyce and colleagues (1984) of 
hyperphosphataemia and focal osteomalacia in pagetic 
patients treated with low-dose etidronate. Thus, 
markedly impaired mineralisation may have occurred in 
both low-dose and high-dose etidronate treated groups to 
account for the observed responses. It is possible that 
even lower doses, such as 200mg of etidronate, might have 
had a lesser effect to impair mineralisation and thus 
might have induced a greater hypocalcaemic effect. 
Parathyroidectomy remains the mainstay for 
treatment of symptomatic hyperparathyroidism. The 
indications for the medical management of primary 
hyperparathyroidism (discussed in Chapter 1) appear to be 
relatively few, particularly if, as suggested by the 
current study, the effects of treatments are incompletely 
effective in reducing calcium and these effects are only 
short-lived. Nonetheless under certain circumstances 
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diphosphonate treatment may be potentially useful. Thus 
a temporary reduction in serum calcium may prove useful 
in assessing the potential benefits of parathyroidectomy 
in patients with non-specific symptoms. In patients with 
chronic renal failure with either secondary or tertiary 
hyperparathyroidism diphosphonates might have a long term 
use in preventing or treating hyperparathyroid bone 
disease. In patients with marked hyperparathyroid bone 
disease severe hypocalcaemia may follow parathyroidectomy 
due to a sudden suppression of PTH-induced bone 
resorption and net entry of calcium into bone (so-called 
"hungry bone" syndrome). Pretreatment of these patients 
with diphosphonates might reduce the prevailing rate of 
bone turnover and thus reduce postoperative hypocalcaemia 
due to this mechanism. Primary hyperparathyroidism is 
commonly found in of postmenopausal women. There is 
concern that the accelerated rate of bone turnover in 
these patients may be associated with a rapid loss of 
bone to precipitate or exacerbate osteoporosis (Nagant de 
Deuxchaisnes et all 1985; Seeman et all 1982). Long-term 
treatment with diphosphonates, by reducing the rate of 
bone turnover, may be beneficial in preventing this 
complication. There are, however, no published studies 
available on these putative roles of diphosphonate 
treatment. 
From the present study, neither high-dose nor 
low-dose etidronate treatment appears to have any role in 
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the treatment of this disorder. However, it is possible 
that if our patients had been given even lower doses of 
etidronate a more marked hypocalcaemic response would 
have occurred. The overall findings concur with the 
results of intravenous diphosphonates in Paget"s disease 
and in hypercalcaemia of malignancy discussed in Chapters 
4 and 5 in which the hypocalcaemic effects of etidronate 
were attenuated due to the associated impairment of 
mineralisation. 
Summary 
1) In previous studies both clodronate and APD have been 
shown to produce a hypocalcaemic effect in patients with 
primary hyperparathyroidism. In other studies high dose 
oral etidronate had no significant effect on calcium but 
there is an anecdotal suggestion that low dose treatment 
may be more effective. 
2) A direct comparison of three regimens was made in the 
present study. 15 hyperparathyroid patients were given 
clodronate 0.8-1.2g/day and 19 received etidronate at 
either 400mg/day (n=9) or 1-1.2g/day (n=10). 
3) Mean concentrations of serum calcium fell 
significantly (but not into the normal range) in the 
clodronate treated group only, despite marked falls in 
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urinary OHP/Cr in all three groups. 
4) An attenuation of the hypocalcaemic and hypocalciuric 
responses to clodronate occurred after 3 months of 
continuous treatment possibly due to "recoupling" of bone 
formation and resorption. 
5) Clodronate, but neither high-dose nor low-dose 
etidronate, may have a useful role in the medical 
management of patients with primary hyperparathyroidism. 
CHAPTER SEVEN 
THE USE OF CLODRONATE IN THE TREATMENT OF IMMOBILISATION 
HYPERCALCAEMIA 
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THE USE OF CLODRONATE IN TREATMENT OF IMMOBILISATION 
HYPERCALCAEMIA 
Introduction 
Hypercalcaemia is a well recognised, albeit 
uncommon, complication of prolonged immobilisation. It 
occurs in patients with high rates of bone turnover, 
including children and adolescents (Claus-Walker et all 
1975; Lerman et all 1977; Van Zuiden et all 1982) and in 
patients with Paget"s disease of bone (Reifenstein & 
Albright, 1944). In adults with previously normal bones 
hypercalcaemia is rare (Mason, 1957), but may be more 
common than hitherto recognised (Heath et all 1972). The 
mechanism of hypercalcaemia is thought to be an increase 
in net bone resorption due to both a suppression of bone 
formation and an increase in osteoclastic bone resorption 
(Minaire et all 1974,1982). 
Two cases of immobilisation hypercalcaemia in 
adults with previously normal bone turnover and their 
responses to treatment with clodronate are reported here. 
At the time of this study there were no previous reports 
of the use of diphosphonates in the treatment of this 
disorder. These cases have previously been the subject 
of a short report (Yates et al, 1984). 
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Case reports 
Two female patients, aged 43 years (Patient 1) 
and 32 years (patient 2), developed severe hypercalcaemia 
following a prolonged period of immobilisation. Blood 
and urine collections and biochemical measurements were 
performed as described in chapter 2. 
Patient 1 developed severe widespread flaccid 
paralysis over 36 hours in March 1981 due to acute 
fulminating post-infective polyneuritis. Assisted 
ventilation was required for 23 weeks, this period being 
complicated by autonomic dysfunction, chest infection and 
thrombo-embolic episodes. By February 1982 she had 
regained grade 3 power in the proximal leg muscles, 
although power of the distal muscle groups was still very 
poor and she was unable to stand unaided. At this time, 
11 months after the onset of her illness, she developed 
malaise, nausea, vomiting and constipation and became 
clinically dehydrated. The serum calcium concentration 
was markedly increased (3.92mmol/l). Treatment with 
continuous intravenous saline 31/day for 19 days resulted 
in a small and transient fall in plasma calcium followed 
by an increase to 3.66mmol/1 despite continued treatment. 
During this period serum iPTH was undetectable and 
1,25(OH)2D3 concentrations were low (Table 7.1). Serum 
creatinine was normal although renal function (endogenous 
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creatinine clearance) was reduced at 41 ml/min. 
Patient 2 underwent renal transplantation for 
end-stage renal failure 3 months before presentation. At 
that time she had no evidence of bone disease as judged 
by a radiographic skeletal survey and serum activity of 
alkaline phosphatase. However, 14 months previously she 
had been treated with alphacalcidol (1-alpha OH-D3) for 
hyperparathyroid bone disease. Apart from one rejection 
episode, renal function was stable (creatinine clearance 
= 38m1/min) and immunosuppression was maintained with 
azathioprine and prednisolone. She was discharged home 
but readmitted 3 days later with cough and dyspnoea 
subsequently attributed to a cytomegaloviral infection. 
She became increasingly hypoxic and required tracheostomy 
and assisted ventilation for 4 weeks. For the following 
2 weeks she was unable to move her limbs due to a 
peripheral motor neuropathy which was confirmed by 
electromyography and nerve conduction studies. Power 
returned gradually over the subsequent 2 months but was 
associated with a progressive rise in the serum calcium 
(to 3.54mmol/1) despite treatment with prednisolone. 
Serum iPTH was undetectable and the concentration of 
1,25(OH)2D3 was low (Table 7.1) 
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Skeletal radiographs were normal in both 
patients and in the one patient examined (Patient 1) a 
bone scan showed no evidence of extraskeletal 
calcification. Both patients had biochemical evidence 
for increased bone resorption as judged by urinary Ca/Cr 
and OHP/Cr (Table 7.1) 
Both patients were treated with clodronate 
(Figure 7.1). Patient 1 received 100mg intravenously 
daily for 3 days followed by 13 days of treatment by 
mouth (1.6g/day). Patient 2 was initially given 5 days 
of oral clodronate 1.6g/day. Both patients became 
normocalcaemic within 5 days (Figure 7.1). There were 
similar, though less marked, falls in serum phosphate. 
When treatment was stopped after 5 days in Patient 2, 
hypercalcaemia recurred, but responded to further 
treatment. Fasting urinary Ca/Cr, initially high in both 
patients, fell to normal within 2 weeks from the start of 
treatment. In Patient 1 there was a transient rise in 
urinary Ca/Cr when clodronate was stopped after 1 month 
of treatment although hypercalcaemia did not recur. 
Urinary OHP/Cr was little changed initially in either 
patient but subsequently decreased gradually over 4 to 6 
months. 
Discussion 
These two patients were unusual in that they 
Treatment with CI2MDP 
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Figure 7.1 Effects of treatment with clodronate on 
serum calcium and urinary Ca/Cr in 2 adults with 
immobilisation hypercalcaemia. Patient l'is denoted by 
circles and Patient 2 by squares. 
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, 
were adults with severe hypercalcaemia due to 
immobilisation but without fracture, coexisting Paget's 
disease or marked renal failure (Drivas et al, 1975). In 
common with adolescents, bone resorption, as judged by 
OHP/Cr, was markedly increased. This notion is supported 
by the finding of hypercalciuria, in common with the 
general experience of others in immobilised adults 
(Minaire et al, 1974; Whedon & Shorr, 1957). Increased 
intestinal absorption of calcium might also augment 
urinary calcium excretion. However, the measurement of 
fasting Ca/Cr, which eliminates the effects of gut 
derived calcium, was increased in both our patients. 
Moreover, the dietary intake of calcium was low and serum 
concentration of 1,25(OH)2D3 were low, suggesting that 
intestinal absorption of calcium was also likely to be 
low. The mechanism for the low concentrations of 
1,25(OH)2D3 was probably related to low PTH 
concentrations and high plasma calcium, both factors 
which reduce the activity of the 1-alpha hydroxylase 
enzyme in man (Norman et al, 1982). Whereas 
hypercalciuria is common in adults following 
immobilisation (Whedon & Shorr, 1957; Lutwak et al, 
1969), significant hypercalcaemia is extremely rare. 
This raises the possibility that increased delivery of 
calcium to the ECF from sources other than bone, or its 
reduced clearance from the circulation, may have 
contributed to hypercalcaemia. Both patients were 
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recovering from muscle paralysis, so that a high calcium 
content of damaged muscle fibres could have contributed 
to hypercalcaemia. However, no evidence for 
extraskeletal calcification was found in either patient 
as judged by radiographic criteria or the more sensitive 
index of scintigraphy. Creatinine clearance was impaired 
in both patients even though serum creatinine 
concentrations were normal. Impairment of renal function 
would not cause, but is likely to have contributed to, 
hypercalcaemia by decreasing the ability to clear large 
fluxes of calcium from the ECF. Serum iPTH was low in 
our patients, in common with the experience of others 
(Rosen et al, 1978; Stewart et al, 1982; Claus-Walker et 
al, 1977) indicating that hyperparathyroidism did not 
account for the hypercalcaemia. In both cases, 
therefore, marked bone resorption appeared to be the 
major mechanism for hypercalcaemia. 
These conclusion are supported by the response 
of these patients to suppression of bone resorption with 
clodronate. The effects of clodronate on immobilisation 
hypercalcaemia have not been previously reported, 
although this agent has been shown to inhibit bone loss 
in experimental animals (Fleisch et all 1969b) and in 
paraplegia (Minaire et all 1982). Etidronate has been 
used successfully to treat immobilisation hypercalcaemia 
(flagg et all 1984; Merli et all 1984) but its effect on 
mineralisation may limit the hypocalcaemic action. 
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Although severe hypercalcaemia following 
immobilisation is rare, accelerated bone loss appears to 
be universal. Thus, treatment with diphosphonates may be 
potentially useful, not only for immobilisation 
hypercalcaemia, but also for the prevention of the 
progressive osteoporosis associated with prolonged 
immobilisation. 
Summary 
1) Two adult patients developed marked hypercalcaemia 
associated with prolonged immobilisation. 
2) In both patients hypercalcaemia resulted from 
increased bone resorption in association with impaired 
renal glomerular function, and thus impaired calcium 
excretion. 
3) Treatment with clodronate decreased bone resorption 
and thereby reduced serum calcium in both patients. This 
agent may also be useful in preventing osteoporosis 
associated with immobilisation. 
CONCLUDING REMARKS 
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CONCLUDING REMARKS 
These studies have provided new information on 
several aspects of the effects of diphosphonates in 
disorders of the skeleton and of calcium metabolism. 
Many of the objectives stated earlier in this work have 
been at least partly met. To summarise these: - 
1) The effects of different diphosphonates were directly 
compared, particularly in patients with Paget's disease 
of bone. All three diphosphonates investigated, 
including the hitherto clinically untested diphosphonate, 
AHDP, effectively inhibited bone resorption when given in 
short intravenous courses. AHDP appears to be a more 
potent inhibitor of bone resorption than either 
clodronate or etidronate and is likely to be a useful 
agent in the treatment of both Paget's disease and 
hypercalcaemia of malignancy. Although all three 
intravenously-administerd diphosphonates tested were 
shown to inhibit the uptake of mineral into bone, this 
effect was only partial and short-lived following 
treatment with either clodronate or AHDP whereas a 
sustained and complete block of mineralisation occurred 
following treatment with etidronate. The effects of 
these agents on serum calcium are explicable in terms of 
their effects on the influx and efflux of calcium between 
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bone and the ECF compartment. Because etidronate 
completely inhibiting skeletal mineralisation, and thus 
calcium entry into bone, this agent has no acute 
hypocalcaemic effect in Paget"s disease. For this 
reason, and as confirmed by the clinical studies reported 
herein, etidronate appears to be less suitable than 
either clodronate or AHDP in the treatment of 
hypercalcaemic disorders associated with increased bone 
resorption. 
TmP/GFR and serum phosphate increased 
significantly in response to all three intravenously 
administered diphosphonates. However, the extent and 
time course of these phosphate responses appeared to be 
related to the effects of these agents on mineralisation 
indicating a possible causal relationship. Further 
studies of the interrelationship between impaired 
mineralisation and renal tubular transport of phosphate, 
which might involve a humoral signal between bone and 
kidney, are required. 
2) The effects of diphosphonates in Paget's disease, 
hypercalcaemia of malignancy and primary 
hyperparathyroidism were compared. Despite differences 
in underlying mechanisms of disease it was found that 
effects of diphosphonates on bone turnover and calcium 
metabolism in one disorder, such as Paget's disease, were 
similar to those observed in the other disorders. Thus, 
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by studying the effects of diphosphonates in several 
disorders a more complete picture of diphosphonate 
effects and of relative differences between 
diphosphonates was obtained. 
3) Previously untried treatment regimens with short 
intravenous courses of diphosphonates were studied and 
compared with a long-term oral treatment of established 
efficacy. The suppression of biochemical markers of bone 
turnover following short intravenous courses of 
diphosphonate treatment in previously untreated patients 
with Paget"s disease was similar to that during prolonged 
oral therapy and was sustained for approximately one year 
in the case of treatment with intravenous clodronate. 
Such responses have not previously been described and may 
help to shed further light on the mechanism of action of 
diphosphonates. These new treatment regimens offer an 
attractive alternative mode of treatment for this 
disorder. 
4) The initial degree of pagetic activity was found to 
be an important consideration in the assessment of 
biochemical response in individual patients with Pagetos 
disease. Although, previous treatment with 
diphosphonates appeared to be associated with an impaired 
response to further treatment with diphosphonates, on 
closer examination this effect could be entirely 
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attributed to the effect of incomplete relapse before 
re-treatment. If allowance for these effects is not made 
they may result in considerable bias between treatment 
groups which are not well matched for their degree of 
pagetic activity and the proportion of re-treated 
patients. As very many diphosphonate treatment options 
exist it is important to be able to evaluate these 
economically using relatively small numbers of patients 
and also to be able to compare results from different 
studies. Some methods to facilitate such comparisons 
have been presented in this work. 
5) A dose-response relationship was established for 
intravenous clodronate in treatment of Paget's disease of 
bone. 
6) The use of clodronate in the treatment of 
immobilisation hypercalcaemia had not previously been 
described and was studied in two adult patients reported 
in this thesis. This form of treatment was found to be 
effective and may, by implication, also have a role in 
the prevention of the bone loss that is otherwise an 
inevitable consequence of prolonged immobility or 
weightlessness in space. 
Although these various findings represent a 
considerable advance in the knowledge of the effects of 
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diphosphonates in skeletal disease, the studies were of 
necessity limited and there remain many unanswered 
questions. For example, it is possible that prolonged 
suppression of Pagetic activity, perhaps with continuous 
or intermittant diphosphonate therapy, might eradicate 
the pool of pagetic osteoclasts and thus "cure" of the 
disease may be obtained. Certainly some patients remain 
in biochemical remission 5 years or more after a single 
course of treatment. However, others relapse even after 
such a prolonged interval and thus it is not yet possible 
to determine whether cure of the disease, as opposed to 
its long-term control, is a real prospect. Neither is it 
known whether true resistance to diphosphonate treatment 
might develop in some patients after prolonged repeated 
exposure. When the answers to such questions become 
available the way in which diphosphonates are used to 
treat disorders of bone turnover may be further 
rationalised. 
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